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A B S T R A C T
Background
Miscarriage is a common complication of pregnancy that can be caused by a wide range of factors. Poor dietary intake of vitamins
has been associated with an increased risk of miscarriage, therefore supplementing women with vitamins either prior to or in early
pregnancy may help prevent miscarriage.
Objectives
The objectives of this review are to determine the effectiveness and safety of any vitamin supplementation, on the risk of spontaneous
miscarriage, maternal adverse outcomes and fetal and infant adverse outcomes.
Search strategy
We searched the Cochrane Pregnancy and Childbirth Group Trials Register (8 September 2004), the Cochrane Central Register of
Controlled Trials (The Cochrane Library, Issue 2, 2003) and MEDLINE (1966 to May 2003), Current Contents (1998 to May 2003)
and EMBASE (1980 to May 2003).
Selection criteria
All randomised and quasi-randomised trials comparing one or more vitamins with either placebo, other vitamins, no vitamins or other
interventions, prior to conception, periconceptionally or in early pregnancy (less than 20 weeks’ gestation).
Data collection and analysis
Two review authors independently assessed trials for inclusion, extracted data and assessed trial quality.
Main results
We identified seventeen trials assessing supplementation with any vitamin(s) starting prior to 20 weeks’ gestation and reporting at least
one primary outcome that were eligible for the review. Overall, the included trials involved 35,812 women and 37,353 pregnancies.
Two trials were cluster randomised and contributed data for 20,758 women and 22,299 pregnancies in total. No difference was seen
between women taking any vitamins compared with controls for total fetal loss (relative risk (RR) 1.05, 95% confidence interval (CI)
0.95 to 1.15), early or late miscarriage (RR 1.08, 95% CI 0.95 to 1.24) or stillbirth (RR 0.85, 95% CI 0.63 to 1.14) and most of the
other primary outcomes, using fixed-effect models. For the other primary outcomes, women given any type of vitamin(s) compared
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with controls were less likely to develop pre-eclampsia (RR 0.68, 95% CI 0.54 to 0.85, four trials, 5580 women) and more likely to
have a multiple pregnancy (RR 1.38, 95% CI 1.12 to 1.70, three trials, 20,986 women).
Authors’ conclusions
Taking vitamin supplements, alone or in combination with other vitamins, prior to pregnancy or in early pregnancy, does not prevent
women experiencing miscarriage or stillbirth. However, women taking vitamin supplements may be less likely to develop pre-eclampsia
and more likely to have a multiple pregnancy.
P L A I N L A N G U A G E S U M M A R Y
Vitamin supplementation for preventing miscarriage
Supplementing women with any vitamins, alone or in combination with other vitamins, does not reduce the number of women who
miscarry or have a stillbirth.
Poor diet, without enough vitamins, has been associated with an increased risk of women losing their baby in early pregnancy. Taking
vitamin supplements prior to pregnancy or in early pregnancy may reduce the risk of miscarriage, but this review did not find this to be
the case. However, women taking vitamin supplements may be less likely to develop pre-eclampsia and more likely to have a multiple
pregnancy. More research is needed.
B A C K G R O U N D
Miscarriage or pregnancy loss within the first 20 weeks of gesta-
tion is a frequent complication of pregnancy, with 12% to 16% of
all clinically recognised pregnancies ending inmiscarriage (Everett
1997; Regan 1989). Recurrent miscarriage, defined as the occur-
rence of three or more consecutive spontaneous miscarriages, af-
fects one to two per cent of women of reproductive age (Coulam
1991). Miscarriage is associated with significant maternal mor-
bidity including haemorrhage and infection and, in some cases,
maternal death (NHMRC 2001), with maternal death more com-
mon in countries that are resource-poor (Goyaux 2001). Women
experiencing miscarriage may suffer significant psychological and
emotional stress. Grief experienced by women and their families
can be complicated by feelings of self-blame, anxiety and depres-
sion, and social withdrawal and marital disturbances may result
(Lee 1996). This emotional distress may be further compounded
when women experience recurrent miscarriage.
Care of women suffering miscarriage is complicated by different
definitions, disagreement on its validity as a clinical disorder and
poor quality data on women not requiring hospital or outpatient
treatment.Miscarriage can be caused by awide range of factors and
determining the aetiology of miscarriage is often difficult, with a
variety of underlying mechanisms being potentially responsible.
Up to two thirds of early pregnancy losses (miscarriage before 12
weeks’ gestation), are associated with chromosomal abnormalities
(Stern 1996).While early miscarriages are more likely to be associ-
ated with chromosomal abnormalities and defective placental de-
velopment, latemiscarriage (miscarriage occurring between12 and
20 weeks’ gestation) may be more likely due to structural problems
of the uterus and/or cervix, such as cervical incompetence.Women
experiencing recurrent miscarriage may often have an underlying
medical condition such as autoimmune disease, i.e. systemic lupus
erythematosus and antiphospholipid syndrome, or other blood
clotting disorders such as hyperhomocysteinemia (high levels of
homocysteine in the blood) or another thrombophilia (Preston
1996) . Recurrent miscarriage is thought to involve an underly-
ing placental vascular pathology seen also in pre-eclampsia, in-
trauterine growth restriction and placental abruption (Ray 1999).
Current therapies being considered for the prevention of miscar-
riage include progesterone and immunotherapy and these topics
are covered in other Cochrane reviews (Oates-Whitehead 2003;
Scott 2003).
Vitamins are essential nutrients required for a range of functions
in the body. Vitamins are either water soluble, such as vitamin C
and the B group vitamins (including folate) or fat soluble such
as vitamin A, D, E and K. Vitamins are obtained from the diet
and also from dietary supplements of either individual vitamin
preparations or a multivitamin preparation. Multivitamins con-
tain a range of vitamins and minerals usually in doses similar to
the recommended dietary intakes. Folate, vitamin B6 and vitamin
2Vitamin supplementation for preventing miscarriage (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
B12 have been recommended for women with hyperhomocys-
teinemia, and therefore supplementation may influence the risk
of spontaneous miscarriage in these women. Similarly, oxidative
stress, where there is overproduction of reactive oxygen molecules
leading to decreased levels of antioxidants, has been linked to spon-
taneous and recurrent miscarriage (Jauniaux 2000; Simsek 1998).
Therefore, intake of antioxidant vitamins such as vitamin C and
vitamin E may be an important factor associated with the risk of
miscarriage.One observational study has demonstrated an associa-
tion between the risk of spontaneous early miscarriage and dietary
factors, with a high risk associated with poor intake of green veg-
etables, fruit and dairy products coupled with a high intake of fat
(Di Cintio 2001). Little information is available about the impact
of vitamins on the risk of early versus late miscarriage, however, di-
etary factors could theoretically influence structural abnormalities
such as cervical incompetence. There is a growing body of research
investigating the relationship between nutrition and placental de-
velopment, fetal growth, pregnancy outcomes and adult diseases
(Godfrey 1996; Morris 2001; NRC 1989). Therefore, adequate
maternal nutrition, particularly vitamin intake, may be an impor-
tant factor in preventing spontaneous miscarriage. There is cur-
rently little information about the most appropriate vitamin type
or combination; therefore, this review will cover all vitamin types.
Similarly, many commercially available vitamin preparations con-
tain a range of combinations of vitamins; therefore, this review
will pool all vitamin types together initially to determine overall
if any vitamins and any improvement in maternal nutrition helps
to prevent miscarriage. Individual vitamin types will also be dis-
cussed separately.
The use of any vitamin supplements in pregnancy needs to be care-
fully monitored and evaluated for safety and efficacy. This is par-
ticularly true for early pregnancy use, where there is the potential
for teratogenicity. High maternal levels of preformed vitamin A
(retinoic acid) are known to induce spontaneous miscarriage and
malformations involving the central nervous systems and cardiac
development (WHO 1998). Potential teratogenic effects of other
vitamins have not been reported. In contrast, folate supplementa-
tion and multivitamin supplementation have been associated with
a decreased risk of neural tube defects (Lumley 2001b). Pericon-
ceptional folate andmultivitamin supplementation for the preven-
tion of neural tube defects has been covered in another Cochrane
review (Lumley 2001b). Concerns have been raised about the im-
pact of folate and multivitamin supplementation on the rate of
multiple births (Lumley 2001a; Lumley 2001b); however, further
research is needed to establish a direct causal relationship. Potential
side-effects of vitamins can occur with hypervitaminosis (excessive
ingestion of one or more vitamins). Hypervitaminosis A (vitamin
A poisoning) has been associated with irritability, fatigue, changes
in the skin, hair loss, headache, and abdominal discomfort (Olsen
1999). Similarly hypervitaminosis D (vitamin D poisoning) has
been associated with nausea, vomiting, weakness, disturbed diges-
tion, and elevated blood and tissue calcium levels (Olsen 1999).
For vitamin E, non-randomised controlled clinical trials of vita-
min E supplementation in a variety of doses have failed to demon-
strate any consistent side-effects (Bendich 1993). However, there
has been limited evaluation of the use of these and other vitamins
in pregnancy. While water soluble vitamins such as vitamin C and
the B group vitamins are easily excreted by the body, the fat soluble
vitamins A, D, E and K may accumulate in the body and in the
developing fetus. The safety of using these vitamins needs to be
clearly demonstrated before they can be recommended for routine
antenatal care.
The aims of this review are to identify all published and unpub-
lished randomised controlled trials that investigate vitamins for
the prevention of miscarriage and to assess the benefits and hazards
of women using vitamins for the prevention of miscarriage.
O B J E C T I V E S
The objectives of this review are:
(1) to determine the effectiveness and safety of any vitamin sup-
plementation taken by women prior to conception, periconcep-
tionally and in early pregnancy on the risk of:
(a) spontaneous miscarriage;
(b) maternal adverse outcomes;
(c) fetal and infant adverse outcomes.
(2) If vitamins are effective, to determine which of these agents
are best and to compare vitamins with other interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised trials and quasi-randomised trials comparing one
or more vitamins with either placebo, other vitamins, no vitamins
or other interventions, prior to conception, periconceptionally or
in early to mid-pregnancy.
Types of participants
Pregnant women (less than 20 weeks’ gestation) or women in the
reproductive age group planning on becoming pregnant in the
near future, regardless of whether they are at low or high risk of
having a miscarriage.
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Types of interventions
Comparisons of any vitamin(s) alone or in combinationwith other
agents with either placebo, other vitamin(s), no vitamin(s) or other
interventions for the prevention of miscarriage, either in areas
where there is inadequate dietary intake or where there is presumed
adequate intake of that vitamin(s).
Types of outcome measures
Main outcomes
For the woman
1. Fetal loss, incidence of early and late miscarriage (early
miscarriage defined as spontaneous pregnancy loss less than 12
weeks’ gestation, late miscarriage defined as spontaneous
pregnancy loss greater than or equal to 12 and less than 20
weeks).
2. Placental abruption.
3. Pre-eclampsia.
4. Psychological effects (anxiety and depression).
For the infant
1. Stillbirth, perinatal or neonatal death.
2. Preterm birth (defined as birth less than 37 weeks’
gestation).
3. Birthweight.
4. Small-for-gestational age (birthweight less than the third
centile or the most extreme centile reported).
5. Congenital malformations.
Other outcomes
1. Multiple pregnancy (including only trials supplementing
women prior to or around the time of conception).
2. Very preterm birth (defined as less than 34 weeks’
gestation).
3. Apgar score less than seven at five minutes.
4. Use of blood transfusion for the mother.
5. Anaemia (maternal and infant).
6. Placental weight.
7. Methods of feeding: breastfeeding, formula or both.
8. Subsequent fertility (subsequent pregnancy rate per couple
or as defined by the authors).
9. Poor growth at childhood follow up.
10. Disability at childhood follow up.
11. Adverse effects of vitamin supplementation sufficient to
stop supplementation, such as manifestations of
hypervitaminosis, headache, nausea, vomiting, diarrhoea.
12. Maternal views of care.
Use of health service resources
1. Gynaecological hospital admission.
2. Admission to neonatal intensive care unit.
3. Healthcare costs.
Search methods for identification of studies
Electronic searches
We searched theCochrane Pregnancy andChildbirthGroupTrials
Register by contacting the Trials Search Co-ordinator (8 Septem-
ber 2004).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. monthly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness search of a further 37 journals.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via
the current awareness service can be found in the ’Search strategies
for identification of studies’ section within the editorial informa-
tion about the Cochrane Pregnancy and Childbirth Group.
Trials identified through the searching activities described above
are given a code (or codes) depending on the topic. The codes are
linked to review topics. The Trials Search Co-ordinator searches
the register for each review using these codes rather than keywords.
In addition, we searched CENTRAL (The Cochrane Library Issue
2, 2003) for the following terms: miscarriage*, spontaneous abor-
tion, recurrent abortion, spontaneous pregnancy loss, recurrent
pregnancy loss, fetal death, vitamin*, folate, folic acid.
We searched MEDLINE (1966 to May 2003), Current Contents
(1998 to May 2003) and EMBASE (1980 to May 2003) for po-
tentially eligible studies, using the search strategy in Appendix 1.
We did not apply any language restrictions.
Data collection and analysis
Two review authors assessed potentially eligible trials found af-
ter the literature search for their suitability for inclusion in the
review. Decisions regarding inclusion were made separately and
results compared. Any disagreement was resolved through discus-
sion. Trials that supplemented women in early and mid pregnancy
were considered eligible for inclusion. Supplementation occurring
in mid pregnancy was not specified in the original protocol for
this review, however, this was amended to be in line with other
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miscarriage reviews such as ’Progestogen for preventing miscar-
riage’ (Oates-Whitehead 2003). Similarly, we specified in the orig-
inal protocol that we would exclude studies reporting greater than
20% losses to follow up. In this review we have included studies
that reported more than 20% losses to follow up and undertaken
further analyses based on various aspects of trial quality, including
the percentage of losses to follow up reported.
The authors deemed it important to include any supplementation
trials, where supplementation began prior to 20 weeks’ gestation,
and where at least one main outcome as specified in the review
was reported, even if the intervention was not specifically for the
prevention of miscarriage. We excluded trials where the onset of
supplementation occurred definitely after 20 weeks’ gestation. We
included trials where the onset of supplementation occurred both
prior to and after 20 weeks’ gestation, and when it could not be es-
tablished whether the majority of the women started supplemen-
tation prior to 20 weeks’ gestation. Where trials recruited women
prior to becoming pregnant, we reported the denominators for
each trial as all women randomised; or where there was accurate
information about the number of women in each trial who be-
came pregnant, we reported the denominators as the number of
women randomised and with a confirmed pregnancy. Two authors
extracted data using an agreed format, and again we resolved dis-
crepancies through discussion. We entered and double checked
the data.
We assessed the validity of each included trial according to the
criteria outlined in the Cochrane Reviewers’ Handbook (Alderson
2004). We assessed trials with a grade allocated to each trial on
the basis of allocation concealment: A (adequate), B (unclear) or
C (inadequate). Where the method of allocation concealment was
unclear, we attempted to contact authors to provide further details.
We assessed blinding, completeness of follow up and placebo con-
trol for each outcome using the following criteria.
For completeness of follow up:
A. less than three per cent of participants excluded;
B. three per cent to 9.9 per cent of participants excluded;
C. ten per cent to 19.9 per cent of participants excluded;
D. greater than or equal to 20 per cent of participants excluded.
For blinding of assessment of outcome:
A. double blind, neither investigator nor participant knew or were
likely to guess the allocated treatment;
B. single blind, either the investigator or the participant knew
the allocation. Or, the trial is described as double blind, but side-
effects of one or other treatment mean that it is likely that for a
significant proportion (equal to or greater than 20 per cent) of
participants the allocation could be correctly identified;
C. no blinding, both investigator and participant knew (or were
likely to guess) the allocated treatment;
D. unclear.
For use of placebo control:
A. placebo controlled;
B. unclear whether placebo controlled;
C. no placebo control.
We carried out statistical analyses using the Review Manager soft-
ware (RevMan 2004), with results presented as summary rela-
tive risk for dichotomous outcomes and weighted mean differ-
ence for continuous outcomes. We adopted a generic inverse vari-
ance approach for the meta-analyses for dichotomous outcomes
where trials using cluster-randomisation techniques were included
(Alderson 2004). We applied tests of heterogeneity between tri-
als to assess the significance of any differences between trials (I2
greater than or equal to 50%) and we explored possible causes of
heterogeneity. We calculated summary relative risks using a fixed-
effect model. If heterogeneity was detected, we performed sub-
group analyses for the main outcomes by risk of miscarriage, time
of trial entry, type of vitamin used, vitamin dosage, use of placebo,
adequacy of prior dietary intake of vitamins. We modelled het-
erogeneity that was not explained by subgroup analyses using a
random-effects analysis.
Where possible, women were classified into subgroups based on:
1. their risk of spontaneous miscarriage (high risk defined as
the presence of medical conditions associated with miscarriage
such as hyperhomocysteinemia, thrombophilia,
antiphospholipid syndrome, systemic lupus erythematosus; low
risk defined as none of the above conditions);
2. their risk of recurrent miscarriage (high risk defined as two
or more previous consecutive spontaneous miscarriages, and or
the presence of medical conditions associated with miscarriage
such as hyperhomocysteinemia, thrombophilia,
antiphospholipid syndrome, systemic lupus erythematosus; low
risk defined as none of the above conditions);
3. the dose of vitamin(s) (below or above the recommended
dietary intake);
4. the duration of vitamin usage;
5. low or adequate dietary vitamin intake at trial entry (low
intake defined as less than the recommended daily intake for each
vitamin in that setting, as measured by dietary questionnaire).
All included trials were included in the initial analyses which were
performed by any vitamin to include all vitamin combinations
and then by individual vitamin type. We carried out sensitivity
analyses to explore the effect of trial quality. This involved analysis
based on an A, B or C rating of allocation concealment, blinding
of assessment of outcome and placebo control. We compared the
results of high-quality studies with those of poorer quality studies,
where studies rated A were compared with those rated B or C.
R E S U L T S
Description of studies
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See:Characteristics of included studies; Characteristics of excluded
studies.
See tables ’Characteristics of included studies’ and ’Characteristics
of excluded studies’ for details of individual studies.
Excluded studies
Thirty-five trials were excluded, of which twelve reported no clin-
ically meaningful data in a format suitable for inclusion (Hibbard
1968; Laurence 1981; Lira 1989; Meirinho 1987; Mock 2002;
Moldenhauer 2002; Semba 2001; Suharno 1993; Tanumihardjo
2002; Thauvin 1992; Villamor 2002; Vutyavanich 1995). Eight
trials did not clearly report the gestational age when supplemen-
tation was started (Biswas 1984; Fletcher 1971; Hampel 1974;
Lumeng 1976; Schuster 1984; Trigg 1976 ) or did not report out-
comes separately for women starting supplementation prior to 20
weeks (Ferguson 1955; Giles 1971). Eleven trials (Baumslag 1970;
Blot 1981; Chanarin 1968; Colman 1974; Coutsoudis 1999;
Dawson 1962; Edelstein 1968; Hankin 1966; Marya 1981; Metz
1965; Owen 1966) reported supplementation after 20 weeks’ ges-
tation. One trial (Ross 1985) did not specify the contents of the
supplements, while one trial was excluded as all women were given
the supplement and there was no appropriate control (Hunt 1984)
and two were non-randomised (Smithells 1981; Ulrich 1999).
Three other trials (Beazley 2002; Chaudhuri 1969; Rivas 2000)
supplemented women for the prevention of pre-eclampsia, and
did not report any outcomes related to pregnancy loss. These trials
are covered in the Cochrane review ’Antioxidants for preventing
pre-eclampsia’ (Rumbold 2003).
Included studies
We identified seventeen trials assessing supplementation with any
vitamin(s) starting prior to 20 weeks’ gestation. The included tri-
als involved 35,812 women, and some of these women were preg-
nant more than once in the study period, resulting in data being
contributed for 37,353 pregnancies in total. Many of the trials
assessed interventions not specifically for the prevention of mis-
carriage. Four of the included studies were assessing folic acid sup-
plementation for the prevention of neural tube defects (Czeizel
1994; ICMR 2000; Kirke 1992; MRC 1991). For the purpose of
this review however, the authors deemed it important to include
any supplementation trials, where supplementation began prior
to 20 weeks’ gestation, and where at least one main outcome as
specified in the review was reported.
Participants
The demographic and obstetric characteristics of women varied
widely between the trials (See table ’Characteristics of included
studies’), as did the gestational age at trial entry and the type
of supplements. Some trials enrolled women prior to conception
(Czeizel 1994; Hemmi 2003; ICMR 2000; Kirke 1992; MRC
1991) and asked women to continue taking the supplements
up until the second or third missed menstrual period. One trial
(Katz 2000) supplemented women from before to conception,
through pregnancy and up to 3.5 years postpartum. Other tri-
als enrolled women in the first trimester (Briscoe 1959) or in
early to mid pregnancy (Chappell 1999; Correia 1982; Fawzi
1998; Fleming 1968; Kumwenda 2002; People’s League 1942;
Rush 1980; Schmidt 2001; Steyn 2003). Two trials (Fawzi 1998;
Kumwenda 2002) involved vitamin A supplementation in women
seropositive for the Human Immunodeficiency Virus. The trials
were conducted in both resource-rich and resource-poor coun-
tries including the United States (Briscoe 1959; Rush 1980),
UnitedKingdom (Chappell 1999; People’s League 1942), Portugal
(Correia 1982), Hungary (Czeizel 1994), Tanzania (Fawzi 1998),
Nigeria (Fleming 1968), Japan (Hemmi 2003), India (ICMR
2000),Nepal (Christian 2003; Katz 2000), the Republic of Ireland
(Kirke 1992), Malawi (Kumwenda 2002), Indonesia (Schmidt
2001), South Africa (Steyn 2003) and one trial involved 33 inter-
national centres (MRC 1991).
Interventions
The seventeen trials assessed a range of vitamin supplements,
alone or in combination with other supplements. The vitamins
included vitamin A, alone or with iron, folate, zinc or multi-
vitamins (Christian 2003; Fawzi 1998; Katz 2000; Kumwenda
2002; Schmidt 2001), vitamin C with or without multivitamins
or vitamin E (Briscoe 1959; Chappell 1999; Hemmi 2003; Steyn
2003), folate with or without multivitamins and/or iron (Correia
1982; Czeizel 1994; Fleming 1968; ICMR 2000; Kirke 1992;
MRC1991) andmultivitamins alone (People’s League 1942; Rush
1980). The doses of vitamins were similar for the vitamin C sup-
plementation trials (range 400 mg to 1000 mg). However, they
varied widely between trials for the folate (range 0.3 mg to 10
mg), multivitamins and vitamin A trials (range 5000 international
units (IU) to 23,300 IU).
Data from six trials could not be included in the analysis of ’any
vitamins versus no or minimal vitamins’ because the trials either
had more than two treatment arms or compared one or more vita-
min interventions with each other. For example, one trial (Fawzi
1998) using a 2 x 2 factorial design compared vitamin A supple-
ments with or without multivitamins versus multivitamins (ex-
cluding vitamin A) or placebo. However, results were not explicitly
presented for each group. Similarly, two trials (Kumwenda 2002;
Schmidt 2001) compared vitamin A supplements with iron and
folate versus iron and folate alone, and one trial with five treatment
arms (Christian 2003) compared multivitamins with iron, folate
and vitamin A verus iron, folate and vitamin A alone. Other trials
compared folic acid alone with multivitamins plus folic acid or
multivitamins excluding folic acid (Kirke 1992) or multivitamins
with vitamin E compared with multivitamins without vitamin E
(Rush 1980). Data from these trials were used only in the sub-
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analyses according to vitamin type as none of the treatment arms
were comparable to the control groups used in the trials included
in the ’any vitamins versus no or minimal vitamins’ comparisons.
Outcomes
Main outcomes
Fifteen trials reported either pregnancy loss as miscarriage or still-
birth. Two trials (Christian 2003; Correia 1982) were included as
they reported main outcomes (perinatal death, neonatal death, in-
fant death, preterm birth, birthweight, small-for-gestational age),
however, information on miscarriage or stillbirth was either not
reported separately or at all. The outcome ’total fetal loss’ in-
cluded both miscarriage or stillbirth, and overcame problems with
different definitions of miscarriage and stillbirth. For some tri-
als, miscarriage was considered to occur up until 26 or 28 weeks’
gestation, while other studies reported miscarriage as pregnancy
loss prior to 20 weeks’ gestation, and stillbirth as pregnancy loss
greater or equal to 20 weeks’ gestation. Other studies did not
specify their definition of miscarriage or stillbirth. For the other
main outcomes for the mother, one trial reported placental abrup-
tion (Chappell 1999), and another trial (Steyn 2003) reported
antepartum haemorrhage including placental abruption. Four tri-
als (Chappell 1999; Fleming 1968; People’s League 1942; Steyn
2003) reported pre-eclampsia or ’toxaemia’, no trials reported
any psychological effects. For the infant, perinatal death was re-
ported in two trials (Christian 2003; Steyn 2003), neonatal death
in six trials (Christian 2003; Czeizel 1994; Katz 2000; People’s
League 1942; Rush 1980; Steyn 2003), preterm birth in seven tri-
als (Chappell 1999; Christian 2003; Czeizel 1994; Fleming 1968;
Katz 2000; Rush 1980; Steyn 2003), birthweight in four trials
(Christian 2003; Correia 1982; Czeizel 1994; Kumwenda 2002),
small-for-gestational age in six trials (Chappell 1999; Christian
2003; Czeizel 1994b; Fawzi 1998; Fleming 1968; ICMR 2000)
and congenital malformations in three trials (Czeizel 1994; Kirke
1992; MRC 1991). In this review, congenital malformations cov-
eredmalformations excluding neural tube defects, as these are cov-
ered in the Cochrane review ’Periconceptional supplementation
with folate and/or multivitamins for preventing neural tube de-
fects’ (Lumley 2001b).
Other outcomes
Five trials reported multiple pregnancy (Czeizel 1994b; Fleming
1968; ICMR 2000; Katz 2000; Kumwenda 2002), one trial re-
ported very preterm birth (Steyn 2003), one trial reported in-
fant anaemia at six weeks and 12 months (Kumwenda 2002),
one trial reported placental weight (Correia 1982) and another
trial reported on weight and length at six weeks and four months
(Kumwenda 2002). One trial also reported on mode of feeding as
the number of women breastfeeding (People’s League 1942). The
following outcomes were not reported by any of the trials: Ap-
gar score less than seven at five minutes, use of blood transfusion
for the mother, maternal anaemia, subsequent fertility, disability
at childhood follow up, adverse effects of supplementation, and
maternal views of care. One trial (Steyn 2003) reported on the
duration of admission to the neonatal intensive care unit, how-
ever, no trials reported any other measures of use of health service
resources.
Additional outcomes
One trial (Steyn 2003) reported birthweight as the median birth-
weight and range; however, these data were not in a format suitable
for inclusion in the birthweight comparisons (see Table 1). One
trial (Christian 2003) reported infant death and this outcome has
been included in the ’other outcomes reported’ for the multivita-
min and folic acid comparisons .
Risk of bias in included studies
Randomisation
Two trials (Fleming 1968; People’s League 1942) used quasi-ran-
dom allocation methods involving alternate allocation of partici-
pants. Similarly, two trials (Christian 2003; Katz 2000) used clus-
ter randomisation to allocate subdistricts within Nepal to each
treatment arm and randomised women by “drawing numbered
identical chits from a hat, blocked on subdistrict”.
Allocation concealment
Concealment of allocation was reported in five trials by either the
use of opaque sealed envelopes (Kirke 1992) or third party ran-
domisation, where participants were randomly allocated to each
group either by an individual not directly involved in the re-
search or via telephone or computer allocation (Chappell 1999;
Kumwenda 2002; MRC 1991; Steyn 2003). Of the remaining
twelve trials, the degree of concealment was unclear for ten tri-
als including the two cluster trials (Briscoe 1959; Christian 2003;
Correia 1982; Czeizel 1994; Fawzi 1998; Hemmi 2003; ICMR
2000; Katz 2000; Rush 1980; Schmidt 2001) and for two trials
was inadequate (Fleming 1968; People’s League 1942).
Losses to follow up
Two trials did not report on losses to follow up (Briscoe 1959;
Steyn 2003). Where reported, losses to follow up were less than
three per cent for four trials (Chappell 1999; Czeizel 1994; Katz
2000; Kirke 1992), three to 9.9 per cent for two trials (Fawzi 1998;
MRC1991) and ten to 19.9 per cent for five trials (Christian 2003;
Hemmi 2003; Kumwenda 2002; People’s League 1942; Schmidt
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2001). Four trials (Correia 1982; Fleming 1968; ICMR 2000;
Rush 1980) had greater than 20 per cent of participants excluded.
Blinding
Seven trials reported that women and their carers and/or study
investigators were blinded to the treatment allocation (Briscoe
1959; Chappell 1999; Christian 2003; Fawzi 1998; Fleming 1968;
Katz 2000; MRC 1991); however, few studies explicitly reported
that outcome assessors were blind to the treatment allocation. Four
trials used the term “double blinded” but gave no details (Correia
1982; ICMR 2000; Schmidt 2001, Steyn 2003); for two trials
participants were blinded (Kirke 1992; Kumwenda 2002); and for
four trials it was unclear who, if any, was blinded (Czeizel 1994;
Hemmi 2003; People’s League 1942; Rush 1980).
Use of placebo
A placebo was given in eight trials (Briscoe 1959; Chappell 1999;
Correia 1982; Fawzi 1998; ICMR 2000; Katz 2000; MRC 1991;
Steyn 2003); seven trials gave a control tablet containing ei-
ther trace elements, iron, zinc or other vitamins (Christian 2003;
Czeizel 1994; Fleming 1968; Kirke 1992; Kumwenda 2002; Rush
1980; Schmidt 2001); and two trials used no placebo (Hemmi
2003; People’s League 1942).
Effects of interventions
Seventeen trials are included, involving 35,812women and37,353
pregnancies.
Any vitamins versus no vitamins (or minimal
vitamins)
Primary outcomes
For the outcomes of miscarriage and stillbirth, ten trials con-
tributed data which included 31,167 pregnancies (Briscoe 1959;
Chappell 1999; Czeizel 1994; Fleming 1968; Hemmi 2003;
ICMR 2000; Katz 2000;MRC 1991; People’s League 1942; Steyn
2003). No difference was seen between women given any type
of vitamin(s) compared with controls for total fetal loss (relative
risk (RR) 1.05, 95% confidence interval (CI) 0.95 to 1.15), early
or late miscarriage (RR 1.08, 95% CI 0.95 to 1.24) or stillbirth
(RR 0.85, 95% CI 0.63 to 1.14), using fixed-effect models. These
findings occurred regardless of whether the trials started supple-
mentation prior to pregnancy, in the first twelve weeks of preg-
nancy, before 20 weeks’ gestation or both prior to and after 20
weeks’ gestation. For the other primary outcomes, women given
any type of vitamin(s) compared with controls were less likely to
develop pre-eclampsia (RR 0.68, 95% CI 0.54 to 0.85, four tri-
als, 5580 women (Chappell 1999; Fleming 1968; People’s League
1942; Steyn 2003)). No significant difference was seen between
women given any type of vitamin(s) compared with controls for
placental abruption (RR 0.34, 95% CI 0.04 to 3.19, one trial,
283 women (Chappell 1999)), antepartum haemorrhage includ-
ing placental abruption (RR 7.00, 95% CI 0.88 to 55.86, one
trial, 200 women (Steyn 2003)), perinatal death (RR 0.51, 95%
CI 0.05 to 5.54, one trial, 182 women (Steyn 2003)), neonatal
death (RR 1.12, 95% CI 0.95 to 1.32, four trials, 25,121 women
(Czeizel 1994b; Katz 2000;People’s League 1942; Steyn 2003)),
preterm birth (RR 1.06 95% CI 0.95 to 1.18, five trials, 23,433
women (Chappell 1999; Czeizel 1994; Fleming 1968; Katz 2000;
Steyn 2003)), small-for-gestational-age infants (RR 1.02 95% CI
0.82 to 1.27, four trials, 5406 women (Chappell 1999; Czeizel
1994; Fleming 1968; ICMR 2000)) or congenital malformations
(RR 1.50, 95% CI 0.73 to 3.06, two trials, 6679 women (Czeizel
1994;MRC1991)). Significant heterogeneity was found for birth-
weight. No significant difference was seen between women given
any type of vitamin(s) compared with controls for birthweight
(weighted mean difference (WMD) 140.37 g, 95% CI -160.58 to
441.32, two trials, 4891 women (Correia 1982; Czeizel 1994b))
using a random-effects model.
Secondary outcomes
Women given any type of vitamin(s) compared with controls were
more likely to have a multiple pregnancy (RR 1.38, 95% CI 1.12
to 1.70, three trials, 20,986 women (Czeizel 1994b; ICMR 2000;
Katz 2000)) and greater placental weight (WMD 96.00 g, 95%
CI 30.73 to 161.27, one trial, 29 women (Correia 1982)). No
overall difference was seen between women given any vitamin(s)
compared with controls for the outcomes very preterm birth (RR
1.30, 95% CI 0.78 to 2.17, one trial, 200 women (Steyn 2003)),
the number of women breastfeeding (RR 0.98, 95% CI 0.96 to
1.01, one trial, 4878 women (People’s League 1942)) or the dura-
tion of admission to the neonatal intensive care unit (WMD 1.30
days, 95% CI -0.28 to 2.88, one trial, 181 women (Steyn 2003)).
No other secondary outcomes were reported.
Further analyses by quality rating
Five trials had an allocation concealment rating of ’A’ (Chappell
1999; Kirke 1992; Kumwenda 2002; MRC 1991; Steyn 2003),
ten trials had a rating of ’B’ (Briscoe 1959; Christian 2003; Correia
1982; Czeizel 1994; Fawzi 1998;Hemmi 2003; ICMR2000; Katz
2000; Rush 1980; Schmidt 2001) and two trials had a rating of
’C’ (Fleming 1968; People’s League 1942). A total of ten trials
involving 31,167 women were included in the sensitivity analyses
of primary outcomes based on allocation concealment (Briscoe
1959; Chappell 1999; Czeizel 1994; Fleming 1968;Hemmi 2003;
ICMR 2000; Katz 2000;MRC 1991; People’s League 1942; Steyn
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2003). No difference was seen in total fetal loss between women
supplemented with any vitamins compared with controls for those
trials with an allocation concealment rating of ’A’ (RR 0.98, 95%
CI 0.84 to 1.14, three trials, 2300 women (Chappell 1999; MRC
1991; Steyn 2003)), a rating of ’B’ (RR 1.03, 95%CI 0.98 to 1.09,
five trials, 23,771 women (Briscoe 1959; Czeizel 1994; Hemmi
2003; ICMR 2000; Katz 2000)) or those rated ’C’ (RR 0.92, 95%
CI 0.77 to 1.10, two trials, 5096 women (Fleming 1968; People’s
League 1942)). Similarly, no difference was seen between women
supplemented with any vitamins compared with controls for early
or late miscarriage or stillbirth for any of the comparisons based
on allocation rating.
Further analyses by use of placebo
Ten trials used a placebo or trace element control (Briscoe 1959;
Chappell 1999; Correia 1982; Czeizel 1994; Fawzi 1998; Fleming
1968; ICMR 2000; Katz 2000; MRC 1991; Steyn 2003), five tri-
als compared different combinations of vitamins (Christian 2003;
Fawzi 1998; Kumwenda 2002; Rush 1980; Schmidt 2001) and
two trials used no placebo control (Hemmi 2003; People’s League
1942). No difference was seen between women given any vitamins
compared with controls for total fetal loss for those trials using
a placebo (RR 1.03, 95% CI 0.98 to 1.08, eight trials, 26,122
women (Briscoe 1959; Chappell 1999; Czeizel 1994; Fleming
1968; ICMR 2000; Katz 2000; MRC 1991; Steyn 2003)) and for
those trials with no placebo (RR 0.92, 95% CI 0.77 to 1.10, two
trials, 5045 women (Hemmi 2003; People’s League 1942)). Sim-
ilarly no difference was seen between women given any vitamins
compared with controls for early or late miscarriage or stillbirth
for any of the comparisons based on use of placebo.
Further analyses by losses to follow up
Three trials reported less than three per cent losses to follow up
(Chappell 1999; Czeizel 1994; Katz 2000), one trial reported three
to less than 10 per cent losses to follow up (MRC 1991), two
trials reported between ten and less than twenty per cent losses
to follow up (Hemmi 2003; People’s League 1942), two trials
reported over twenty per cent losses to follow up (Fleming 1968;
ICMR 2000) and two trials did not state any losses to follow
up (Briscoe 1959; Steyn 2003). No difference was seen between
women given any vitamins compared with controls for total fetal
loss for any of the comparisons based on the percentage of losses
to follow up reported. Similarly, no difference was seen between
women supplemented with any vitamins compared with controls
for early or late miscarriage or stillbirth for any of the comparisons
based on losses to follow up.
Vitamin C supplementation
The trials involving vitamin C supplementation included the fol-
lowing interventions: vitaminC plusmultivitamins versus placebo
plus multivitamins (Briscoe 1959), vitamin C and vitamin E sup-
plementation versus placebo (Chappell 1999) and vitaminC alone
versus no supplement or placebo (Hemmi 2003; Steyn 2003). No
significant difference was seen in the risk of total fetal loss be-
tween women receiving vitamin C with multivitamins compared
with placebo plus multivitamins (RR 1.32, 95% CI 0.63 to 2.77,
one trial, 406 women (Briscoe 1959)), vitamin C and vitamin
E compared with placebo (RR 0.50, 95% CI 0.05 to 5.49, one
trial, 283 women (Chappell 1999)) or vitamin C compared with
no supplement or placebo (RR 1.28, 95% CI 0.58 to 2.83, two
trials, 224 women (Hemmi 2003; Steyn 2003)). Similarly, there
was no overall difference seen in early or late miscarriage between
women receiving vitamin C with multivitamins compared with
placebo plus multivitamins (RR 1.32, 95% CI 0.63 to 2.77, one
trial, 406 women (Briscoe 1959)) or vitamin C compared with
no supplement or placebo (RR 1.17, 95% CI 0.52 to 2.65, two
trials, 224 women (Hemmi 2003; Steyn 2003)). No significant
difference was seen in the risk of stillbirth between women receiv-
ing vitamin C and vitamin E compared with placebo (RR 0.50,
95% CI 0.05 to 5.49, one trial, 283 women (Chappell 1999))
or vitamin C compared with placebo (RR 3.00, 95% CI 0.12 to
72.77, one trial, 200 women (Steyn 2003)).
For the other primary and secondary outcomes reported, no sig-
nificant difference was seen in the risk of placental abruption be-
tween women receiving vitamin C and vitamin E compared with
placebo (RR 0.34, 95% CI 0.04 to 3.19, one trial, 283 women
(Chappell 1999)), or the risk of antepartum haemorrhage includ-
ing placental abruption between women receiving placebo com-
pared with controls (RR 7.00, 95% CI 0.88 to 55.86, one trial,
200 women (Steyn 2003)). Women were at decreased risk of pre-
eclampsia when they received vitamin C and vitamin E compared
with placebo (RR0.46, 95%CI0.24 to 0.91, one trial, 283women
(Chappell 1999)), but not when they received vitamin C alone
compared with placebo (RR 1.00, 95% CI 0.21 to 4.84, one trial,
200 women (Steyn 2003)). When women were given vitamin C
compared with placebo, there was no significant difference seen
in the risk of perinatal death (RR 0.51, 95% CI 0.05 to 5.54, one
trial, 182 women (Steyn 2003)) or neonatal death (RR 0.69, 95%
CI 0.12 to 4.03, one trial, 181 women (Steyn 2003)). Women
supplemented with vitamin C compared with placebo were at in-
creased risk of having a preterm birth (RR 1.43, 95% CI 1.03 to
1.99, one trial, 200 women (Steyn 2003)); however, no increased
risk of preterm birth was seen when women were given vitamin C
in addition to vitamin E compared with placebo (RR 1.21, 95%
CI 0.38 to 3.87, one trial, 283 women (Chappell 1999)). No sig-
nificant difference was seen in the risk of having a small-for-gesta-
tional-age infant when women were given vitamin C and vitamin
E compared with controls (RR 0.74, 95% CI 0.50 to 1.08, one
trial, 283 women (Chappell 1999)) or in the rate of very preterm
birth betweenwomen receiving vitamin C compared with placebo
(RR 1.30, 95% CI 0.78 to 2.17, one trial, 200 women (Steyn
2003)).
9Vitamin supplementation for preventing miscarriage (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vitamin A supplementation
The trials involving vitamin A supplementation included the
following interventions: vitamin A and/or beta-carotene versus
placebo (Katz 2000), vitamin A with or without multivitamins
versus multivitamins (excluding vitamin A) or placebo (Fawzi
1998) and vitamin A plus iron and folate versus iron and folate
(Kumwenda 2002; Schmidt 2001). No difference was seen in total
fetal loss, betweenwomen given vitamin A compared with placebo
(RR 1.04, 95% CI 0.92 to 1.17, one trial, 11,723 women (Katz
2000)), beta-carotene compared with placebo (RR 1.03, 95% CI
0.91 to 1.16, one trial, 11,303 women (Katz 2000)), vitamin A
compared with beta-carotene (RR 1.01, 95% CI 0.90 to 1.14,
one trial, 11,720 women (Katz 2000)), vitamin A or beta-carotene
compared with placebo (RR 1.05, 95% CI 0.91 to 1.21, one trial,
17,373 women (Katz 2000)), vitamin A with or without multivi-
tamins compared with multivitamins or placebo (RR 0.80, 95%
CI 0.53 to 1.21, one trial, 1074 women (Fawzi 1998)) or vitamin
A with iron and folate compared with iron and folate (RR 1.34,
95% CI 0.67 to 2.65, two trials, 940 women (Kumwenda 2002;
Schmidt 2001)). Similarly, no differences were seen in the rate
of early or late miscarriage, stillbirth, neonatal death or preterm
birth between women given any type of vitamin A, alone or in
combination with beta-carotene, multivitamin or iron and folate,
compared with controls. Infants of women given vitamin A with
iron and folate compared with iron and folate alone had higher
birthweight (WMD 90.00 g, 95% CI 2.68 to 177.32, one trial,
594 women (Kumwenda 2002)). However, no difference was seen
in the number of infants born small-for-gestational age between
women given vitamin A with or without multivitamins compared
with multivitamins or placebo (RR 0.84, 95% CI 0.58 to 1.21,
one trial, 1075 women (Fawzi 1998)).
The rate of multiple pregnancy was higher in women given either
vitaminA or beta-carotene comparedwith placebo (RR1.39, 95%
CI 1.05 to 1.84, one trial, 15,845 women (Katz 2000)). Increases
in the rate of multiple pregnancy were also seen for women given
vitaminA versus placebo (RR1.35, 95%CI 0.99 to 1.85, one trial,
10,697 women (Katz 2000)) and beta-carotene versus placebo
(RR 1.37, 95% CI 1.00 to 1.88, one trial, 10,294 women (Katz
2000)). No difference was seen for vitamin A versus beta-carotene
(RR 1.03, 95% CI 0.77 to 1.37, one trial, 10,699 women (Katz
2000)). No difference was seen in very preterm birth between
women given vitamin A with or without multivitamins compared
with multivitamins or placebo (RR 1.11, 95% CI 0.71 to 1.74,
one trial, 1075 women (Fawzi 1998)). Fewer infants of women
given vitamin A and iron and folate compared with iron and folate
alone had anaemia at six weeks (RR 0.58, 95% CI 0.45 to 0.75,
one trial, 562 infants (Kumwenda 2002)); however, at 12 months,
no difference was seen (RR 1.03, 95% CI 0.88 to 1.20, one trial,
478 infants (Kumwenda 2002)). At six weeks of age, infants of
women given vitamin A and iron and folate compared with iron
and folate alone had greater weight (WMD 169 g, 95% CI 16.55
to 321.45, one trial, 546 infants (Kumwenda 2002)) and length
(WMD 0.70 cm, 95% CI 0.15 to 1.25, one trial, 546 infants
(Kumwenda 2002)); however, at four months of age no significant
difference was seen in weight (WMD -100.00 g, 95% CI -377.14
to 177.14, one trial, 148 infants (Schmidt 2001)) or length (WMD
-0.50 cm, 95% CI -1.33 to 0.33, one trial, 148 infants (Schmidt
2001)).
Multivitamin supplementation
The trials involving multivitamin supplementation included the
following interventions: multivitamins with or without folic acid
versus no multivitamins or folic acid (Czeizel 1994; MRC 1991),
multivitamins with or without folic acid versus folic acid (Kirke
1992; MRC 1991), multivitamins with or without vitamin A ver-
sus vitamin A or placebo (Fawzi 1998), multivitamins versus con-
trol (People’s League 1942), multivitamins with vitamin E versus
multivitaminswithout vitaminE or control (Rush 1980) andmul-
tivitamins with folic acid, iron, zinc and vitamin A versus no mul-
tivitamin and folic acid, iron, zinc, vitamin A (Christian 2003).
Total fetal loss was significantly lower in women who were given
multivitamins with or without vitamin A compared with those re-
ceiving vitamin A or placebo (RR 0.60, 95% CI 0.39 to 0.91, one
trial, 1074 women (Fawzi 1998)).However, given that this finding
has occurred during subgroup analyses, and the comparison group
contains women receiving either vitamin A or placebo, caution
should be taken in interpretation. No other differences were seen
in total fetal loss for women receivingmultivitamins with folic acid
versus no multivitamins or folic acid (RR 1.09, 95% CI 0.95 to
1.25, three trials, 6883 women (Czeizel 1994; ICMR 2000; MRC
1991)), multivitamins without folic acid versus no multivitamins
or folic acid (RR 0.83, 95%CI 0.56 to 1.25, one trial, 907 women
(MRC 1991)), multivitamins with or without folic acid versus no
multivitamins or folic acid (RR 0.91, 95% CI 0.65 to 1.27, one
trial, 1368 women (MRC 1991)), multivitamins with folic acid
versus folic acid (RR 1.03, 95% CI 0.72 to 1.48, two trials, 1096
women (Kirke 1992; MRC 1991)), multivitamins without folic
acid versus folic acid (RR 0.90, 95% CI 0.62 to 1.30, two trials,
1090 women (Kirke 1992; MRC 1991)), multivitamins with or
without folic acid versus folic acid (RR 0.95, 95%CI 0.69 to 1.30,
two trials, 1644 women (Kirke 1992;MRC 1991)), multivitamins
versus control (RR 0.83, 95% CI 0.58 to 1.17, one trial, 5021
women (People’s League 1942)) and multivitamins with vitamin
E versus multivitamins without vitamin E or control (RR 0.92,
95% CI 0.46 to 1.83, one trial, 823 women (Rush 1980)). No
other differences were seen for early or late miscarriage or stillbirth
for any of the multivitamin comparisons.
For the other primary outcomes, women receiving multivitamins
compared with control were at lower risk of pre-eclampsia (RR
0.70, 95% CI 0.55 to 0.90, one trial, 5021 women (People’s
League 1942)). There were no differences demonstrated in the risk
of perinatal death (RR 1.11, 95% CI 0.98 to 1.26, one trial, 4308
women (Christian 2003)) or neonatal death for any of themultivi-
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tamin comparisons.Nodifferencewas seen inpretermbirth, birth-
weight, congenital malformations, maternal anaemia, the number
of women breastfeeding or infant death, between women given
multivitamins alone or with folic acid, vitamin A, vitamin E or
iron and zinc compared with controls. A small reduction was
demonstrated for the risk of having an infant with birthweight less
than 2500 g for women receiving multivitamins with folic acid,
iron, zinc and vitamin A versus folic acid, iron, zinc, vitamin A
and no multivitamin (RR 0.95, 95% CI 0.90 to 1.00, one trial,
3325 women (Christian 2003); however, no difference was seen
in small-for-gestational-age infants when defined as birthweight
less than the 10th centile or birthweight less than 2500 g, between
women receiving other combinations of multivitamins. Women
given multivitamins with folic acid compared with no multivita-
mins or folic acid were more likely to have a multiple pregnancy
(RR 1.36, 95% CI 1.00 to 1.85, two trials, 5141 women (Czeizel
1994b; ICMR 2000)).
Folic acid supplementation
The trials involving folic acid supplementation included the fol-
lowing interventions: folic acid with or without multivitamins
compared with no folic acid or multivitamins (Czeizel 1994;
ICMR 2000; MRC 1991), folic acid with or without multivi-
tamins compared with multivitamins (Kirke 1992; MRC 1991),
folic acid with iron, zinc, multivitamins and vitamin A compared
with vitamin A alone (Christian 2003), folic acid and iron com-
pared with iron (Fleming 1968) and folic acid compared with
placebo (Correia 1982). No significant difference was seen in the
risk of total fetal loss between women receiving folic acid with
multivitamins compared with no folic acid or multivitamins (RR
1.09, 95% CI 0.95 to 1.25, three trials, 6883 women (Czeizel
1994; ICMR 2000; MRC 1991)); folic acid without multivita-
mins compared with no folic acid or multivitamins (RR 0.95,
95% CI 0.64 to 1.40, one trial, 903 women (MRC 1991)); folic
acid with or without multivitamins compared with no folic acid
or multivitamins (RR 0.97, 95% CI 0.69 to 1.35, one trial, 1364
women (MRC 1991)); folic acid with multivitamins compared
with multivitamins (RR 1.15, 95% CI 0.80 to 1.67, two trials,
1102 women (Kirke 1992; MRC 1991)); folic acid without mul-
tivitamins compared with multivitamins (RR 1.12, 95% CI 0.77
to 1.62, two trials, 1090 women (Kirke 1992; MRC 1991)); folic
acid with or without multivitamins compared with multivitamins
(RR 1.14, 95% CI 0.82 to 1.57, two trials, 1644 women (Kirke
1992; MRC 1991)); and folic acid with iron compared with iron
(RR 0.23, 95% CI 0.01 to 4.59, one trial, 75 women (Fleming
1968)). No differences were seen in the risk of early or late mis-
carriage, stillbirth, pre-eclampsia, perinatal death, neonatal death,
preterm birth, small-for-gestational-age infants (birthweight less
than 10th centile), congenital malformations or infant death be-
tweenwomen given folic acid, alone or withmultivitamins or iron,
compared with controls.
Women given folic acid compared with placebo had a greater pla-
cental weight (WMD 96 g, 95% CI 30.73 to 161.27, one trial,
29 women (Correia 1982)), their infants had greater birthweight
(WMD 312 g, 95% CI 108.52 to 515.48, one trial, 29 women
(Correia 1982)); however, no difference was seen in birthweight
betweenwomen given folic acid andmultivitamins comparedwith
no folic acid or multivitamins (WMD 3.00 g, 95% CI -24.15 to
30.15, one trial, 4862 women (Czeizel 1994)). Women receiving
folic acid with iron, zinc, multivitamins and vitamin A compared
with vitamin A alone were less likely to have an infant with a birth-
weight less than 2500 g (RR 0.94, 95% CI 0.90 to 0.99, one trial,
3325 women (Christian 2003)); however, no differences were seen
in birthweight less than 2500 g for women any of the other folic
acid comparisons. Women receiving folic acid and multivitamins
compared with no folic acid or multivitamins were more likely to
have a multiple pregnancy (RR 1.36, 95% CI 1.00 to 1.85, two
trials, 5141 women (Czeizel 1994b; ICMR 2000)). Fewer women
given folic acid with iron, zinc, multivitamins and vitamin A com-
pared with vitamin A alone had anaemia in the third trimester
(RR 0.83, 95% CI 0.77 to 0.91, one trial, 813 women (Christian
2003)); however, there no differences were seen for any of the folic
acid comparisons for severe maternal anaemia.
Subgroup analyses by women’s risk of spontaneous or
recurrent miscarriage
Information enabling women to be classified at high or low risk of
either spontaneous miscarriage or recurrent miscarriage was not
clearly stated in any of the trials. One trial (Briscoe 1959) included
women they termed ’habitual aborters’ (i.e. experienced recurrent
miscarriage) as well as women at high risk of miscarriage (more
than two previous miscarriages and/or bleeding in the pregnancy)
and low-risk women (two or less previous miscarriages and no
bleeding in the pregnancy). After classifying women into these
groups, the number of women in each group was too small to per-
mit any meaningful comparisons and subanalyses were therefore
not performed.
Subgroup analyses by dose of vitamins and duration
of vitamin usage
Subgroup analyses by dose of vitamin(s) (below or above the rec-
ommended dietary intake) were complicated by the limited num-
ber of studies in each vitamin group, and by the use of multivi-
tamin supplements. For many of the vitamin types and for those
reporting pregnancy loss outcomes, all of the trials supplemented
women with amounts that were above the recommended dietary
intake. Similarly, the durationof vitaminusagewas complicated by
the fact that many of the trials had wide recruitment periods, and
one trial (Katz 2000) supplemented women up until three years
postpartum. Subgroup analyses were therefore not performed.
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Subgroup analyses by dietary intake of vitamins
Five trials (Fleming 1968;Kumwenda 2002; People’s League 1942;
Schmidt 2001; Steyn 2003) reported information about women’s
nutritional status or the percentage of women that were dietary
deficient at trial entry for the vitamin of interest. There were not
enough trials within each vitamin group to assess the role of sup-
plementation in women with dietary deficient intakes of the indi-
vidual vitamins and results were not reported separately for women
with a low dietary vitamin intake; therefore, no subgroup analyses
could be performed.
D I S C U S S I O N
We did not find any evidence to support the use of any vitamins
for preventing either early or late miscarriage or stillbirth.Women
given multivitamins with or without vitamin A compared with
those receiving vitamin A alone or placebo, were at lower risk of
’total fetal loss’. However, given this finding occurred in additional
analyses by type of vitamin and the control group involved either
vitamin A supplementation or placebo, there should be caution
when interpreting these findings. Similarly, the Cochrane review
’Vitamin A supplementation during pregnancy’ found no benefit
for the risk of perinatal mortality with vitamin A supplementation
(van den Broek 2002). For the other primary outcomes, supple-
menting women with any vitamins was associated with a signif-
icant reduction in the risk of pre-eclampsia, both when women
were given vitamin C and E supplements, and when women were
supplemented with multivitamins. The role of vitamins in the
prevention of pre-eclampsia is explored in the Cochrane review
’Antioxidants for preventing pre-eclampsia’ (Rumbold 2003). Sig-
nificant heterogeneity was detected for birthweight in the com-
parisons of ’any vitamin versus no or minimal vitamins’. One ex-
planation for finding heterogeneity may be in the combination
of all trials regardless of vitamin type. When subgroup analyses
were conducted by individual vitamin type, heterogeneity was no
longer apparent for birthweight.
Women given any vitamins alone or in combination with other
vitamins were more likely to have a multiple pregnancy. These
differences persisted in the additional analyses by type of vitamin,
whereby vitamin A, multivitamins and folic acid were found to
be associated with an increase in multiple pregnancy. These find-
ings are in agreement with the Cochrane review ’Periconceptional
supplementation with folate and/or multivitamins for preventing
neural tube defects’ (Lumley 2001b), as well as a re-analysis of
individual trial data (Czeizel 1994b) and several other large co-
hort studies on the rate of twinning amongst users of multivita-
mins and folic acid (Ericson 2001), and after food fortification
with folic acid (Waller 2003). The potential mechanisms of ac-
tion behind the vitamins and their impact on multiple pregnancy
are not well understood, although there is some speculation that
the vitamins may influence the rate of twinning rather than im-
proving the survival of multiple fetuses (Katz 2001). An increase
in multiple pregnancy along with increases in perinatal morbidity
and mortality is of concern, however, as direct causality is yet to
be established, further monitoring of pre and peri-conceptional
vitamin supplementation is required.
For the individual vitamins, vitamin C supplementation was as-
sociated with a small increase in the risk of preterm birth. One
trial, involving 200 women at high risk of giving birth preterm,
contributed data for this outcome. The authors of this trial con-
cluded that the increase in preterm birth in the vitamin group did
not translate into poorer neonatal outcome (Steyn 2003). Further
studies are required before any recommendations can be made re-
garding vitamin C supplementation. Vitamin A supplementation
was associated with small increases in birthweight, infant weight
and length at six weeks’ of age, and decreases in infant anaemia at
six weeks’ of age. Similarly folic acid supplementation was associ-
ated with increases in placental weight and birthweight. However,
the differences in birthweight and infant growth observed were
small and may not be clinically relevant. Many of these findings
include data contributed from small individual trials, hence read-
ers should be cautioned from drawing any firm conclusions from
results of single trials often with small sample sizes.
The review included trials that randomised women prior to con-
ception, however, in some cases, not all women enrolled in these
trials fell pregnant during the study period. Some of the trials re-
ported outcomes only for women falling pregnant, whereas other
trials did not distinguish betweenwomen that were never pregnant
and women that may have been pregnant but were lost to follow
up. The outcomes in this review relating to pregnancy complica-
tions are not relevant for the women that never became pregnant
during the study period. In this review, where trials provided ac-
curate information about the number of women who joined the
study and became pregnant in the time period, we included this
number in the totals, rather than the number of women that may
have been randomised. Where it was not clear about the exact
number of women with a confirmed pregnancy, we included all
women that had been randomised. This may therefore mean that
women in the denominator were never pregnant during the study
period. By including these women who were never pregnant in
the totals, the review assumes that if these women had become
pregnant, theywould not have had amiscarriage, which is unlikely
to be entirely correct. Including these women creates the potential
to underestimate any treatment effects observed.
Similarly, for one large trial (Katz 2000), some women were preg-
nant more than once during the study period. In this trial, the
denominators reported are the total number of pregnancies dur-
ing the study period, not the total number of women randomised,
which incorrectly assumes that each data point included is inde-
pendent from the next. This has the potential to either under-
estimate or overestimate the results, depending on whether the
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women contributing data for more than one pregnancy may be
more or less susceptible to experiencing miscarriage or stillbirth.
One way to overcome this may be to summarise the data for each
woman so that there is only one set of data points for each woman;
however, we were unable to do this for this particular study.
Many of the trials included in the review were not of high quality,
either due to poor allocation concealment or large losses to follow
up, which increases the risk of bias in the results. The data were
also complicated by differing definitions of miscarriage. For some
trials, miscarriage was considered to occur up until 26 or 28 weeks’
gestation, while other studies reported miscarriage as pregnancy
loss prior to 20 weeks’ gestation, and stillbirth as pregnancy loss
greater or equal to 20 weeks’ gestation. Other studies did not
specify their definition of miscarriage or stillbirth. In addition to
the problems with differing definitions, the timing of the onset of
vitamin supplementation for some of the included trials occurred
inmid pregnancy, whichmay limit the impact of supplementation
on the risk ofmiscarriage. The review attempted to overcome these
issues by using the outcome ’total fetal loss’, which included either
miscarriage or stillbirth.
Few studies recorded or reported any information about side-ef-
fects of vitamin supplementation, and the currently available evi-
dence shows nomaternal or infant adverse health effects of vitamin
supplementation. No trials reported on any potential psychologi-
cal effects such as anxiety and depression, for women experiencing
miscarriage or stillbirth.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Any vitamins, alone or in combination with other vitamins do not
help prevent either early or late miscarriage or stillbirth. Supple-
menting women with multivitamins, with or without folic acid,
may increase the risk of having a multiple birth, which may con-
fer increases in perinatal morbidity and mortality. Supplementa-
tion with any vitamins was associated with a reduced risk of pre-
eclampsia, and for vitaminA,multivitamins and folic acid,modest
increases in birthweight and measures of infant growth were seen;
however, further studies are required to confirm these findings.
Implications for research
The impact of vitamin supplementation on birthweight and mea-
sures of infant growth is unclear. Any future studies of vitamin
supplementation should focus on women at high risk of miscar-
riage, assess the most appropriate vitamin type and dosage, show
it is beneficial without causing any harms to the mother or fetus
and include assessments of any psychological effects.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Briscoe 1959
Methods Randomisation and allocation concealment: unclear, no methodological details given, dubious as the
number of women allocated to the treatment group was more than double that allocated to the placebo
group. “Unselected patients were each given 200 capsules... these were given a code, unknown to us and
contained either an inert powder or 100 mg each of ascorbic acid and hesperidin.”
Blinding of outcome assessment: women and study investigators did not know the treatment codes
Documentation of exclusion: none reported.
Use of placebo control: placebo given; however, all women received an additionalmultivitamin supplement
Participants 406 women were recruited in the study. Eligible women were “unselected patients” in private obstetrics
care, that were less than or equal to 10 weeks’ pregnant, and were eligible regardless of whether they were
currently bleeding or the number of previous pregnancies. Women greater than 10 weeks’ gestation were
excluded. 406 women were randomised to either vitamin C (n = 303) or placebo (n = 103) no losses to
follow up were reported. 77 women in the study had more than 2 previous miscarriages and/or bleeding
in the pregnancy, and 329 had 2 or less miscarriages and no bleeding in the pregnancy
Interventions All women were given 200 tablets, containing either 100 mg each of ascorbic acid and hesperidin or
placebo (an inert powder).
The study lasted for 7 weeks. For the first two weeks, women were asked to take 8 tablets daily (i.e. daily
800 mg each of vitamin C and hesperidin or placebo). For the following 5 weeks, women took 4 tablets
daily (i.e. daily 400 mg each of vitamin C and hesperidin or placebo). All women received a multiple
vitamin supplement containing 50 mg vitamin C
Outcomes 1. Spontaneous miscarriage.
2. Spontaneous miscarriage in women with 2 or fewer previous miscarriages and no bleeding in the current
pregnancy.
3. Spontaneous miscarriage in women with more than 2 previous miscarriages and/or bleeding in the
current pregnancy.
4. Spontaneous miscarriage in women who experienced recurrent miscarriage
Notes Women’s risk of spontaneous and recurrent miscarriage is unclear, as there is no information about
concurrent medical conditions or other risk factors for miscarriage. 9 of the 406 women were classified as
experiencing recurrent miscarriage.
No information is available about women’s nutritional status.
No sample-size calculation reported.
Intention-to-treat analyses performed (no losses to follow up reported).
Compliance: no compliance information reported.
Location: Philadelphia, USA.
Timeframe: unclear.
Risk of bias
Item Authors’ judgement Description
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Briscoe 1959 (Continued)
Allocation concealment? Unclear B - Unclear
Chappell 1999
Methods Randomisation and allocation concealment: a computer-generated randomisation list using blocks of
10 was given to the hospital pharmacy departments. Researchers allocated the next available number to
participants and women collected the trial tablets from the pharmacy department
Blinding of outcome assessment: women, caregivers and researchers were blinded to the treatment allo-
cation until recruitment, data collection and laboratory analyses were complete
Documentation of exclusion: 123 (43.5%) women were excluded, of which, 70 women were withdrawn
because their second Doppler scan was normal. Pregnancy outcome data were reported for all women
randomised
Use of placebo control: placebo control.
Participants 283 women were recruited into the study. Inclusion criteria: abnormal Doppler waveform in either uterine
artery at 18-22 weeks’ gestation or a history in the preceding pregnancy of pre-eclampsia necessitating
delivery before 37 weeks’ gestation, eclampsia or the syndrome of HELLP.
Exclusion criteria: heparin or warfarin treatment, abnormal fetal-anomaly scan or multiple pregnancy.
Women were randomised at 18-22 weeks’ gestation; however, women with a previous history who were
identified at an earlier stage were randomised at 16 weeks’ gestation. Women with abnormal Doppler
waveform analysis returned for a second scan at 24 weeks’ gestation, those with a normal waveform at this
time stopped treatment and were withdrawn from the study. The remaining women who had persistently
abnormal waveforms, and those with a previous history or pre-eclampsia remained in the study and were
seen every 4 weeks through the rest of pregnancy. 1512 women underwent Doppler screening, 273 women
had abnormal waveforms and of these, 242 women consented to the study. An additional 41 women
who had a history of pre-eclampsia consented. 283 women were randomised to either the vitamin C and
E group (n = 141) or the placebo group (n = 142), 72 women had normal Doppler scans at 24 weeks’
gestation and 24 women did not return for a second scan and were withdrawn. A further 27 women
withdrew from the trial after 24 weeks’ gestation for various reasons. In total, 160 women completed the
trial protocol until delivery, 79 in the vitamin C and E group and 81 in the placebo group. Pregnancy
outcome data were presented for all women randomised (n = 283) as well as only for those women
completing the trial protocol (n = 160)
Interventions Women randomised to the vitamin C and E group received tablets containing 1000 mg vitamin C daily
and capsules containing 400 IU vitamin E daily.
Women randomised to the placebo group received tablets containing microcrystalline cellulose and soya
bean oil, that were identical in appearance to the vitamin C tablets and vitamin E capsules. After 24 weeks’
gestation women were seen every 4 weeks, and blood samples were taken at each visit
Outcomes 1. Ratio of PAI-1 to PAI-2.
2. Incidence of pre-eclampsia.
3. Placental abruption.
4. Spontaneous preterm delivery (< 37 weeks).
5. Intrauterine death.
6. Small-for-gestational-age infants (on or below the 10th centile).
7. Mean systolic and diastolic blood pressure before delivery.
8. Gestational age at delivery (median, IQR).
9. Birthweight (median, IQR).
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Chappell 1999 (Continued)
10. Birthweight centile (median, IQR).
Notes Women’s risk of spontaneous and recurrent miscarriage is unclear, women were at high risk of pre-
eclampsia.
No information is available about women’s nutritional status.
Sample-size calculation reported, based on a 30% reduction in PAI-1.
Intention-to-treat analyses performed.
Compliance: “within the treated group, plasma ascorbic acid concentration increased by 32%frombaseline
values and plasma alpha-tocopherol increased by 54%”.
Location: London, UK.
Timeframe: unclear.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Christian 2003
Methods Randomisation and allocation concealment: cluster randomisation of 30 “village development communi-
ties” using blocks of 5 within each community, randomisation occurred by “drawing numbered identical
chits from a hat”
Blinding of outcome assessment: women, field staff, investigators and statisticians did not know the
treatment codes until the end of the study
Documentation of exclusion: 534 (10.7%) women or infants were excluded and 343 (6.7%) infants were
lost to follow up
Use of placebo control: no placebo given, women in the control group were given vitamin A only
Participants All women of reproductive age in the 30 village development communities were considered eligible.
Women who were currently pregnant, breastfeeding a baby < 9 months’ old, menopausal, sterilised or
widowed were excluded.
Within the timeframe, 14,185 women were identified as likely to become pregnant. Of these, 4998
pregnancies were confirmed with urine testing; however, 4926 women remained in the trial with 72
women excluded either due to false positive pregnancy testing, unknown outcomes or induced abortions.
Women were allocated to either vitamin A control (n = 1037), folic acid (n = 929), folic acid-iron (n = 940)
, folic acid-iron-zinc (n = 982) or multiple micronutrients (n = 1038). 830 pregnancies (16.8%) ended in
either miscarriage, stillbirth or maternal death. The remaining pregnancies resulted in 4130 livebirths. Of
these, 805 (19.5%) were excluded as they were either lost to follow up or birthweight was measured after
72 hours after birth. The final analysis involved 3325 infants allocated to control (n = 685), folic acid (n
= 628), folic acid-iron (n = 635), folic acid-iron-zinc (n = 672) or multiple micronutrients (n = 705)
Interventions Women were allocated to one of five groups:
1. control (1000 mcg vitamin A);
2. folic acid (400 mcg, 1000 mcg vitamin A);
3. folic acid-iron (60 mg ferrous fumarate, 400 mcg folic acid, 1000 mcg vitamin A);
4. folic acid-iron-zinc (30mg zinc sulphate, 60mg ferrous fumarate, 400mcg folic acid, 1000 mcg vitamin
A);
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Christian 2003 (Continued)
5. multiple micronutrients-folic acid-iron-zinc (60 mg ferrous fumarate, 400 mcg folic acid, 30 mg zinc
sulphate,1000 mcg vitamin A, 10 mcg vitamin D,10 mg vitamin E, 1.6 mg vitamin B-1, 1.8 mg vitamin
B-2, 20 mg niacin, 2.2 mg vitamin B-6, 2.6 mcg vitamin B12, 100 mg vitamin C, 65 mcg vitamin K, 2.
0 mg copper, 100 mg magnesium).
At enrolment women received 15 caplets and were instructed to take one caplet every night. Women were
then visited by field staff twice a week to monitor compliance and replenish supplies of the caplets
Outcomes 1. Perinatal death, defined as stillbirths (gestational age >= 28 wk) and deaths among liveborn infants in
the first 7 days of life.
2. Neonatal deaths, defined as deaths from 0 to 28 days of life.
3. Infant death, defined as deaths from 0 to 90 days of life.
4. Birthweight.
5. Length.
6. Chest circumference.
7. Head circumference.
8. Low birthweight (< 2500 g).
9. Small-for-gestational age (below 10th centile for USA national reference for fetal growth).
10. Preterm birth (< 37 weeks).
“The rate if miscarriage did not differ by treatment group and ranged between 12% and 15% (data not
show)”. “Miscarriage was defined as a pregnancy that ended in a fetal loss before 28 wk of gestation.”
Notes The following information was given about multiple births: “the numbers of twin pregnancies (34 pairs
of liveborn twins and 8 pairs with one stillborn) was comparable across treatment groups”.
Women’s risk of spontaneous and recurrent miscarriage is unclear, as there is no information about
concurrent medical conditions or other risk factors for miscarriage.
Information on women’s diet was recorded; however, no information was reported about micronutrient
intake, including vitamin A.
Sample-size calculation reported, 1000 pregnancies per group allowed for aminimumdetectable difference
of 75 g in birthweight, and >= 34% reduction in fetal loss and >= 45% reduction in infant mortality, with
80% power.
Intention-to-treat analyses performed and the relative risks and confidence intervals were adjusted to
account for any cluster design effect.
Compliance: median compliance during pregnancy was 88%.
Location: Salarhi, Nepal.
Timeframe: December 1998-April 2001.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Correia 1982
Methods Randomisation and allocation concealment: unclear, “randomised” stated in text but no details given
Blinding of outcome assessment: “double blind clinical test” stated in the text
Documentation of exclusion: 16 women (35%) excluded.
Use of placebo control: placebo control.
Participants 45 women were initially recruited into the study; however, results are presented for 29 women (folic acid
group n = 16, placebo group n = 13). Women were excluded if they had any “pathological data” or if there
was “evidence of neglect”. No other details given
Interventions Women were randomised to either daily ingestion of 10 mg folic acid or placebo. Women were asked to
take the tablets from between 12 and 16 weeks until the end of pregnancy
Outcomes 1. Fetal weight (birthweight).
2. Placental weight.
Notes Women risk of spontaneous and recurrentmiscarriage is unclear.Women’s nutritional status is also unclear.
No sample-size calculation reported.
Compliance: unclear, no details given.
Country: Portugal.
Timeframe: unknown.
Published in Portuguese.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Czeizel 1994
Methods Randomisation and allocation concealment: unclear, “women agreed to their allocation on the basis of a
random table”
Blinding of outcome assessment: unclear, women were aware of the “blind use of one of two kinds of
tablets”, but no other details given
Documentation of exclusion: 49 women (1%) were lost to follow up and excluded
Use of placebo control: “trace element control” given.
Participants 7765 women were recruited into the study. Women participating in the HOFPP who volunteered to take
part, were not currently pregnant, and who conceived within 12 months of ceasing contraception. In the
first two years of the HOFPP, women were also required to be aged < 35 years, and not to have had a
previous pregnancy except a prior induced abortion. 7905 women were approached, of which 140 refused
participation, 7765 were randomised and 5502 women had a confirmed pregnancy and were allocated
to either multivitamins (n = 2819) or control (n = 2683). 49 women of the 5502 confirmed pregnancies
were lost to follow up
Interventions Womenwere providedwithmultivitamin or trace element ’control’ from at least 28 days before conception
continuing until at least the second missed menstrual period.
The multivitamin with folate contained 6000 IU vitamin A, 1.6 mg vitamin B1, 1.8 mg vitamin B2, 2.6
24Vitamin supplementation for preventing miscarriage (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Czeizel 1994 (Continued)
mg vitamin B6, 4.0 mcg vitamin B12, 100 mg vitamin C, 500 IU vitamin D, 15 mg vitamin E, 19 mg
nicotinamide, 10 mg calcium pantothenate, 0.2 mg biotin, 0.8 mg folic acid, 125 mg calcium, 125 mg
phosphorus, 100 mg magnesium, 60 mg iron, 1 mg copper, 1 mg manganese, 7.5 mg zinc.
The trace element control contained 7.5 mg vitamin C, 1 mg copper, 1 mg manganese and 7.5 mg zinc
Outcomes 1. Neural tube defects and other birth defects.
2. Miscarriage.
3. Ectopic pregnancy.
4. Termination of pregnancy.
5. Live births.
6. Stillbirths.
7. Multiple gestation.
Subgroup data is available on menstrual cycle, first trimester symptoms and sexual activity
Notes Women’s risk of spontaneous and recurrent miscarriage is unclear.
Information on their dietary status is unknown.
No sample-size calculation reported.
Partial intention-to-treat analyses performed.
Compliance: compliance was assessed by questioning, checking the tick-off on the basal temperature chart
and counting of unused tablets. 70% of women in the multivitamin group and 71% in the control group
took the full course of the supplements, with an additional 20% and 21% in the multivitamin and control
groups respectively receiving a partial course of supplementation.
Location: Hungary.
Time frame: 1 February 1984-30 April 1992.
The denominators used for this trial are the number ofwomen randomised andwith a confirmedpregnancy
(i.e. 2819 for the multivitamin group and 2683 for the control group)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Fawzi 1998
Methods Randomisation and allocation concealment: block randomisation using blocks of 20, eligible women were
“assigned the next numbered bottle of regimen”. The study used a 2 by 2 factorial design and women were
randomised to 1 of 4 groups. Tablets were indistinguishable and packaged in identically coded bottles
Blinding of outcome assessment: women and study investigators were unaware of the treatment allocation,
no information given about blinding of outcome assessors
Documentation of exclusion: 64 women (6%) were lost to follow up and excluded
Use of placebo control: placebo given.
Participants 1085 women were recruited into the study. Pregnant women between 12 and 27 weeks’ gestation who
were HIV-1 infected, living in Dar es Salaam and intended to stay there for at least one year were eligible
for the study. Women not HIV-1 positive or moving out of Dar es Salaamwere excluded. 13,879 pregnant
women consented to be HIV-1 tested, of which 1806 were positive, and 1085 were randomised. Of these,
3 women were not pregnant and 7 women died before delivery and were excluded from the trial. Of the
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Fawzi 1998 (Continued)
remaining 1075 women, 54 women (5%) were lost to follow up by the time of delivery, leaving birth
outcomes reported for 1021 women. Women were randomised to 1 of 4 groups: vitamin A (n = 269),
multivitamins excluding vitamin A (n = 269); multivitamins including vitamin A (n = 270) or placebo (n
= 267)
Interventions Women were randomised to 1 of 4 groups:
1. vitamin A (30 mg beta-carotene plus 5000 IU preformed vitamin A);
2. multivitamins excluding vitamin A (20 mg vitamin B1, 20 mg vitamin B2, 25 mg vitamin B6, 100 mg
niacin, 50 mcg vitamin B12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid);
3. multivitamins including vitamin A, all formulated in 2 tablets; or
4. placebo.
All women received 400mg ferrous sulphate and5mg folate daily, aswell as 500mg chloroquine phosphate
weekly. At delivery, all women taking vitamin A were to receive an additional oral dose of 200,000 IU
vitamin A and the others an extra dose of a placebo. Pill counts were conducted at each visit and new
tablets were given out at each visit
Outcomes 1. Miscarriage, defined as delivery before 28 weeks’ gestation.
2. Stillbirth, defined as delivery of a dead baby at or after 28 weeks’ gestation.
3. Fetal death, defined as either miscarriage or stillbirth.
4. Low birthweight, defined as birthweight less than 2500 g.
5. Very low birthweight, defined as birthweight less than 2000 g.
6. Preterm delivery, defined as delivery before 37 weeks.
7. Severe preterm birth, defined as delivery before 34 weeks.
8. Small-for-gestational age, defined as birth weight less than the 10th percentile for gestational age
Notes Women’s risk of spontaneous and recurrent miscarriage was unclear, although may be increased due to
their HIV-1 positive status.
Women’s nutritional status is also unclear.
Figures change with serial publications, particularly for secondary outcomes, and results are not reported
separately for the individual 4 groups. Results are reported as: any multivitamins, multivitamin, any
vitamin A or no vitamin A.
Sample-size calculation performed allowing for 20% loss to follow up.
Intention-to-treat analyses performed.
Compliance: compliance assessed by the percentage of prescribed tablets absent from the returned bottles,
and in plasma vitamin A concentrations in a subset of 100 women. Median compliance assessed using
pill counts was 90% by the time of delivery.
Location: Tanzania.
Timeframe: April 1995-July 1997.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Fleming 1968
Methods Randomisation and allocation concealment: quasi-randomised, alternate women were allocated to receive
folic acid or placebo according to the order in which they attended antenatal clinic. No other method-
ological details were given
Blinding of outcome assessment: women and investigators were blinded to the treatment allocation, until
after the completion of the trial
Documentation of exclusion: 21 women (28%) excluded from the analysis
Use of placebo control: control tablet containing iron given
Participants 75 women were recruited into the trial. Women were eligible if they were primigravida, less than 26 weeks’
pregnant (range of gestation 10-26 weeks’), with haematocrit value (PCV) 27 per cent or more, and who
had not received treatment so far as was known. Women with Haemoglobin (Hb) SC, Hb.SS, Hb.CC
were excluded. Alternate patients were allocated to group A (placebo) or B (folic acid). 75 women were
included (40 in group A and 35 in group B) initially; however, only 26 in group A and 28 in group B
completed the trial. 16 women (10 in group A and 8 in group B) defaulted from the trial, 3 (2 in group
A and 1 in group B) were anaemic on the second visit warranting folic acid treatment, 1 in group A self
medicated with folic acid and 1 in group A ’aborted’
Interventions All women received antimalarials and iron supplements as per the standard antenatal care at the hospital.
Women in group B received 5 mg folic acid tablets on each attendance, which was fortnightly initially
and weekly in the last trimester.
Group A received “one tablet of lactose base and colouring matter in the same manner.”
Outcomes 1. PCV and reticulocyte index.
2. Serum folic acid concentration and ’megaloblastic score’.
3. Malarial infection.
4. Maternal morbidity (pyelonephritis, pre-eclamptic toxaemia, septicaemia, puerperal psychosis).
5. Prematurity.
6. Birthweight (mean birthweight but no standard deviation).
7. Fetal mortality.
Notes Results not reported as intention to treat; however, where possible, the review authors included data in
the review as intention to treat.
Unclear of women’s risk of spontaneous and recurrent miscarriage.
16 women in the trial showed evidence of folate deficiency at trial entry.
Sample-size calculation: none reported.
No intention-to-treat analyses performed.
Compliance: no compliance information reported specifically; however, women were “seen to swallow”
the tablets at their fortnightly and weekly visits.
Location: Nigeria.
Time frame: unclear.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
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Hemmi 2003
Methods Randomisation and allocation concealment: unclear, “patients were randomly assigned to the control
group or the study group”. No other methodological details given
Blinding of outcome assessment: unclear, no details given.
Documentation of exclusion: 28 women (19%) in the control group were excluded, no details for given
for the exclusion
Use of placebo control: no placebo control.
Participants 150 women were recruited into the study. Women with a luteal phase defect, as described by a peak
serum P level < 120 mg/mL in the mid-luteal phase measured at 3 time points, were eligible and invited
to participate. Luteal phase defects were ascertained in two consecutive menstrual cycles, and the third
cycle was the intervention cycle. Women receiving IVF-ET treatment were excluded. 313 women were
considered for enrolment in the study, 150 (48%) were randomised. 28 women were withdrawn from the
control group, leaving 122 women in the study, who were allocated to vitamin C (n = 76) or control (n =
46). 5 women in the control group and 19 women in the vitamin C group became pregnant during the
study period
Interventions Women in the intervention group took 750 mg vitamin C per day from the first day of the third menstrual
cycle until a urinary pregnancy test was positive. Pregnancy rate was checked up until 6 months after the
study cycle was started. Women in the control group received no supplementation and no treatment was
given in the third cycle
Outcomes 1. Serum P concentrations.
2. Serum E2 (oestrogen) concentrations.
3. Pregnancy rate.
4. Miscarriage.
Notes Women’s risk of spontaneous or recurrent miscarriage was unclear according to criteria specified in the
review.
Their dietary intake of vitamin C is unknown.
No sample-size calculation was reported.
Analyses were not based on intention to treat.
Compliance: no details of any compliance assessments were given.
Country: Japan.
Time frame: January 1997-December 2000.
The denominators used for this trials are the number of women randomised and with a confirmed
pregnancy (i.e. 19 for the vitamin group and 5 for the control group)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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ICMR 2000
Methods Randomisation and allocation concealment: unclear, “containers of vitamin or placebo capsules were given
a random number” and “the key to random numbers was kept at the ICMR Headquarters”. No other
methodological details were given
Blinding of outcome assessment: “double blind” mentioned in the text, but no details given
Documentation of exclusion: 187 women (40%) were excluded from the analysis
Use of placebo control: placebo control.
Participants 466 women were recruited into the study. Women who had previously given birth to a child with an open
NTD, and planned to have another child were eligible and invited to participate. This was regardless
of their parity, number of previous births with an NTD, age, consanguinity, and socio-economic status.
Women who had previously given birth to a child with closed spina bifida, or with a history of diabetes
or abnormal fasting and post-prandial blood sugar, history of epilepsy, congenital anomalies indicative of
a genetic syndrome in the previous NTD, history of vitamin intake in the 3 months prior to enrolment,
and pregnancy were excluded. 466 women were enrolled and randomised to either vitamin (n = 231) or
placebo (n = 235), of these women, 90 were lost to follow up immediately and 71 did not conceive until
the final follow up. Of the remaining 305 women who were known to become pregnant (vitamin n = 152,
placebo n = 153), pregnancy outcomes were unknown for 26 women. In the paper, 279 of the initial 466
women were included in the analysis; however, in this review results are presented for main outcomes on
an intention-to-treat basis (i.e. n = 466)
Interventions The folic acid containing multivitamin included 120 mg ferrous sulphate, 240 mg calcium phosphate,
4000 IU vitamin A, 400 IU vitamin D, 2.5 mg vitamin B1, 2.5 mg vitamin B2, 2 mg vitamin B6, 15 mg
nicotinamide, 40 mg vitamin C, 4 mg folic acid, 10 mg zinc.
The placebo tablets contained the following trace elements: 120 mg ferrous sulphate and 240 mg calcium
phosphate. Both capsules were identical in appearance and women were provided with the tablets from
at least 28 days before conception and continuing until at least the second missed menstrual period
Outcomes 1. Recurrence of neural tube defects.
2. Livebirths.
3. Stillbirths.
4. Spontaneous and induced abortion.
5. Multiple birth.
Notes The risk profile of women in the trial for spontaneous and recurrent miscarriage is unclear, as is the dietary
intake of participants.
Sample-size calculation performed, assuming a 20 per cent drop out rate. The trial was terminated after
publication of the MRC trial in 1991.
Compliance: compliance was assessed at 3 monthly visits, by checking a diary card maintained by the
woman and the number of capsules returned. If the total number of missed days in 3 months did not
exceed 10 days, and the total number of missed days at a stretch did not exceed three, compliance was
taken as satisfactory. Women not meeting the above criteria were excluded if they became pregnant in
that particular quarter. No compliance data are specifically reported.
Analyses not based on intention to treat.
Country: India.
Time frame: 1988-1991.
The denominators used for this trial are based on the number of women randomised (i.e. 231 for the
vitamin group and 235 for the placebo group). There was not enough information to accurately confirm
the number of women that did or did not become pregnant due to the large number of losses to follow
up
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Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Katz 2000
Methods Randomisation and allocation concealment: cluster randomised. 270 centres in the Salarhi district, Nepal,
were involvedwhich included 30 subdistricts eachwith 9wards. Eachwardwas assigned to 1 of 3 treatment
groups. “Wards were assigned by a random draw of numbered chits, blocked on subdistrict”
Blinding of outcome assessment: women and study investigators were not aware of the treatment codes.
Maternal mortality was assessed by study investigators blinded to treatment allocation, no details were
given for other outcomes
Documentation of exclusions: 157 (1%) women were lost to follow up and excluded
Use of placebo: placebo control.
Participants 15,832 women were recruited into the study. All married women of child bearing age in the Salarhi
district, Nepal, were eligible and invited to participate in the study. Women migrating into the study
area, or women that were never pregnant or refused participation, or women who migrated before being
pregnant, were excluded from the analysis. Eligible women were identified from census data and marriage
registers. 44,646 women were recruited, of which 1136 (2.5%) were excluded as they either emigrated
before becoming pregnant, died or refused consent. During the study period 15,832 women identified
themselves as being pregnant, and 157 women were lost to follow up in the postpartum period. Results are
reported for 17,373 pregnancies, allocated to the following groups: vitamin A (n = 6070), beta-carotene
(n = 5650) or placebo (n = 5653). Denominators for the treatment groups vary for the measures of early
infant mortality, due to losses to follow up after birth
Interventions The three treatment groups consisted of a weekly single oral supplement of either:
1. 23,300 IU preformed vitamin A as retinyl palmitate;
2. 42 mg of all trans beta-carotene;
3. placebo.
All capsules contained mg dl-alpha-tocopherol as an antioxidant. Women took the tablets prior to con-
ception, during pregnancy and postpartum, for a total of 3.5 years
Outcomes 1. Fetal loss, defined as any reported miscarriage, stillbirth or maternal death during pregnancy. The
outcomes were based on self reports, and women who reported to be pregnant for >= 6 weeks but then
no longer reported being pregnant were considered to have had a miscarriage.
Serial publications also reported neonatal death.
Notes Women’s risk profile for spontaneous or recurrent miscarriage was unclear, as was their dietary intake of
vitamin A.
Compliance: women were distributed the capsules in their home on a weekly basis, receipt of capsules
was noted only if the distributor observed the woman swallowing the capsule. Over half of the women
who became pregnant during the study received over 80% of their intended supplements, and 75% of
pregnant women received at least half of their eligible doses.
Therewere serial publications of this study causing the study numerators anddenominators to vary between
published versions, and multiple pregnancy figures reported did not include higher order pregnancies.
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Sample-size calculation performed.
Partial intention-to-treat analyses, and the relative risks and confidence intervals were adjusted to account
for any cluster design effect.
Country: Nepal.
Timeframe: April 1994-September 1997.
The denominators used for this trial are the number of women randomised who identified themselves as
pregnant (i.e. 6070 for the vitamin A group, 5650 for the beta-carotene group and 5653 for the placebo
group)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kirke 1992
Methods Randomisation and allocation concealment: block randomisation, stratified by hospital, using “consecu-
tively numbered, opaque, sealed envelopes”
Blinding of outcome assessment: women and study investigators were initially blinded to the treatment
allocation, however the tablet preparations were changed after 55 women were randomised and after this
only participants were blinded
Documentation of exclusion: 3 women (1%) were lost to follow up and excluded
Use of placebo control: 3 treatment regimens were assessed, no placebo control
Participants 354 women were recruited into the study. Women with a previous neural tube defect defined as anen-
cephalus, iniencephalus, encephalocoele, and spina bifida aperta, who were not pregnant when contacted
but were planning a future pregnancy, were eligible and invited to participate. Women were identified
from case registers at the participating hospitals. Women with conditions likely to result in impaired
absorption from the gastrointestinal tract were excluded.
435 women were approached, of which 354 (84%) consented and were randomised to either F (n = 115 ),
MV (n = 119) or MF (n = 120). 16 women did not become pregnant, and 75 women withdrew; however,
their pregnancy outcome status was known, and 18 of these women subsequently became pregnant after
withdrawing. 3 women were lost to follow up. 281 women (93 in the F group, 93 in the MF group and
95 in the MV group) became pregnant in the study period and their pregnancy outcome was known
Interventions Indistinguishable trial tablets were initially made by Beecham and Glaxo, however Beecham withdrew
their support after 55 women had been randomised. After this time a commercially available pregnavite
Forte F was used (MF tablet) and Antigen Pharmaceuticals produced a white multivitamin tablet without
folic acid. This was associated with a loss of blinding. Women were randomised to one of three treatments:
1. folic acid alone (F);
2. multivitamin with folic acid (MF);
3. multivitamin with no folic acid (MV).
The F and MF resulted in a daily dose of 0.3 mg folic acid. The MF and MV resulted in a daily dose
of 4000 IU vitamin A, 400 IU calciferol, 1.5 mg thiamine hydrochloride, 1.5 mg riboflavine, 1 mg
pyridoxine hydrochloride, 15 mg nicotinamide, 40 mg ascorbic acid, 480 mg calcium phosphate, and
252 mg ferrous sulphate. Women took the tablets for at least 2 months prior to conception and until the
date of the 3rd missed period
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Kirke 1992 (Continued)
Outcomes 1. Recurrence risk of neural tube defects.
2. Spontaneous abortion.
3. Ectopic pregnancy.
4. Livebirth.
5. Stillbirth.
6. Congenital malformations excluding neural tube defects.
Notes The trial was stopped after there were poor recruitment rates and birth rates. A sample-size calculation
required 462 women to show a reduction in neural tube defects from 5% to 1%. Data from 106 women
who were already pregnant at time of recruitment are also included.
The risk profile of women in the trial for spontaneous and recurrent miscarriage is unclear, as is their
dietary intake.
Compliance: compliance was assessed on tablet counts and blood tests; however, the results are not
presented.
Intention-to-treat analyses were performed.
Country: Republic of Ireland.
Timeframe: December 1981-January 1988.
The denominators used for this trial are the number of women randomised who became pregnant in the
study period and their pregnancy outcome was known (i.e. 93 in the F group, 93 in the MF group and
95 in the MV group)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Kumwenda 2002
Methods Randomised controlled trial of vitamin A, iron and folate supplementation versus iron and folate only,
during pregnancy, to improve infant outcomes born to women infected with HIV in Malawi
Randomisation and allocation concealment: “treatment assignment was determined by use of a computer’s
random-number generator” and “mothers were assigned an original study identification number at en-
rolment and were given the next sequentially numbered opaque bottle with supplements”. “Treatment
assignment was concealed by prepacking study supplements in sequentially numbered series assigned to
study identification numbers.”
Blinding of outcome assessment: unclear, not specifically stated, but participants were blind to their
treatment allocation
Documentation of exclusion: 63 (9%) women were lost to follow up and 14 (2%) pairs of twins were
excluded
Use of placebo control: control tablets containing iron and folate were given
Participants Pregnant women between 18 and 29 weeks’ gestation and infected with HIV. The average gestation of
participants was 23 weeks. 693 women were enrolled and allocated to either vitamin A (n = 340) or control
(n = 357), of which pregnancy outcomes were known for 623 women. 63 women were lost to follow up
and 14 sets of twins were excluded due to their higher risk of low birthweight and infant mortality
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Interventions All women received orally administered daily doses of 30 mg iron and 400 mcg folate during the study.
Women in the intervention group received 10,000 IU vitamin A (3 mg retinol equivalent) orally, in
addition to the iron and folate supplements. Women were asked to take the tablets from enrolments until
delivery. Tablet counts were conducted every 4 weeks. All women received 30 mg retinol equivalents at 6
weeks postpartum, according to standard postpartum care in Malawi
Outcomes 1. Infant haemoglobin level at 6 weeks and 12 months of age.
2. Percentage of infants with anaemia at 6 weeks of age and at 12 months, defined as a haemoglobin level
of < 110 g/L.
3. Birthweight.
4. Percentage of infants < 2500 g at birth.
5. Weight and length at 6 weeks, 14 weeks and 6 months of age.
6. Transmission ofHIV to the infant, infant mortality at < 6 weeks of age, at 12 months and at 24 months.
7. Stillbirth and spontaneous abortion (undefined).
Notes Women’s risk of spontaneous and recurrent miscarriage is unclear, although may be increased due to their
HIV status.
50% of women in the vitamin A group and 51% of women in the control group had deficient levels of
vitamin A (defined as plasma vitamin A < 0.70 umol/L) at trial entry.
Sample-size calculation performed.
No intention-to-treat analyses were performed.
Compliance: more than 95% of women in both groups took > 90% of study supplements, as ascertained
by tablet counts.
Location: Malawi.
Timeframe: November 1995-December 1996.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
MRC 1991
Methods Randomisation and allocation concealment: third party randomisation, “randomisation was carried out
through the Clinical Trials Service Unit in Oxford”. Randomisation was stratified by centre
Blinding of outcome assessment: women, caregivers and study investigators were blinded to the treatment
allocation
Documentation of exclusion: 164 women (9%) excluded.
Use of placebo control: placebo control.
Participants 1817 women were recruited into the study. Women who had a previous pregnancy affected by a neural
tube defect, and were planning another pregnancy and not already taking supplements were eligible for
the study. Women whose affected child had Meckel’s syndrome and those women with epilepsy were
excluded. 1817 women were randomised to either F (n = 449), MV (n = 453), MF (n = 461) or P (n = 454)
, of which, 1195 were informative pregnancies that is, where the outcome of NTD or not was definitely
known (F n = 298, MV n = 302, MF n = 295, P n = 300). Results for pregnancy loss are reported for both
informative and not informative pregnancies. 164 women were excluded as they may have been pregnant
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at the time of randomisation
Interventions Women were randomised into 1 of 4 groups:
1. 4 mg, 240 mg di-calcium phosphate and 120 mg ferrous sulphate (F);
2. 4000 IU vitamin A, 400 IU calciferol, 1.5 mg thiamine hydrochloride, 1.5 mg riboflavine, 1 mg
pyridoxine hydrochloride, 15 mg nicotinamide, 40 mg ascorbic acid, 240 mg di-calcium phosphate and
120 mg ferrous sulphate (MV);
3. folic acid combined with the multivitamins specified above (MF);
4. placebo containing 240 mg di-calcium phosphate and 120 mg ferrous sulphate only (P).
Women took the tablets prior to conception and attended the site every 3 months to collect additional
supplies and again during the 12th week of pregnancy. No special dietary advice was given to women
Outcomes 1. Neural tube defect and other birth defects.
2. Spontaneous abortions.
3. Ectopic pregnancy.
4. Termination or pregnancy.
5. Livebirth.
6. Stillbirth.
7. Multiple pregnancy.
Subsequent publications report on blood folate and zinc concentrations
Notes The trial was stopped early after there were 1195 informative pregnancies, according to prespecified
stopping rules. The aim of the study was to obtain information on at least 2000 informative pregnancies
unless a sufficiently clear result emerged sooner.
Women’s risk profile for spontaneous and recurrent miscarriage was unclear, as was their nutritional status.
Compliance: compliance based on self reports, and data were available for women with an informative
pregnancy only, where 79 (6%) women reported they stopped taking their capsules before their last
scheduled visit.
Intention-to-treat analyses are reported in this review including not informative pregnancies (i.e. n =
1817).
Location: multi-national study coordinated from the United Kingdom.
Timeframe: July 1983-April 1991.
The denominators used for this trial are the number of women randomised i.e. (449 for the F group, 453
for the MV group, 461 for the MF and 454 for the P group). There was no information provided about
any women randomised that did not become pregnant in the study period
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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People’s League 1942
Methods Randomisation and allocation concealment: “women enrolled at the antenatal clinic were divided into
two main groups by placing them alternatively on separate lists”
Blinding of outcome assessment: unclear, no information given on blinding of participants, carers or
outcome assessors
Documentation of exclusion: 622 (11%) women were excluded.
Use of placebo control: no placebo given.
Participants 5644 women were recruited into the study. All women attending the antenatal clinics and who were less
than or equal to 24 weeks’ gestation and who were in ’good health’ were eligible for the study. Women who
were more than 24 weeks’ gestation and women who suffered from any disease or physical abnormality
were excluded from the study. After enrolment, women who had twin births and who miscarriage at an
early stage were also excluded.
5644 women were initially enrolled in the study of which 5022 (89%) remained in the study. Of the 622
(11%) women withdrawn from the trial, 494 were evacuated from the London area (due to World War
2), 39 women had twin births and 89 women miscarried at an early stage. 5022 women remained in the
study and were allocated to wither multivitamins (n = 2510) or control (n = 2512). Women were further
divided into primiparae and multiparae, and various age groups
Interventions Women allocated to the treatment group were given daily vitamin C 100 mg, ferrous iron 0.26 g, calcium
0.26 g, minute quantities of iodine, manganese and copper, adsorbate of vitamin B1 containing all factors
of the B complex and halibut liver oil 0.36 g containing vitamin A (52,000 IU per g) and vitamin D
(2500 IU per g).
Women allocated to the control group received no placebo.
Outcomes 1. Toxaemia classified into subgroups based on: hypertension only, albuminuria with or without hyper-
tension, or hypertension with albuminuria (pre-eclampsia).
2. Maternal sepsis.
3. Length of gestation (categorised as less than 40 weeks, 40 weeks, and greater than 40 weeks).
4. Percentage of women breastfeeding.
5. Stillbirth.
6. Neonatal mortality (defined as death before 8 days).
7. Birthweight (pounds) (only reported for primiparae and multiparae separately)
Notes Women risk status for spontaneous and recurrent miscarriage is unclear.
Dietary intake at trial entry: “vitamin C shortage affected about half the women”.
Intention-to-treat analyses: not performed.
Compliance: unclear, no information provided.
Sample-size calculation: unclear. “It was decided that the investigation should include a minimum of 5000
pregnant women”. No other details given.
Location: England.
Timeframe: 1938-1939.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
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Rush 1980
Methods Randomisation and allocation concealment: unclear, women were allocated to groups based on “random
assignment”. Randomisation was stratified on pre-pregnancy weight, weight gain during pregnancy, pre-
vious low birthweight infant and protein intake. No other methodological details given
Blinding of outcome assessment: unclear, women were allocated to 2 forms of treatment or control,
where both treatments were given as a canned beverage and the control group were given standard oral
multivitamins. No information is given on blinding of outcome assessors
Documentation of exclusion: 237 women (22%) were excluded.
Use of placebo control: no placebo, the control group received standard prenatal multivitamin supplements
Participants 1051 women were recruited into the study. Women eligible were Black, English speaking, and not greater
than 30 weeks’ gestation. They also had one of the following criteria: low pre-pregnant weight (under 110
pounds at conception); low weight gain at the time of recruitment; at least 1 previous low birthweight
infant; a history of protein intake of less than 50 g in the 24 hours preceding recruitment. Women were
not eligible if they were known to be seeking a termination, had specific chronic health disorders, if they
admitted to recent use of narcotics or heavy use of alcohol, or weighed >= 140 pounds at conception.
The mean gestation at enrolment ranged from 16-18 weeks for the treatment groups.
1225 women were invited to join the study, of which 1051 (84%) consented. Of these, 237 (22%) were
excluded and 814 women (77%) remained active in the study until delivery and were allocated to one of
three groups: supplement (n = 263), complement (n = 272) or control (n = 279)
Interventions Women were randomised to 1 of 3 groups:
1. high protein supplement (daily 40 g animal protein, 470 calories, 1000mg calcium, 100mgmagnesium,
60 mg iron, 4 mg zinc, 2 mg copper, 150 mcg iodine, 6000 IU vitamin A, 400 IU vitamin D, 30 USPU
vitamin E, 60 mg vitamin C, 3 mg vitamin B1, 15 mg vitamin B2, 15 mg niacin, 2.5 mg vitamin B6, 1
mg pantothenic acid, 200 mcg biotin, 350 mcg folic acid, 8 mcg vitamin B12);
2. balanced protein-energy complement (6 g animal protein, 250 mg calcium, 12 mg magnesium, 40 mg
iron, 0.084 mg zinc, 0.15 mg copper, 100 mcg iodine, 4000 IU vitamin A, 400 IU vitamin D, 60 mg
vitamin C, 3 mg vitamin B1, 15 mg vitamin B2, 10 mg niacin, 3 mg vitamin B6, 1 mg pantothenic acid,
350 mcg folic acid, 3 mcg vitamin B12);
3. control (250 mg calcium, 0.15 mg magnesium, 117 mg iron, 0.85 mg zinc, 0.15 mg copper, 100 mcg
iodine, 4000 IU vitamin A, 400 IU vitamin D, 60 mg vitamin C, 3 mg vitamin B1, 2 mg vitamin B2,
10 mg niacin, 3 mg vitamin B6, 1 mg pantothenic acid, 350 mcg folic acid, 3 mcg vitamin B12).
Women received the high protein or balanced protein-energy supplements in the format of a drink.
Women in the control group received a standard oral prenatal multivitamin supplement
Outcomes 1. Total weight gain, average weight gain and early weight gain during pregnancy.
2. Duration of gestation (presented as cumulative rates of delivery from life tables for each treatment
group).
3. Preterm birth < 37 weeks.
4. Fetal death (before < 20 weeks’ gestation and >= 20 weeks’ gestation).
5. Neonatal death ( according to gestation at delivery).
6. Birthweight (mean).
7. Somatic measures of infant growth at 1 year of age.
8. Psychological measures at 1 year of age.
Notes Women’s risk of spontaneous and recurrent miscarriage is unclear, as there is no information about concur-
rent medical conditions or other risk factors for miscarriage. Women in the trial had a low caloric intake
at trial entry, and unexpectedly, an adequate protein intake. No other specific nutritional information is
reported.
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Rush 1980 (Continued)
Sample-size calculation reported: 250 women were required in each treatment group to show a 125 g
difference in birthweight. A 25% loss to follow up was incorporated into the sample size.
Intention-to-treat analyses not performed.
There were 9 sets of twins amongst the three treatment groups.
Compliance: “on average, about three quarters of the prescribed amount of beverage was probably in-
gested”.
Location: New York City, USA.
Timeframe: 1969-1976.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Schmidt 2001
Methods Randomisation and allocation concealment: unclear, women were “randomly assigned on an individual
basis, to double-blind, weekly supplementation until delivery”
Blinding of outcome assessment: unclear, double blind stated in text but no details given
Documentation of exclusion: 42 women (17%) were lost to follow up and excluded
Use of placebo control: control tablets containing iron and folate were given
Participants 243 women were recruited into this study. Pregnant women between 16 and 20 weeks’ gestation, aged
between 17 and 35 years old, with a parity < 6 and haemoglobin level between 80-140 g/l, were eligible
for this study. Women were randomised to receive either vitamin A plus iron and folate (n = 122) or iron
and folate only (n = 121). Of these 22 (18%) and 20 (17%) women in vitamin A plus iron and folate and
the iron and folate groups respectively, dropped out between enrolment and the follow up at 4 months
Interventions Women were randomised to a weekly supplementation with 120 mg ferrous sulfate and 500 mcg folic
acid, with or without vitamin A (2400 retinol equivalents). Women were asked to take the trial tablets
from between 16 and 20 weeks’ gestation until birth
Outcomes 1. Stillbirth.
2. Concentrations of haemoglobin, serum ferritin and serum transferrin receptors, at or near term.
3. Concentrations of iron and vitamin A in breastmilk.
4. Haemoglobin and serum vitamin A concentrations in the mother and infant at 4 months postpartum.
5. General health, growth and development measures in the first year of life
Notes Women risk status for spontaneous and recurrent miscarriage is unclear.
At baseline, between 13% and 17% of women had marginal vitamin A deficiency 44% to 50% of women
were anaemic.
Sample-size calculation performed allowing for a 50% drop out during the study period.
Intention-to-treat analyses were not performed.
Compliance: adherence to the tablet intake was assessed through interview during a postnatal home visit,
which revealed that the median tablet intake was 50 tablets (i.e. 25 weeks), while only 17% of the subjects
took more than ninety tablets.
Location: Indonesia.
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Schmidt 2001 (Continued)
Serial publications of this data report different denominators.
Time frame: November 1997-May 1998.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Steyn 2003
Methods Randomisation and allocation concealment: “randomisationwas undertakenby computer-generatednum-
bers”. Roche Pharmaceutical supplied numbered containers with either vitamin C or matching placebo,
and they retained the study code until completion of the study. No other methodological details given
Blinding of outcome assessment: “double blind” stated, Roche Pharmaceuticals retained the code until
completion of the study
Documentation of exclusion: none reported.
Use of placebo control: placebo control.
Participants 200 women were recruited into the study. Women with a history of a previous mid trimester abortion
(defined as spontaneous expulsion of the uterine contents between 13 and 26 weeks’ gestational age), or
previous preterm labour, and less than 26 weeks’ gestation were eligible and invited to participate. Women
with iatrogenic causes of their previous preterm labour such as previous induction of labour before term
for severe pre-eclampsia, were excluded. 203 consecutive women were approached, of which 200 (98.5%)
consented and were randomised to either vitamin C (n = 100) or placebo (n = 100). No losses to follow
up were reported
Interventions Twice daily tablet of either 250 mg vitamin C or placebo, from trial entry until 34 weeks’ gestation. All
women were tested for bacterial vaginosis and all women with positive cultures for Mycoplasma hominis
(and between 22 and 32 weeks’ gestation) were treated with erythromycin for 7 days
Outcomes 1. Preterm labour, defined as spontaneous onset of labour and delivery before 37 completed weeks.
2. The secondary outcomewas perinatal outcome, a composite endpoint includingbirthweight, gestational
age at delivery, perinatal mortality, duration of admission in the neonatal intensive care unit and neonatal
complications.
The age of fetal viability was considered to be 28 weeks’ gestation
Notes Results are from an interim analysis performed when 100 participants were recruited into each arm.
Recruitment was stopped after the interim analysis revealed few differences between the two groups.
Unclear if there was a sample-size calculation performed. Women’s risk profile spontaneous and recurrent
miscarriage is unclear, although they are clearly at high risk of preterm birth. It is also unclear if multiple
births were included.
6 % of women had an inadequate dietary intake of vitamin C, defined as an intake < 67% of the
recommended dietary allowance (70 mg per day).
Compliance: women were requested to bring the containers to each visit and the remaining tablets were
counted to improve and control compliance; however, no compliance data were reported.
Country: South Africa.
Timeframe: unclear.
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Steyn 2003 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
F: folic acid
HELLP syndrome: haemolysis, elevated liver enzymes, low platelet count syndrome
HIV-1: Human Immunodeficiency Virus-1
HOFPP: Hungarian Optimal Family Planning Programme
IQR: interquartile range
IU: international units
IVF-ET: in vitro fertilization and embryo transfer
mcg: micrograms
MF: multivitamins with folic acid
mg: milligrams
MV: multivitamins without folic acid
NTD: neural tube defect
P: progesterone
PAI-1: plasminogen activator inhibitor-1
PAI-2: plasminogen activator inhibitor-2
PCV: packed cell volume
UK: United Kingdom
USA: United States of America
wk: week
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baumslag 1970 Onset of supplementation was > 20 weeks’ gestation.
Women were supplemented with either iron, iron and folic acid or iron, folic acid and vitamin B12 from
“after the 24th week of pregnancy”
Biswas 1984 Unclear of the gestational age at which women entered the trial
Blot 1981 Onset of supplementation was > 20 weeks’ gestation.
Supplementation with either iron and folic acid or iron alone occurred “at the end of the 6th month of
pregnancy”. Unclear if women were randomised to the treatment groups
Chanarin 1968 Onset of supplementation was > 20 weeks’ gestation.
Women were given a folate supplement after the 20th week of pregnancy. Abortion was reported according
to folate status at 15 weeks, prior to supplementation
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(Continued)
Colman 1974 Onset of supplementation was > 20 weeks’ gestation.
Women were supplemented “during the final month of pregnancy”. Outcomes reported included folate red
cell and serum folate concentration and haemoglobin concentration
Coutsoudis 1999 Onset of supplementation was > 20 weeks’ gestation.
Women were given vitamin A and beta-carotene “during the third trimester of pregnancy”
Dawson 1962 Onset of supplementation was > 20 weeks’ gestation.
Women were supplemented with folic acid “on or after the 28th week”. Group allocation was not done
randomly. Reported outcomes include incidence of folic acid deficiency and megaloblastic anaemia, and
haemoglobin concentration
Edelstein 1968 Onset of supplementation was > 20 weeks’ gestation.
Supplementation was started at the 28th week of pregnancy. Outcomes reported included serum folate activity
and serum folic acid, urinary formiminoglutamic acid, serumvitaminB12,meanhaemoglobin and haematocrit
values
Ferguson 1955 Only 24 (9%) of the 269 women in the trial began to participate before 15 weeks of gestation and outcomes
not reported separately according to gestation at enrolment
Fletcher 1971 No inclusion/exclusion criteria reported, unclear of gestational age at enrolment to the study, reports combined
outcomes for “antepartum and threatened or complete abortion” and “stillbirth or neonatal death or congenital
malformation” (not reported separately)
Giles 1971 Onset of supplementation was > 20 weeks’ gestation for a large proportion of the participants.
4 groups in the study, two of which involved supplementation after 20 weeks’ gestation. Results were not
reported separately between groups
Hampel 1974 Unclear of the gestational age at which women entered the trial
Hankin 1966 No main outcomes reported.
Supplementation was from “approximately 20 weeks”, no clinically relevant outcomes, outcomes relating to
vitamin C status in plasma and breast milk reported
Hibbard 1968 No main outcomes reported.
Biochemical measures of blood folate status reported.
Hunt 1984 All women received a multivitamin in addition to the zinc supplement or placebo
Laurence 1981 No main outcomes or pregnancy loss outcomes reported. Miscarriage reported in those women where there
was a neural tube defect, but not in all women according to treatment group
Lira 1989 No main outcomes reported.
Biochemical measures of iron and folate status reported.
Lumeng 1976 Unclear gestational age at enrolment, 5 women were excluded due to abortion, premature labour, inadequate
dietary records or missing more than 3 prenatal visits. Exclusions were not reported by group allocation.
Outcomes related to maternal and fetal plasma levels of pyridoxal 5’-phosphate and coenzyme saturation of
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aspartate aminotransferase and alanine aminotransferase in maternal erthrocytes were reported
Marya 1981 Onset of supplementation was > 20 weeks’ gestation.
Women were supplemented with vitamin D “throughout the 3rd trimester”
Meirinho 1987 No clinical outcomes reported.
Maternal plasma concentrations of trophoblastic protein SP1 were reported
Metz 1965 Onset of supplementation was > 20 weeks’ gestation.
Women were supplemented with either iron or iron and folic acid, or iron, folic acid and vitamin B12.
Supplementation was started after the 24th week of pregnancy
Mock 2002 No main outcome reported.
Women were enrolled in either early or late pregnancy. Biochemical measures of biotin status reported
Moldenhauer 2002 No main outcomes reported.
Unclear if this is a cohort study or randomised trial. Women in this study were participating in a randomised
placebo controlled trial of calcium supplementation, and completed a dietary assessment at 12-21 weeks’
gestation and 29-31 weeks’ gestation. Unclear whether all women took a standard prenatal multivitamin or just
women in the placebo group. Results are presented according to “teens”, “twins” and “singleton” pregnancies,
not according to whether women took the supplement or not. Outcomes reported included dietary intakes of
vitamin C and E (with and without the contribution of the prenatal vitamin supplement)
Owen 1966 Onset of supplementation was > 20 weeks’ gestation.
Women supplemented with oral vitamin K1 “several days before delivery”
Ross 1985 Unclear about content of vitamin supplements.
Women were supplemented with high or low ’bulk’ dietary supplements with vitamins added; however, the
vitamin supplements added were not specified
Schuster 1984 Unclear of gestation at enrolment to the trial.
No pregnancy loss outcomes reported.
Semba 2001 No main outcomes reported.
Women enrolled between 18 and 28 weeks’ gestation, no clinical outcomes reported, only haemoglobin and
plasma erythropoietin concentrations
Smithells 1981 Non-randomised study of periconceptional multivitamin supplementation for the prevention of neural tube
defects
Suharno 1993 No main outcomes reported.
Anaemic pregnant women were enrolled between 16 and 24 weeks’ gestation. The only clinical outcome
reported was the percentage of women with anaemia following treatment with a combination of vitamin A
and iron or placebo
Tanumihardjo 2002 No main outcomes reported.
Mean gestation at enrolment was 17.6 weeks, no clinical outcomes reported, markers of vitamin A and iron
status reported
41Vitamin supplementation for preventing miscarriage (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Thauvin 1992 No main outcomes reported.
Women were supplemented from 3 months gestation, data on pregnancy outcomes including spontaneous
abortion were collected but not reported
Trigg 1976 Unclear of gestation at enrolment to the trial.
Ulrich 1999 Non-randomised study.
Observational cohort study of folic acid users, randomised to different doses of folic acid, but no controls
Villamor 2002 No main outcomes reported.
Women enrolled between 12 and 27 weeks’ gestation, no pregnancy loss or main outcomes reported, only
reports measures of weight gain during pregnancy
Vutyavanich 1995 No main outcomes reported.
Women were enrolled in the study if they were less than 17 weeks’ gestation; however, no pregnancy loss or
main outcomes were reported, only measures of nausea and vomiting
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D A T A A N D A N A L Y S E S
Comparison 1. Any vitamins versus no vitamins (or minimal vitamins)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total fetal loss (including
miscarriages or combined
miscarriages and stillbirths)
10 31167 Relative risk (Fixed, 95% CI) 1.05 [0.95, 1.15]
1.1 Trial entry before
pregnancy
5 25182 Relative risk (Fixed, 95% CI) 1.06 [0.96, 1.17]
1.2 Trial entry < 12 weeks’
gestation
1 406 Relative risk (Fixed, 95% CI) 1.32 [0.63, 2.77]
1.3 Trial entry >= 12 weeks’
and < 20 weeks’ gestation
0 0 Relative risk (Fixed, 95% CI) Not estimable
1.4 Trial entry ’mixed’ both <
20 and >= 20 weeks’ gestation
4 5579 Relative risk (Fixed, 95% CI) 0.87 [0.63, 1.20]
2 Early or late miscarriage 7 8490 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.95, 1.24]
2.1 Trial entry before
pregnancy
4 7809 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.93, 1.24]
2.2 Trial entry < 12 weeks’
gestation
1 406 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.63, 2.77]
2.3 Trial entry >= 12 weeks
but <20 weeks’ gestation
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.4 Trial entry ’mixed’ both <
20 and >= 20 week’s gestation
2 275 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.48, 2.60]
3 Stillbirth 7 13364 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.63, 1.14]
3.1 Trial entry before
pregnancy
3 7785 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.48, 1.85]
3.2 Trial entry < 12 weeks’
gestation
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.3 Trial entry >= 12 weeks’
but < 20 weeks’ gestation
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.4 Trial entry ’mixed’ both <
20 and >= 20 weeks’ gestation
4 5579 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.59, 1.15]
4 Placental abruption 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Placental abruption 1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.04, 3.19]
4.2 Antepartum haemorrhage
including placental abruption
1 200 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.88, 55.86]
5 Psychological effects (anxiety
and depression)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Pre-eclampsia 4 5580 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.54, 0.85]
7 Perinatal death 1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.54]
8 Neonatal death 4 25121 Relative risk (Fixed, 95% CI) 1.12 [0.95, 1.32]
9 Preterm birth 5 23433 Relative risk (Fixed, 95% CI) 1.06 [0.95, 1.18]
10 Very preterm birth 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.3 [0.78, 2.17]
11 Birthweight 2 4891 Mean Difference (IV, Random, 95% CI) 140.37 [-160.58,
441.32]
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12 Small-for-gestational age 4 5406 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.82, 1.27]
12.1 Birthweight less than
10th centile or birthweight <
2500 g
4 5406 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.82, 1.27]
13 Congenital malformations 2 6679 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.73, 3.06]
14 Multiple pregnancy 3 20986 Relative risk (Fixed, 95% CI) 1.38 [1.12, 1.70]
15 Apgar score less than seven at
five minutes
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16 Use of blood transfusion for the
mother
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
17 Anaemia (maternal) 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18 Anaemia (infant) 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
19 Placental weight 1 29 Mean Difference (IV, Fixed, 95% CI) 96.0 [30.73, 161.27]
20 Method of feeding 1 4878 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.96, 1.01]
20.1 Breastfeeding 1 4878 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.96, 1.01]
20.2 Formula 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
20.3 Breastfeeding and
formula
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
21 Subsequent fertility 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
22 Poor growth at childhood
follow up
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
23 Disability at childhood follow
up
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
24 Any adverse effects of vitamin
supplementation sufficient to
stop supplementation
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
25 Maternal views of care 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
26 Gynaecological hospital
admission
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
27 Admission to neonatal intensive
care unit
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
28 Health care costs 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
29 Duration of admission to the
neonatal intensive care unit
1 181 Mean Difference (IV, Fixed, 95% CI) 1.30 [-0.28, 2.88]
Comparison 2. Any vitamins (by allocation concealment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total fetal loss (including
miscarriage or combined
miscarriages and stillbirths)
10 31167 Relative risk (Fixed, 95% CI) 1.02 [0.97, 1.07]
1.1 Allocation concealment =
A
3 2300 Relative risk (Fixed, 95% CI) 0.98 [0.84, 1.14]
1.2 Allocation concealment =
B
5 23771 Relative risk (Fixed, 95% CI) 1.03 [0.98, 1.09]
1.3 Allocation concealment =
C
2 5096 Relative risk (Fixed, 95% CI) 0.92 [0.77, 1.10]
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2 Early or late miscarriage 7 8490 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.95, 1.24]
2.1 Allocation concealment =
A
2 2017 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.73, 1.34]
2.2 Allocation concealment =
B
4 6398 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.96, 1.30]
2.3 Allocation concealment =
C
1 75 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 9.03]
3 Stillbirth 7 13364 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.63, 1.14]
3.1 Allocation concealment =
A
3 2300 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.21, 1.96]
3.2 Allocation concealment =
B
2 5968 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.52, 2.43]
3.3 Allocation concealment =
C
2 5096 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.58, 1.15]
Comparison 3. Any vitamins (by use of placebo)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total fetal loss (including
miscarriage or combined
miscarriages and stillbirths)
10 31167 Relative risk (Fixed, 95% CI) 1.02 [0.97, 1.07]
1.1 Placebo control 8 26122 Relative risk (Fixed, 95% CI) 1.03 [0.98, 1.08]
1.2 No placebo control 2 5045 Relative risk (Fixed, 95% CI) 0.92 [0.77, 1.10]
2 Early or late miscarriage 7 8490 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.95, 1.24]
2.1 Placebo control 6 8466 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.95, 1.24]
2.2 No placebo control 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.10, 6.06]
3 Stillbirth 7 13364 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.63, 1.14]
3.1 Placebo control 6 8343 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.49, 1.69]
3.2 No placebo control 1 5021 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.58, 1.17]
Comparison 4. Any vitamins (by losses to follow up)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total fetal loss (including
miscarriage or combined
miscarriages and stillbirths)
10 31167 Relative risk (Fixed, 95% CI) 1.02 [0.97, 1.07]
1.1 Less than 3% losses to
follow up
3 23158 Relative risk (Fixed, 95% CI) 1.04 [0.98, 1.09]
1.2 3 to < 10% losses to follow
up
1 1817 Relative risk (Fixed, 95% CI) 0.96 [0.82, 1.14]
1.3 10 to < 20% losses to
follow up
2 5045 Relative risk (Fixed, 95% CI) 0.92 [0.77, 1.10]
1.4 >= 20% losses to follow up 2 541 Relative risk (Fixed, 95% CI) 0.75 [0.50, 1.12]
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1.5 Not stated 2 606 Relative risk (Fixed, 95% CI) 1.14 [0.85, 1.52]
2 Early or late miscarriage 7 8490 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.95, 1.24]
2.1 Less than 3% losses to
follow up
1 5502 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.97, 1.34]
2.2 3 to < 10% losses to follow
up
1 1817 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.69, 1.32]
2.3 10 to < 20% losses to
follow up
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.10, 6.06]
2.4 >= 20 % losses to follow
up
2 541 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.18, 1.06]
2.5 Not stated 2 606 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.73, 2.28]
3 Stillbirth 7 13364 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.63, 1.14]
3.1 Less than 3% losses to
follow up
2 5785 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.46, 2.37]
3.2 3 to < 10% losses to follow
up
1 1817 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.10, 1.98]
3.3 10 to < 20% losses to
follow up
1 5021 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.58, 1.17]
3.4 >= 20% losses to follow up 2 541 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.20, 3.28]
3.5 Not stated 1 200 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.77]
Comparison 5. Vitamin C
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total fetal loss 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Vitamin C +
multivitamins versus placebo
plus multivitamins
1 406 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.63, 2.77]
1.2 Vitamin C and vitamin E
versus placebo
1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.05, 5.49]
1.3 Vitamin C versus no
supplement/placebo
2 224 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.58, 2.83]
2 Early or late miscarriage 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Vitamin C +
multivitamins versus placebo
plus multivitamins
1 406 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.63, 2.77]
2.2 Vitamin C versus no
supplement/placebo
2 224 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.52, 2.65]
3 Stillbirth 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Vitamin C and vitamin E
versus placebo
1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.05, 5.49]
3.2 Vitamin C versus placebo 1 200 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.77]
4 Antepartum haemorrhage and
placental abruption
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Vitamin C and vitamin
E versus placebo - placental
abruption only
1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.04, 3.19]
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4.2 Vitamin C versus placebo
- antepartum haemorrhage
including placental abruption
1 200 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.88, 55.86]
5 Pre-eclampsia 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Vitamin C and vitamin E
versus placebo
1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.24, 0.91]
5.2 Vitamin C versus placebo 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.21, 4.84]
6 Perinatal death 1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.54]
6.1 Vitamin C versus placebo 1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.54]
7 Neonatal death 1 181 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.12, 4.03]
7.1 Vitamin C versus placebo 1 181 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.12, 4.03]
8 Preterm birth 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Vitamin C and vitamin E
versus placebo
1 283 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.38, 3.87]
8.2 Vitamin C versus placebo 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [1.03, 1.99]
9 Small-for-gestational age 1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.50, 1.08]
9.1 Vitamin C and vitamin E
versus placebo
1 283 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.50, 1.08]
10 Very preterm birth 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.3 [0.78, 2.17]
10.1 Vitamin C versus placebo 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.3 [0.78, 2.17]
Comparison 6. Vitamin A
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total fetal loss (including
miscarriages or combined
miscarriages and stillbirths)
4 Relative risk (Fixed, 95% CI) Subtotals only
1.1 Vitamin A versus placebo 1 11723 Relative risk (Fixed, 95% CI) 1.04 [0.92, 1.17]
1.2 B-carotene versus placebo 1 11303 Relative risk (Fixed, 95% CI) 1.03 [0.91, 1.16]
1.3 Vitamin A versus
B-Carotene
1 11720 Relative risk (Fixed, 95% CI) 1.01 [0.90, 1.14]
1.4 Vitamin A or B-carotene
versus placebo
1 17373 Relative risk (Fixed, 95% CI) 1.05 [0.91, 1.21]
1.5 Vitamin A (with/without
multivitamins) versus
multivitamins or placebo
1 1074 Relative risk (Fixed, 95% CI) 0.80 [0.53, 1.21]
1.6 Vitamin A + iron + folate
versus iron + folate
2 940 Relative risk (Fixed, 95% CI) 1.34 [0.67, 2.65]
2 Early or late miscarriage 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Vitamin A (with/without
multivitamins) versus
multivitamins or placebo
1 1075 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.37, 1.55]
2.2 Vitamin A + iron + folate
versus iron + folate
1 697 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.47, 4.59]
3 Stillbirth 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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3.1 Vitamin A (with/without
multivitamins) versus
multivitamins or placebo
1 1075 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.60, 1.79]
3.2 Vitamin A + iron + folate
versus iron + folate
2 940 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.53, 3.01]
4 Neonatal death 1 Relative risk (Fixed, 95% CI) Subtotals only
4.1 Vitamin A versus placebo 1 10214 Relative risk (Fixed, 95% CI) 1.09 [0.92, 1.30]
4.2 B-carotene versus placebo 1 9788 Relative risk (Fixed, 95% CI) 1.09 [0.91, 1.30]
4.3 Vitamin A versus
B-Carotene
1 10228 Relative risk (Fixed, 95% CI) 1.0 [0.85, 1.18]
4.4 Vitamin A or B-carotene
versus placebo
1 15115 Relative risk (Fixed, 95% CI) 1.09 [0.91, 1.30]
5 Preterm birth 2 Relative risk (Fixed, 95% CI) Subtotals only
5.1 Vitamin A versus placebo 1 11723 Relative risk (Fixed, 95% CI) 1.04 [0.89, 1.21]
5.2 B-carotene versus placebo 1 11303 Relative risk (Fixed, 95% CI) 1.01 [0.86, 1.18]
5.3 Vitamin A versus
B-Carotene
1 11720 Relative risk (Fixed, 95% CI) 1.03 [0.88, 1.20]
5.4 Vitamin A or B-carotene
versus placebo
1 17373 Relative risk (Fixed, 95% CI) 1.02 [0.89, 1.17]
5.5 Vitamin A (with/without
multivitamins) versus
multivitamins or placebo
1 1075 Relative risk (Fixed, 95% CI) 1.07 [0.84, 1.37]
6 Birthweight 1 594 Mean Difference (IV, Fixed, 95% CI) 90.0 [2.68, 177.32]
6.1 Vitamin A + iron + folate
versus iron + folate
1 594 Mean Difference (IV, Fixed, 95% CI) 90.0 [2.68, 177.32]
7 Small-for-gestational age 1 1075 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.58, 1.21]
7.1 Vitamin A (with/without
multivitamins) versus
multivitamins or placebo
1 1075 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.58, 1.21]
8 Multiple pregnancy 1 Relative risk (Fixed, 95% CI) Subtotals only
8.1 Vitamin A versus placebo 1 10697 Relative risk (Fixed, 95% CI) 1.35 [0.99, 1.85]
8.2 B-carotene versus placebo 1 10294 Relative risk (Fixed, 95% CI) 1.37 [1.00, 1.88]
8.3 Vitamin A versus
B-Carotene
1 10699 Relative risk (Fixed, 95% CI) 1.03 [0.77, 1.37]
8.4 Vitamin A or B-carotene
versus placebo
1 15845 Relative risk (Fixed, 95% CI) 1.39 [1.05, 1.84]
9 Very preterm birth 1 1075 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.71, 1.74]
9.1 Vitamin A (with/without
multivitamins) versus
multivitamins or placebo
1 1075 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.71, 1.74]
10 Infant anaemia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Infant anaemia at 6
weeks’ of age - vitamin A + iron
+ folate versus iron + folate
1 562 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.45, 0.75]
10.2 Infant anaemia at 12
months - vitamin A + iron +
folate versus iron + folate
1 478 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.88, 1.20]
11 Poor growth at childhood
follow up
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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11.1 Weight (g) at 6 weeks:
vitamin A + iron + folate versus
iron + folate
1 546 Mean Difference (IV, Fixed, 95% CI) 169.0 [16.55, 321.
45]
11.2 Length (cm) at 6 weeks:
vitamin A + iron + folate versus
iron + folate
1 546 Mean Difference (IV, Fixed, 95% CI) 0.70 [0.15, 1.25]
11.3 Weight (g) at 4 months:
vitamin A + iron + folate versus
iron + folate
1 148 Mean Difference (IV, Fixed, 95% CI) -100.0 [-377.14,
177.14]
11.5 Length (cm) at 4 months:
vitamin A + iron + folate versus
iron + folate
1 148 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.33, 0.33]
Comparison 7. Multivitamin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total fetal loss (including
miscarriages or combined
miscarriages and stillbirths)
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Multivitamin + folic acid
versus no multivitamin/folic
acid
3 6883 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.95, 1.25]
1.2 Multivitamin without
folic acid versus no
multivitamin/folic acid
1 907 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.56, 1.25]
1.3 Multivitamins
with/without folic acid versus
no multivitamins/folic acid
1 1368 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.65, 1.27]
1.4 Multivitamin + folic acid
versus folic acid
2 1096 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.72, 1.48]
1.5 Multivitamin without
folic acid versus folic acid
2 1090 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.62, 1.30]
1.6 Multivitamin
with/without folic acid versus
folic acid
2 1644 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.69, 1.30]
1.7 Multivitamin
with/without vitamin A versus
vitamin A or placebo
1 1074 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.39, 0.91]
1.8 Multivitamins versus
control
1 5021 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.58, 1.17]
1.9 Multivitamin + vitamin
E versus multivitamin without
vitamin E or controls
1 823 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.46, 1.83]
2 Early or late miscarriage 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Multivitamin + folic acid
versus no multivitamin/folic
acid
3 6883 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.94, 1.26]
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2.2 Multivitamin without
folic acid versus no
multivitamin/folic acid
1 907 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.59, 1.34]
2.3 Multivitamin
with/without folic acid versus
no multivitamin/folic acid
1 1368 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.67, 1.34]
2.4 Multivitamin + folic acid
versus folic acid
2 1096 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.72, 1.49]
2.5 Multivitamin without
folic acid versus folic acid
2 1090 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.61, 1.31]
2.6 Multivitamin
with/without folic acid versus
folic acid
2 1644 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.70, 1.33]
2.7 Multivitamin + vitamin
E versus multivitamin without
vitamin E or controls
1 823 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.26, 4.13]
3 Stillbirth 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Multivitamin + folic acid
versus no multivitamin/folic
acid
3 6883 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.51, 2.09]
3.2 Multivitamin without
folic acid versus no
multivitamin/folic acid
1 907 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.76]
3.3 Multivitamin
with/without folic acid versus
no multivitamin/folic acid
1 1368 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.06, 1.97]
3.4 Multivitamin + folic acid
versus folic acid
2 1096 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.14, 6.88]
3.5 Multivitamin without
folic acid versus folic acid
2 1090 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.20, 4.88]
3.6 Multivitamin
with/without folic acid versus
folic acid
2 1644 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.19, 4.15]
3.7 Multivitamin versus
control
1 5021 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.58, 1.17]
3.8 Multivitamin + vitamin
E versus multivitamin without
vitamin E or controls
1 823 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.39, 1.98]
4 Pre-eclampsia 1 5021 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.55, 0.90]
4.1 Multivitamin versus
control
1 5021 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.55, 0.90]
5 Perinatal death 1 4308 Relative risk (Fixed, 95% CI) 1.11 [0.98, 1.26]
5.1 Multivitamin + folic acid
+ iron + zinc + vitamin A
versus folic acid + iron + zinc +
vitamin A
1 4308 Relative risk (Fixed, 95% CI) 1.11 [0.98, 1.26]
6 Neonatal death 4 Relative risk (Fixed, 95% CI) Subtotals only
6.1 Multivitamin + folic acid
versus no multivitamin/folic
acid
1 4930 Relative risk (Fixed, 95% CI) 1.59 [0.30, 8.30]
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6.2 Multivitamin + vitamin
E versus multivitamin without
vitamin E or controls
1 787 Relative risk (Fixed, 95% CI) 1.44 [0.91, 2.27]
6.3 Multivitamin versus
control
1 4895 Relative risk (Fixed, 95% CI) 1.0 [0.75, 1.34]
6.4 Multivitamin + folic acid
+ iron + zinc + vitamin A
versus folic acid + iron + zinc +
vitamin A
1 4122 Relative risk (Fixed, 95% CI) 1.15 [0.97, 1.36]
7 Preterm birth 3 Relative risk (Fixed, 95% CI) Subtotals only
7.1 Multivitamin + folic acid
versus no multivitamin/folic
acid
1 5502 Relative risk (Fixed, 95% CI) 1.01 [0.91, 1.12]
7.2 Multivitamin + folic acid
+ iron + zinc + vitamin A
versus folic acid + iron + zinc +
vitamin A
1 3320 Relative risk (Fixed, 95% CI) 0.98 [0.90, 1.07]
7.3 Multivitamin + vitamin
E versus multivitamin without
vitamin E or controls
1 814 Relative risk (Fixed, 95% CI) 0.99 [0.85, 1.15]
8 Birthweight 1 4862 Mean Difference (IV, Fixed, 95% CI) 3.0 [-24.15, 30.15]
8.1 Multivitamin + folic acid
versus no multivitamin/folic
acid
1 4862 Mean Difference (IV, Fixed, 95% CI) 3.0 [-24.15, 30.15]
9 Small-for-gestational age 3 Relative risk (Fixed, 95% CI) Subtotals only
9.1 Multivitamin + folic acid
versus no multivitamin/folic
acid
1 4862 Relative risk (Fixed, 95% CI) 1.09 [0.94, 1.26]
9.2 Multivitamin + folic acid
versus no multivitamin/folic
acid (birthweight < 2500 g)
1 186 Relative risk (Fixed, 95% CI) 0.91 [0.63, 1.32]
9.3 Multivitamin + folic acid
+ iron + zinc + vitamin A
versus folic acid + iron + zinc +
vitamin A
1 3320 Relative risk (Fixed, 95% CI) 0.98 [0.95, 1.02]
9.4 Multivitamin+folic
acid+iron+zinc+vitamin
A versus folic
acid+iron+zinc+vitamin A
(birthweight < 2500 g)
1 3325 Relative risk (Fixed, 95% CI) 0.95 [0.90, 1.00]
10 Congenital malformations 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Multivitamin + folic acid
versus no multivitamin/folic
acid
2 5777 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.81, 3.53]
10.2 Multivitamin without
folic acid without versus no
multivitamin/folic acid
1 907 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [0.53, 4.86]
10.3 Multivitamin
with/without folic acid versus
no multivitamin/folic acid
1 1368 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.75, 5.26]
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10.4 Multivitamin + folic acid
versus folic acid
2 1096 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.72, 4.04]
10.5 Multivitamin without
folic acid versus folic acid
2 1090 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [0.67, 3.85]
10.6 Multivitamin
with/without folic acid versus
folic acid
2 1644 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [0.76, 3.63]
11 Multiple pregnancy 2 5141 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [1.00, 1.85]
11.1 Multivitamin + folic acid
versus no multivitamin/folic
acid
2 5141 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [1.00, 1.85]
12 Maternal anaemia 1 Relative risk (Fixed, 95% CI) Subtotals only
12.1 Multivitamin + folic
acid + iron + zinc + vitamin A
versus folic acid + iron + zinc +
vitamin A (any anaemia)
1 813 Relative risk (Fixed, 95% CI) 0.92 [0.83, 1.03]
12.2 Multivitamin + folic
acid + iron + zinc+vitamin A
versus folic acid + iron + zinc +
vitamin A (severe anaemia)
1 813 Relative risk (Fixed, 95% CI) 0.82 [0.53, 1.27]
13 Breastfeeding 1 4878 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.96, 1.01]
13.1 Mulitivitamin versus
control
1 4878 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.96, 1.01]
14 Additional outcomes - infant
death
1 4122 Relative risk (Fixed, 95% CI) 1.10 [0.94, 1.29]
14.1 Multivitamin + folic
acid + iron + zinc + vitamin A
versus folic acid + iron + zinc +
vitamin A
1 4122 Relative risk (Fixed, 95% CI) 1.10 [0.94, 1.29]
Comparison 8. Folic acid
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total fetal loss (including
miscarriages or combined
miscarriages and stillbirths)
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Folic acid +
multivitamin versus no folic
acid/multivitamin
3 6883 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.95, 1.25]
1.2 Folic acid without
multivitamin versus no folic
acid/multivitamin
1 903 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.64, 1.40]
1.3 Folic acid with/without
multivitamin versus no folic
acid/multivitamin
1 1364 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.69, 1.35]
1.4 Folic acid + multivitamin
versus multivitamin
2 1102 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.80, 1.67]
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1.5 Folic acid without
multivitamin versus
multivitamin
2 1090 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.77, 1.62]
1.6 Folic acid with or
without multivitamin versus
multivitamin
2 1644 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.82, 1.57]
1.7 Folic acid + iron versus
iron
1 75 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.01, 4.59]
2 Early or late miscarriage 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Folic acid +
multivitamin versus no folic
acid/multivitamin
3 6883 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.94, 1.26]
2.2 Folic acid without
multivitamins versus no folic
acid/multivitamin
1 903 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.65, 1.44]
2.3 Folic acid with/without
multivitamin versus no folic
acid/multivitamin
1 1364 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.70, 1.39]
2.4 Folic acid + multivitamin
versus multivitamin
2 1102 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.80, 1.69]
2.5 Folic acid without
multivitamin versus
multivitamin
2 1090 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.77, 1.64]
2.6 Folic acid with/without
multivitamin versus
multivitamin
2 1642 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.79, 1.51]
2.7 Folic acid + iron versus
iron
1 75 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 9.03]
3 Stillbirth 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Folic acid +
multivitamin versus no folic
acid/multivitamin
3 6883 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.51, 2.09]
3.2 Folic acid without
multivitamin versus no folic
acid/multivitamin
1 903 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.11, 4.02]
3.3 Folic acid with/without
multivitamin versus no folic
acid/multivitamin
1 1364 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.15, 2.96]
3.4 Folic acid + multivitamin
versus multivitamin
2 1102 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.20, 4.99]
3.5 Folic acid without
multivitamin versus
multivitamin
2 1090 Risk Ratio (M-H, Fixed, 95% CI) 4.97 [0.58, 42.29]
3.6 Folic acid with/without
multivitamin versus
multivitamin
2 1644 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.20, 3.53]
3.7 Folic acid + iron versus
iron
1 75 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.02, 9.03]
4 Pre-eclampsia 1 75 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.17, 7.69]
4.1 Folic acid + iron versus
iron
1 75 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.17, 7.69]
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5 Perinatal death 1 4308 Relative risk (Fixed, 95% CI) 0.97 [0.85, 1.11]
5.1 Folic acid + iron + zinc
+ multivitamin + vitamin A
versus vitamin A
1 4308 Relative risk (Fixed, 95% CI) 0.97 [0.85, 1.11]
6 Neonatal death 2 Relative risk (Fixed, 95% CI) Subtotals only
6.1 Folic acid +
multivitamin versus no folic
acid/multivitamin
1 4930 Relative risk (Fixed, 95% CI) 1.59 [0.30, 8.28]
6.2 Folic acid + iron + zinc
+ multivitamin + vitamin A
versus vitamin A
1 4122 Relative risk (Fixed, 95% CI) 0.96 [0.80, 1.14]
7 Preterm birth 3 Relative risk (Fixed, 95% CI) Subtotals only
7.1 Folic acid +
multivitamin versus no folic
acid/multivitamin
1 5502 Relative risk (Fixed, 95% CI) 1.01 [0.91, 1.12]
7.2 Folic acid +
multivitamin versus no folic
acid/multivitamin
1 75 Relative risk (Fixed, 95% CI) 1.01 [0.65, 1.56]
7.3 Folic acid + iron + zinc
+ multivitamin + vitamin A
versus vitamin A
1 3320 Relative risk (Fixed, 95% CI) 1.02 [0.94, 1.11]
8 Birthweight 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Folic acid +
multivitamin versus no folic
acid/multivitamin
1 4862 Mean Difference (IV, Fixed, 95% CI) 3.0 [-24.15, 30.15]
8.2 Folic acid versus placebo 1 29 Mean Difference (IV, Fixed, 95% CI) 312.0 [108.52, 515.
48]
9 Small-for-gestational age 4 Relative risk (Fixed, 95% CI) Subtotals only
9.1 Folic acid +
multivitamin versus no folic
acid/multivitamin
1 4862 Relative risk (Fixed, 95% CI) 1.09 [0.94, 1.26]
9.2 Folic acid + iron + zinc
+ multivitamin + vitamin A
versus vitamin A
1 3320 Relative risk (Fixed, 95% CI) 0.97 [0.92, 1.03]
9.3 Folic acid + iron versus
iron (birthweight < 2500 g)
1 75 Relative risk (Fixed, 95% CI) 1.06 [0.48, 2.33]
9.4 Folic acid +
multivitamin versus no folic
acid/multivitamin (birthweight
< 2500 g)
1 186 Relative risk (Fixed, 95% CI) 0.91 [0.63, 1.32]
9.5 Folic acid + iron + zinc
+ multivitamin + vitamin A
versus vitamin A (birthweight
< 2500 g)
1 3325 Relative risk (Fixed, 95% CI) 0.94 [0.90, 0.99]
10 Congenital malformations 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Folic acid +
multivitamin versus no folic
acid/multivitamin
2 5777 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.81, 3.53]
10.2 Folic acid without
multivitamin versus no folic
acid/multivitamin
1 903 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [0.45, 4.43]
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10.3 Folic acid with/without
multivitamin versus no folic
acid/multivitamin
1 1364 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [0.71, 5.04]
10.4 Folic acid + multivitamin
versus multivitamin
2 1102 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.51, 2.26]
10.5 Folic acid without
multivitamin versus
multivitamin
2 1090 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.26, 1.49]
10.6 Folic acid with or
without multvitamin versus
multivitamin
2 1644 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.43, 1.67]
11 Multiple pregnancy 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Folic acid +
multivitamin versus no folic
acid/multivitamin
2 5141 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [1.00, 1.85]
12 Maternal anaemia 2 Relative risk (Fixed, 95% CI) Subtotals only
12.1 Folic acid + iron + zinc
+ multivitamin + vitamin A
versus vitamin A (any anaemia)
1 813 Relative risk (Fixed, 95% CI) 0.83 [0.77, 0.91]
12.2 Folic acid + iron + zinc
+ multivitamin + vitamin
A versus vitamin A (severe
anaemia)
1 813 Relative risk (Fixed, 95% CI) 0.82 [0.59, 1.16]
12.3 Folic acid + iron versus
iron (severe anaemia)
1 85 Relative risk (Fixed, 95% CI) 1.06 [0.25, 4.42]
13 Placental weight 1 29 Mean Difference (IV, Fixed, 95% CI) 96.0 [30.73, 161.27]
13.1 Folic acid versus placebo 1 29 Mean Difference (IV, Fixed, 95% CI) 96.0 [30.73, 161.27]
14 Additional outcomes - infant
death
1 4122 Relative risk (Fixed, 95% CI) 0.95 [0.81, 1.11]
14.1 Folic acid + iron + zinc
+ multivitamin + vitamin A
versus vitamin A
1 4122 Relative risk (Fixed, 95% CI) 0.95 [0.81, 1.11]
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Analysis 1.1. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 1 Total fetal
loss (including miscarriages or combined miscarriages and stillbirths).
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 1 Total fetal loss (including miscarriages or combined miscarriages and stillbirths)
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Trial entry before pregnancy
Czeizel 1994 2819 2683 0.131 (0.0779) 36.2 % 1.14 [ 0.98, 1.33 ]
Hemmi 2003 19 5 -0.2357 (1.047) 0.2 % 0.79 [ 0.10, 6.15 ]
ICMR 2000 231 235 -0.6162 (0.3959) 1.4 % 0.54 [ 0.25, 1.17 ]
Katz 2000 11720 5653 0.0488 (0.0706) 44.0 % 1.05 [ 0.91, 1.21 ]
MRC 1991 1363 454 -0.0834 (0.1611) 8.5 % 0.92 [ 0.67, 1.26 ]
Subtotal (95% CI) 16152 9030 90.2 % 1.06 [ 0.96, 1.17 ]
Heterogeneity: Chi2 = 4.64, df = 4 (P = 0.33); I2 =14%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Trial entry < 12 weeks’ gestation
Briscoe 1959 303 103 0.2776 (0.3778) 1.5 % 1.32 [ 0.63, 2.77 ]
Subtotal (95% CI) 303 103 1.5 % 1.32 [ 0.63, 2.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
3 Trial entry >= 12 weeks’ and < 20 weeks’ gestation
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Trial entry ’mixed’ both < 20 and >= 20 weeks’ gestation
Chappell 1999 141 142 -0.6931 (1.1986) 0.2 % 0.50 [ 0.05, 5.24 ]
Fleming 1968 35 40 -1.4697 (1.5635) 0.1 % 0.23 [ 0.01, 4.93 ]
People’s League 1942 2510 2511 -0.1863 (0.179) 6.8 % 0.83 [ 0.58, 1.18 ]
Steyn 2003 100 100 0.3221 (0.4412) 1.1 % 1.38 [ 0.58, 3.28 ]
Subtotal (95% CI) 2786 2793 8.2 % 0.87 [ 0.63, 1.20 ]
Heterogeneity: Chi2 = 2.10, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 19241 11926 100.0 % 1.05 [ 0.95, 1.15 ]
Heterogeneity: Chi2 = 8.48, df = 9 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 1.73, df = 2 (P = 0.42), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours vitamins Favours control
56Vitamin supplementation for preventing miscarriage (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 2 Early or
late miscarriage.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 2 Early or late miscarriage
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Trial entry before pregnancy
Czeizel 1994 301/2819 251/2683 71.4 % 1.14 [ 0.97, 1.34 ]
Hemmi 2003 3/19 1/5 0.4 % 0.79 [ 0.10, 6.06 ]
ICMR 2000 6/231 14/235 3.9 % 0.44 [ 0.17, 1.11 ]
MRC 1991 126/1363 44/454 18.3 % 0.95 [ 0.69, 1.32 ]
Subtotal (95% CI) 4432 3377 94.1 % 1.07 [ 0.93, 1.24 ]
Total events: 436 (Vitamin(s)), 310 (Control)
Heterogeneity: Chi2 = 4.70, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 1.00 (P = 0.32)
2 Trial entry < 12 weeks’ gestation
Briscoe 1959 31/303 8/103 3.3 % 1.32 [ 0.63, 2.77 ]
Subtotal (95% CI) 303 103 3.3 % 1.32 [ 0.63, 2.77 ]
Total events: 31 (Vitamin(s)), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
3 Trial entry >= 12 weeks but <20 weeks’ gestation
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Trial entry ’mixed’ both < 20 and >= 20 week’s gestation
Fleming 1968 0/35 1/40 0.4 % 0.38 [ 0.02, 9.03 ]
Steyn 2003 10/100 8/100 2.2 % 1.25 [ 0.51, 3.04 ]
Subtotal (95% CI) 135 140 2.6 % 1.12 [ 0.48, 2.60 ]
Total events: 10 (Vitamin(s)), 9 (Control)
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
Total (95% CI) 4870 3620 100.0 % 1.08 [ 0.95, 1.24 ]
Total events: 477 (Vitamin(s)), 327 (Control)
Heterogeneity: Chi2 = 5.49, df = 6 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
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Analysis 1.3. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 3 Stillbirth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 3 Stillbirth
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Trial entry before pregnancy
Czeizel 1994 11/2819 9/2683 10.3 % 1.16 [ 0.48, 2.80 ]
ICMR 2000 3/231 3/235 3.3 % 1.02 [ 0.21, 4.99 ]
MRC 1991 4/1363 3/454 5.0 % 0.44 [ 0.10, 1.98 ]
Subtotal (95% CI) 4413 3372 18.6 % 0.94 [ 0.48, 1.85 ]
Total events: 18 (Vitamin(s)), 15 (Control)
Heterogeneity: Chi2 = 1.20, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
2 Trial entry < 12 weeks’ gestation
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Trial entry >= 12 weeks’ but < 20 weeks’ gestation
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Trial entry ’mixed’ both < 20 and >= 20 weeks’ gestation
Chappell 1999 1/141 2/142 2.2 % 0.50 [ 0.05, 5.49 ]
Fleming 1968 0/35 1/40 1.6 % 0.38 [ 0.02, 9.03 ]
People’s League 1942 57/2510 69/2511 77.0 % 0.83 [ 0.58, 1.17 ]
Steyn 2003 1/100 0/100 0.6 % 3.00 [ 0.12, 72.77 ]
Subtotal (95% CI) 2786 2793 81.4 % 0.82 [ 0.59, 1.15 ]
Total events: 59 (Vitamin(s)), 72 (Control)
Heterogeneity: Chi2 = 1.02, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 7199 6165 100.0 % 0.85 [ 0.63, 1.14 ]
Total events: 77 (Vitamin(s)), 87 (Control)
Heterogeneity: Chi2 = 2.32, df = 6 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
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Analysis 1.4. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 4 Placental
abruption.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 4 Placental abruption
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Placental abruption
Chappell 1999 1/141 3/142 100.0 % 0.34 [ 0.04, 3.19 ]
Subtotal (95% CI) 141 142 100.0 % 0.34 [ 0.04, 3.19 ]
Total events: 1 (Vitamin(s)), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
2 Antepartum haemorrhage including placental abruption
Steyn 2003 7/100 1/100 100.0 % 7.00 [ 0.88, 55.86 ]
Subtotal (95% CI) 100 100 100.0 % 7.00 [ 0.88, 55.86 ]
Total events: 7 (Vitamin(s)), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
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Analysis 1.6. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 6 Pre-
eclampsia.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 6 Pre-eclampsia
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chappell 1999 11/142 24/142 14.0 % 0.46 [ 0.23, 0.90 ]
Fleming 1968 2/35 2/40 1.1 % 1.14 [ 0.17, 7.69 ]
People’s League 1942 100/2510 143/2511 83.2 % 0.70 [ 0.55, 0.90 ]
Steyn 2003 3/100 3/100 1.7 % 1.00 [ 0.21, 4.84 ]
Total (95% CI) 2787 2793 100.0 % 0.68 [ 0.54, 0.85 ]
Total events: 116 (Vitamin(s)), 172 (Control)
Heterogeneity: Chi2 = 1.88, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00080)
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Analysis 1.7. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 7 Perinatal
death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 7 Perinatal death
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Steyn 2003 1/90 2/92 100.0 % 0.51 [ 0.05, 5.54 ]
Total (95% CI) 90 92 100.0 % 0.51 [ 0.05, 5.54 ]
Total events: 1 (Vitamin(s)), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
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Analysis 1.8. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 8 Neonatal
death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 8 Neonatal death
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Czeizel 1994 2507 2423 1.0647 (1.6288) 0.3 % 2.90 [ 0.12, 70.60 ]
Katz 2000 10228 4887 0.0862 (0.091) 88.4 % 1.09 [ 0.91, 1.30 ]
People’s League 1942 2453 2442 0.3436 (0.2646) 10.5 % 1.41 [ 0.84, 2.37 ]
Steyn 2003 89 92 -0.3711 (0.8964) 0.9 % 0.69 [ 0.12, 4.00 ]
Total (95% CI) 15277 9844 100.0 % 1.12 [ 0.95, 1.32 ]
Heterogeneity: Chi2 = 1.48, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 9 Preterm
birth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 9 Preterm birth
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Chappell 1999 141 142 0.1906 (0.5921) 0.8 % 1.21 [ 0.38, 3.86 ]
Czeizel 1994 2819 2683 0.0198 (0.1045) 26.9 % 1.02 [ 0.83, 1.25 ]
Fleming 1968 35 40 0.0198 (0.4274) 1.6 % 1.02 [ 0.44, 2.36 ]
Katz 2000 11720 5653 0.0198 (0.0698) 60.3 % 1.02 [ 0.89, 1.17 ]
Steyn 2003 100 100 0.3557 (0.168) 10.4 % 1.43 [ 1.03, 1.98 ]
Total (95% CI) 14815 8618 100.0 % 1.06 [ 0.95, 1.18 ]
Heterogeneity: Chi2 = 3.63, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 10 Very
preterm birth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 10 Very preterm birth
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Steyn 2003 26/100 20/100 100.0 % 1.30 [ 0.78, 2.17 ]
Total (95% CI) 100 100 100.0 % 1.30 [ 0.78, 2.17 ]
Total events: 26 (Vitamin(s)), 20 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
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Analysis 1.11. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 11
Birthweight.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 11 Birthweight
Study or subgroup Vitamin(s) Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Correia 1982 16 3440 (304) 13 3128 (255) 44.5 % 312.00 [ 108.52, 515.48 ]
Czeizel 1994 2471 3291 (488) 2391 3288 (478) 55.5 % 3.00 [ -24.15, 30.15 ]
Total (95% CI) 2487 2404 100.0 % 140.37 [ -160.58, 441.32 ]
Heterogeneity: Tau2 = 42255.57; Chi2 = 8.70, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.91 (P = 0.36)
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Analysis 1.12. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 12 Small-
for-gestational age.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 12 Small-for-gestational age
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Birthweight less than 10th centile or birthweight < 2500 g
Chappell 1999 33/141 45/142 31.0 % 0.74 [ 0.50, 1.08 ]
Czeizel 1994 101/2471 81/2391 57.0 % 1.21 [ 0.91, 1.61 ]
Fleming 1968 3/35 3/40 1.9 % 1.14 [ 0.25, 5.30 ]
ICMR 2000 12/96 14/90 10.0 % 0.80 [ 0.39, 1.64 ]
Total (95% CI) 2743 2663 100.0 % 1.02 [ 0.82, 1.27 ]
Total events: 149 (Vitamin(s)), 143 (Control)
Heterogeneity: Chi2 = 4.48, df = 3 (P = 0.21); I2 =33%
Test for overall effect: Z = 0.18 (P = 0.86)
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Analysis 1.13. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 13
Congenital malformations.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 13 Congenital malformations
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Czeizel 1994 7/2471 6/2391 44.8 % 1.13 [ 0.38, 3.35 ]
MRC 1991 27/1363 5/454 55.2 % 1.80 [ 0.70, 4.64 ]
Total (95% CI) 3834 2845 100.0 % 1.50 [ 0.73, 3.06 ]
Total events: 34 (Vitamin(s)), 11 (Control)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
0.1 0.2 0.5 1 2 5 10
Favours vitamins Favours control
Analysis 1.14. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 14 Multiple
pregnancy.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 14 Multiple pregnancy
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Czeizel 1994 2471 2391 0.3436 (0.1589) 44.4 % 1.41 [ 1.03, 1.93 ]
ICMR 2000 137 142 -1.0498 (1.1242) 0.9 % 0.35 [ 0.04, 3.17 ]
Katz 2000 10699 5146 0.3293 (0.1431) 54.7 % 1.39 [ 1.05, 1.84 ]
Total (95% CI) 13307 7679 100.0 % 1.38 [ 1.12, 1.70 ]
Heterogeneity: Chi2 = 1.51, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0023)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 19 Placental
weight.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 19 Placental weight
Study or subgroup Vitamin(s) Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Correia 1982 16 531 (80) 13 435 (96) 100.0 % 96.00 [ 30.73, 161.27 ]
Total (95% CI) 16 13 100.0 % 96.00 [ 30.73, 161.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0039)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
Favours control Favours vitamins
66Vitamin supplementation for preventing miscarriage (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.20. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 20 Method
of feeding.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 20 Method of feeding
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Breastfeeding
People’s League 1942 2088/2443 2117/2435 100.0 % 0.98 [ 0.96, 1.01 ]
Subtotal (95% CI) 2443 2435 100.0 % 0.98 [ 0.96, 1.01 ]
Total events: 2088 (Vitamin(s)), 2117 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
2 Formula
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Breastfeeding and formula
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2443 2435 100.0 % 0.98 [ 0.96, 1.01 ]
Total events: 2088 (Vitamin(s)), 2117 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
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Analysis 1.29. Comparison 1 Any vitamins versus no vitamins (or minimal vitamins), Outcome 29 Duration
of admission to the neonatal intensive care unit.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 1 Any vitamins versus no vitamins (or minimal vitamins)
Outcome: 29 Duration of admission to the neonatal intensive care unit
Study or subgroup Vitamin(s) Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Steyn 2003 89 3.64 (5.6) 92 2.34 (5.2) 100.0 % 1.30 [ -0.28, 2.88 ]
Total (95% CI) 89 92 100.0 % 1.30 [ -0.28, 2.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours vitamins Favours control
68Vitamin supplementation for preventing miscarriage (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Any vitamins (by allocation concealment), Outcome 1 Total fetal loss (including
miscarriage or combined miscarriages and stillbirths).
Review: Vitamin supplementation for preventing miscarriage
Comparison: 2 Any vitamins (by allocation concealment)
Outcome: 1 Total fetal loss (including miscarriage or combined miscarriages and stillbirths)
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Allocation concealment = A
Chappell 1999 141 142 -0.301 (0.6202) 0.2 % 0.74 [ 0.22, 2.50 ]
MRC 1991 1363 454 -0.0362 (0.0834) 8.4 % 0.96 [ 0.82, 1.14 ]
Steyn 2003 100 100 0.1399 (0.2283) 1.1 % 1.15 [ 0.74, 1.80 ]
Subtotal (95% CI) 1604 696 9.7 % 0.98 [ 0.84, 1.14 ]
Heterogeneity: Chi2 = 0.73, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
2 Allocation concealment = B
Briscoe 1959 303 103 0.1206 (0.1955) 1.5 % 1.13 [ 0.77, 1.65 ]
Czeizel 1994 2819 2683 0.0569 (0.0403) 36.2 % 1.06 [ 0.98, 1.15 ]
Hemmi 2003 19 5 -0.1024 (0.5418) 0.2 % 0.90 [ 0.31, 2.61 ]
ICMR 2000 231 235 -0.2676 (0.2048) 1.4 % 0.77 [ 0.51, 1.14 ]
Katz 2000 11720 5653 0.0212 (0.0365) 44.1 % 1.02 [ 0.95, 1.10 ]
Subtotal (95% CI) 15092 8679 83.4 % 1.03 [ 0.98, 1.09 ]
Heterogeneity: Chi2 = 2.87, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
3 Allocation concealment = C
Fleming 1968 35 40 -1.4697 (1.5635) 0.0 % 0.23 [ 0.01, 4.93 ]
People’s League 1942 2510 2511 -0.0809 (0.0926) 6.9 % 0.92 [ 0.77, 1.11 ]
Subtotal (95% CI) 2545 2551 6.9 % 0.92 [ 0.77, 1.10 ]
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 19241 11926 100.0 % 1.02 [ 0.97, 1.07 ]
Heterogeneity: Chi2 = 6.22, df = 9 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 1.83, df = 2 (P = 0.40), I2 =0.0%
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Analysis 2.2. Comparison 2 Any vitamins (by allocation concealment), Outcome 2 Early or late miscarriage.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 2 Any vitamins (by allocation concealment)
Outcome: 2 Early or late miscarriage
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Allocation concealment = A
MRC 1991 126/1363 44/454 18.3 % 0.95 [ 0.69, 1.32 ]
Steyn 2003 10/100 8/100 2.2 % 1.25 [ 0.51, 3.04 ]
Subtotal (95% CI) 1463 554 20.6 % 0.99 [ 0.73, 1.34 ]
Total events: 136 (Vitamin(s)), 52 (Control)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Allocation concealment = B
Briscoe 1959 31/303 8/103 3.3 % 1.32 [ 0.63, 2.77 ]
Czeizel 1994 301/2819 251/2683 71.4 % 1.14 [ 0.97, 1.34 ]
Hemmi 2003 3/19 1/5 0.4 % 0.79 [ 0.10, 6.06 ]
ICMR 2000 6/231 14/235 3.9 % 0.44 [ 0.17, 1.11 ]
Subtotal (95% CI) 3372 3026 79.1 % 1.11 [ 0.96, 1.30 ]
Total events: 341 (Vitamin(s)), 274 (Control)
Heterogeneity: Chi2 = 4.23, df = 3 (P = 0.24); I2 =29%
Test for overall effect: Z = 1.37 (P = 0.17)
3 Allocation concealment = C
Fleming 1968 0/35 1/40 0.4 % 0.38 [ 0.02, 9.03 ]
Subtotal (95% CI) 35 40 0.4 % 0.38 [ 0.02, 9.03 ]
Total events: 0 (Vitamin(s)), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 4870 3620 100.0 % 1.08 [ 0.95, 1.24 ]
Total events: 477 (Vitamin(s)), 327 (Control)
Heterogeneity: Chi2 = 5.49, df = 6 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
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Analysis 2.3. Comparison 2 Any vitamins (by allocation concealment), Outcome 3 Stillbirth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 2 Any vitamins (by allocation concealment)
Outcome: 3 Stillbirth
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Allocation concealment = A
Chappell 1999 1/141 2/142 2.2 % 0.50 [ 0.05, 5.49 ]
MRC 1991 4/1363 3/454 5.0 % 0.44 [ 0.10, 1.98 ]
Steyn 2003 1/100 0/100 0.6 % 3.00 [ 0.12, 72.77 ]
Subtotal (95% CI) 1604 696 7.8 % 0.64 [ 0.21, 1.96 ]
Total events: 6 (Vitamin(s)), 5 (Control)
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Allocation concealment = B
Czeizel 1994 11/2819 9/2683 10.3 % 1.16 [ 0.48, 2.80 ]
ICMR 2000 3/231 3/235 3.3 % 1.02 [ 0.21, 4.99 ]
Subtotal (95% CI) 3050 2918 13.6 % 1.13 [ 0.52, 2.43 ]
Total events: 14 (Vitamin(s)), 12 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
3 Allocation concealment = C
Fleming 1968 0/35 1/40 1.6 % 0.38 [ 0.02, 9.03 ]
People’s League 1942 57/2510 69/2511 77.0 % 0.83 [ 0.58, 1.17 ]
Subtotal (95% CI) 2545 2551 78.6 % 0.82 [ 0.58, 1.15 ]
Total events: 57 (Vitamin(s)), 70 (Control)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 7199 6165 100.0 % 0.85 [ 0.63, 1.14 ]
Total events: 77 (Vitamin(s)), 87 (Control)
Heterogeneity: Chi2 = 2.32, df = 6 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
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Analysis 3.1. Comparison 3 Any vitamins (by use of placebo), Outcome 1 Total fetal loss (including
miscarriage or combined miscarriages and stillbirths).
Review: Vitamin supplementation for preventing miscarriage
Comparison: 3 Any vitamins (by use of placebo)
Outcome: 1 Total fetal loss (including miscarriage or combined miscarriages and stillbirths)
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Placebo control
Briscoe 1959 303 103 0.1206 (0.1955) 1.5 % 1.13 [ 0.77, 1.65 ]
Chappell 1999 141 142 -0.301 (0.6202) 0.2 % 0.74 [ 0.22, 2.50 ]
Czeizel 1994 2819 2683 0.0569 (0.0403) 36.2 % 1.06 [ 0.98, 1.15 ]
Fleming 1968 35 40 -1.4697 (1.5635) 0.0 % 0.23 [ 0.01, 4.93 ]
ICMR 2000 231 235 -0.2676 (0.2048) 1.4 % 0.77 [ 0.51, 1.14 ]
Katz 2000 11720 5653 0.0212 (0.0365) 44.1 % 1.02 [ 0.95, 1.10 ]
MRC 1991 1363 454 -0.0362 (0.0834) 8.4 % 0.96 [ 0.82, 1.14 ]
Steyn 2003 100 100 0.1399 (0.2283) 1.1 % 1.15 [ 0.74, 1.80 ]
Subtotal (95% CI) 16712 9410 92.9 % 1.03 [ 0.98, 1.08 ]
Heterogeneity: Chi2 = 4.89, df = 7 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
2 No placebo control
Hemmi 2003 19 5 -0.1024 (0.5418) 0.2 % 0.90 [ 0.31, 2.61 ]
People’s League 1942 2511 2510 -0.0809 (0.0926) 6.9 % 0.92 [ 0.77, 1.11 ]
Subtotal (95% CI) 2530 2515 7.1 % 0.92 [ 0.77, 1.10 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Total (95% CI) 19242 11925 100.0 % 1.02 [ 0.97, 1.07 ]
Heterogeneity: Chi2 = 6.22, df = 9 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 1.33, df = 1 (P = 0.25), I2 =25%
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Analysis 3.2. Comparison 3 Any vitamins (by use of placebo), Outcome 2 Early or late miscarriage.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 3 Any vitamins (by use of placebo)
Outcome: 2 Early or late miscarriage
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Placebo control
Briscoe 1959 31/303 8/103 3.2 % 1.32 [ 0.63, 2.77 ]
Czeizel 1994 312/2819 260/2683 72.2 % 1.14 [ 0.98, 1.33 ]
Fleming 1968 0/35 1/40 0.4 % 0.38 [ 0.02, 9.03 ]
ICMR 2000 6/231 14/235 3.8 % 0.44 [ 0.17, 1.11 ]
MRC 1991 126/1363 44/454 17.9 % 0.95 [ 0.69, 1.32 ]
Steyn 2003 10/100 8/100 2.2 % 1.25 [ 0.51, 3.04 ]
Subtotal (95% CI) 4851 3615 99.6 % 1.09 [ 0.95, 1.24 ]
Total events: 485 (Vitamin(s)), 335 (Control)
Heterogeneity: Chi2 = 5.41, df = 5 (P = 0.37); I2 =8%
Test for overall effect: Z = 1.21 (P = 0.23)
2 No placebo control
Hemmi 2003 3/19 1/5 0.4 % 0.79 [ 0.10, 6.06 ]
Subtotal (95% CI) 19 5 0.4 % 0.79 [ 0.10, 6.06 ]
Total events: 3 (Vitamin(s)), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 4870 3620 100.0 % 1.09 [ 0.95, 1.24 ]
Total events: 488 (Vitamin(s)), 336 (Control)
Heterogeneity: Chi2 = 5.51, df = 6 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
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Analysis 3.3. Comparison 3 Any vitamins (by use of placebo), Outcome 3 Stillbirth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 3 Any vitamins (by use of placebo)
Outcome: 3 Stillbirth
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Placebo control
Chappell 1999 1/141 2/142 2.2 % 0.50 [ 0.05, 5.49 ]
Czeizel 1994 11/2819 9/2683 10.3 % 1.16 [ 0.48, 2.80 ]
Fleming 1968 0/35 1/40 1.6 % 0.38 [ 0.02, 9.03 ]
ICMR 2000 3/231 3/235 3.3 % 1.02 [ 0.21, 4.99 ]
MRC 1991 4/1363 3/454 5.0 % 0.44 [ 0.10, 1.98 ]
Steyn 2003 1/100 0/100 0.6 % 3.00 [ 0.12, 72.77 ]
Subtotal (95% CI) 4689 3654 23.0 % 0.91 [ 0.49, 1.69 ]
Total events: 20 (Vitamin(s)), 18 (Control)
Heterogeneity: Chi2 = 2.27, df = 5 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
2 No placebo control
People’s League 1942 57/2510 69/2511 77.0 % 0.83 [ 0.58, 1.17 ]
Subtotal (95% CI) 2510 2511 77.0 % 0.83 [ 0.58, 1.17 ]
Total events: 57 (Vitamin(s)), 69 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 7199 6165 100.0 % 0.85 [ 0.63, 1.14 ]
Total events: 77 (Vitamin(s)), 87 (Control)
Heterogeneity: Chi2 = 2.32, df = 6 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
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Analysis 4.1. Comparison 4 Any vitamins (by losses to follow up), Outcome 1 Total fetal loss (including
miscarriage or combined miscarriages and stillbirths).
Review: Vitamin supplementation for preventing miscarriage
Comparison: 4 Any vitamins (by losses to follow up)
Outcome: 1 Total fetal loss (including miscarriage or combined miscarriages and stillbirths)
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Less than 3% losses to follow up
Chappell 1999 141 142 -0.301 (0.6202) 0.2 % 0.74 [ 0.22, 2.50 ]
Czeizel 1994 2819 2683 0.0569 (0.0403) 36.2 % 1.06 [ 0.98, 1.15 ]
Katz 2000 11720 5653 0.0212 (0.0365) 44.1 % 1.02 [ 0.95, 1.10 ]
Subtotal (95% CI) 14680 8478 80.4 % 1.04 [ 0.98, 1.09 ]
Heterogeneity: Chi2 = 0.73, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.18)
2 3 to < 10% losses to follow up
MRC 1991 1363 454 -0.0362 (0.0834) 8.4 % 0.96 [ 0.82, 1.14 ]
Subtotal (95% CI) 1363 454 8.4 % 0.96 [ 0.82, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
3 10 to < 20% losses to follow up
Hemmi 2003 19 5 -0.1024 (0.5418) 0.2 % 0.90 [ 0.31, 2.61 ]
People’s League 1942 2510 2511 -0.0809 (0.0926) 6.9 % 0.92 [ 0.77, 1.11 ]
Subtotal (95% CI) 2529 2516 7.1 % 0.92 [ 0.77, 1.10 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
4 >= 20% losses to follow up
Fleming 1968 35 40 -1.4697 (1.5635) 0.0 % 0.23 [ 0.01, 4.93 ]
ICMR 2000 231 235 -0.2676 (0.2048) 1.4 % 0.77 [ 0.51, 1.14 ]
Subtotal (95% CI) 266 275 1.4 % 0.75 [ 0.50, 1.12 ]
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
5 Not stated
Briscoe 1959 303 103 0.1206 (0.1955) 1.5 % 1.13 [ 0.77, 1.65 ]
Steyn 2003 100 100 0.1399 (0.2283) 1.1 % 1.15 [ 0.74, 1.80 ]
Subtotal (95% CI) 403 203 2.7 % 1.14 [ 0.85, 1.52 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
Total (95% CI) 19241 11926 100.0 % 1.02 [ 0.97, 1.07 ]
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(. . . Continued)
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 6.22, df = 9 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 4.91, df = 4 (P = 0.30), I2 =18%
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Analysis 4.2. Comparison 4 Any vitamins (by losses to follow up), Outcome 2 Early or late miscarriage.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 4 Any vitamins (by losses to follow up)
Outcome: 2 Early or late miscarriage
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Less than 3% losses to follow up
Czeizel 1994 301/2819 251/2683 71.4 % 1.14 [ 0.97, 1.34 ]
Subtotal (95% CI) 2819 2683 71.4 % 1.14 [ 0.97, 1.34 ]
Total events: 301 (Vitamin(s)), 251 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
2 3 to < 10% losses to follow up
MRC 1991 126/1363 44/454 18.3 % 0.95 [ 0.69, 1.32 ]
Subtotal (95% CI) 1363 454 18.3 % 0.95 [ 0.69, 1.32 ]
Total events: 126 (Vitamin(s)), 44 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
3 10 to < 20% losses to follow up
Hemmi 2003 3/19 1/5 0.4 % 0.79 [ 0.10, 6.06 ]
Subtotal (95% CI) 19 5 0.4 % 0.79 [ 0.10, 6.06 ]
Total events: 3 (Vitamin(s)), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
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(. . . Continued)
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
4 >= 20 % losses to follow up
Fleming 1968 0/35 1/40 0.4 % 0.38 [ 0.02, 9.03 ]
ICMR 2000 6/231 14/235 3.9 % 0.44 [ 0.17, 1.11 ]
Subtotal (95% CI) 266 275 4.2 % 0.43 [ 0.18, 1.06 ]
Total events: 6 (Vitamin(s)), 15 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
5 Not stated
Briscoe 1959 31/303 8/103 3.3 % 1.32 [ 0.63, 2.77 ]
Steyn 2003 10/100 8/100 2.2 % 1.25 [ 0.51, 3.04 ]
Subtotal (95% CI) 403 203 5.5 % 1.29 [ 0.73, 2.28 ]
Total events: 41 (Vitamin(s)), 16 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 4870 3620 100.0 % 1.08 [ 0.95, 1.24 ]
Total events: 477 (Vitamin(s)), 327 (Control)
Heterogeneity: Chi2 = 5.49, df = 6 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
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Analysis 4.3. Comparison 4 Any vitamins (by losses to follow up), Outcome 3 Stillbirth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 4 Any vitamins (by losses to follow up)
Outcome: 3 Stillbirth
Study or subgroup Vitamin(s) Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Less than 3% losses to follow up
Chappell 1999 1/141 2/142 2.2 % 0.50 [ 0.05, 5.49 ]
Czeizel 1994 11/2819 9/2683 10.3 % 1.16 [ 0.48, 2.80 ]
Subtotal (95% CI) 2960 2825 12.5 % 1.05 [ 0.46, 2.37 ]
Total events: 12 (Vitamin(s)), 11 (Control)
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
2 3 to < 10% losses to follow up
MRC 1991 4/1363 3/454 5.0 % 0.44 [ 0.10, 1.98 ]
Subtotal (95% CI) 1363 454 5.0 % 0.44 [ 0.10, 1.98 ]
Total events: 4 (Vitamin(s)), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
3 10 to < 20% losses to follow up
People’s League 1942 57/2510 69/2511 77.0 % 0.83 [ 0.58, 1.17 ]
Subtotal (95% CI) 2510 2511 77.0 % 0.83 [ 0.58, 1.17 ]
Total events: 57 (Vitamin(s)), 69 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
4 >= 20% losses to follow up
Fleming 1968 0/35 1/40 1.6 % 0.38 [ 0.02, 9.03 ]
ICMR 2000 3/231 3/235 3.3 % 1.02 [ 0.21, 4.99 ]
Subtotal (95% CI) 266 275 4.9 % 0.81 [ 0.20, 3.28 ]
Total events: 3 (Vitamin(s)), 4 (Control)
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
5 Not stated
Steyn 2003 1/100 0/100 0.6 % 3.00 [ 0.12, 72.77 ]
Subtotal (95% CI) 100 100 0.6 % 3.00 [ 0.12, 72.77 ]
Total events: 1 (Vitamin(s)), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 7199 6165 100.0 % 0.85 [ 0.63, 1.14 ]
Total events: 77 (Vitamin(s)), 87 (Control)
Heterogeneity: Chi2 = 2.32, df = 6 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
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Analysis 5.1. Comparison 5 Vitamin C, Outcome 1 Total fetal loss.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 5 Vitamin C
Outcome: 1 Total fetal loss
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C + multivitamins versus placebo plus multivitamins
Briscoe 1959 31/303 8/103 100.0 % 1.32 [ 0.63, 2.77 ]
Subtotal (95% CI) 303 103 100.0 % 1.32 [ 0.63, 2.77 ]
Total events: 31 (Vitamin C), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
2 Vitamin C and vitamin E versus placebo
Chappell 1999 1/141 2/142 100.0 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 141 142 100.0 % 0.50 [ 0.05, 5.49 ]
Total events: 1 (Vitamin C), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
3 Vitamin C versus no supplement/placebo
Hemmi 2003 3/19 1/5 16.5 % 0.79 [ 0.10, 6.06 ]
Steyn 2003 11/100 8/100 83.5 % 1.38 [ 0.58, 3.27 ]
Subtotal (95% CI) 119 105 100.0 % 1.28 [ 0.58, 2.83 ]
Total events: 14 (Vitamin C), 9 (Control)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 5.2. Comparison 5 Vitamin C, Outcome 2 Early or late miscarriage.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 5 Vitamin C
Outcome: 2 Early or late miscarriage
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C + multivitamins versus placebo plus multivitamins
Briscoe 1959 31/303 8/103 100.0 % 1.32 [ 0.63, 2.77 ]
Subtotal (95% CI) 303 103 100.0 % 1.32 [ 0.63, 2.77 ]
Total events: 31 (Vitamin C), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
2 Vitamin C versus no supplement/placebo
Hemmi 2003 3/19 1/5 16.5 % 0.79 [ 0.10, 6.06 ]
Steyn 2003 10/100 8/100 83.5 % 1.25 [ 0.51, 3.04 ]
Subtotal (95% CI) 119 105 100.0 % 1.17 [ 0.52, 2.65 ]
Total events: 13 (Vitamin C), 9 (Control)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
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Analysis 5.3. Comparison 5 Vitamin C, Outcome 3 Stillbirth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 5 Vitamin C
Outcome: 3 Stillbirth
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C and vitamin E versus placebo
Chappell 1999 1/141 2/142 100.0 % 0.50 [ 0.05, 5.49 ]
Subtotal (95% CI) 141 142 100.0 % 0.50 [ 0.05, 5.49 ]
Total events: 1 (Vitamin C), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
2 Vitamin C versus placebo
Steyn 2003 1/100 0/100 100.0 % 3.00 [ 0.12, 72.77 ]
Subtotal (95% CI) 100 100 100.0 % 3.00 [ 0.12, 72.77 ]
Total events: 1 (Vitamin C), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 5.4. Comparison 5 Vitamin C, Outcome 4 Antepartum haemorrhage and placental abruption.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 5 Vitamin C
Outcome: 4 Antepartum haemorrhage and placental abruption
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C and vitamin E versus placebo - placental abruption only
Chappell 1999 1/141 3/142 100.0 % 0.34 [ 0.04, 3.19 ]
Subtotal (95% CI) 141 142 100.0 % 0.34 [ 0.04, 3.19 ]
Total events: 1 (Vitamin C), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
2 Vitamin C versus placebo - antepartum haemorrhage including placental abruption
Steyn 2003 7/100 1/100 100.0 % 7.00 [ 0.88, 55.86 ]
Subtotal (95% CI) 100 100 100.0 % 7.00 [ 0.88, 55.86 ]
Total events: 7 (Vitamin C), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
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Analysis 5.5. Comparison 5 Vitamin C, Outcome 5 Pre-eclampsia.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 5 Vitamin C
Outcome: 5 Pre-eclampsia
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C and vitamin E versus placebo
Chappell 1999 11/141 24/142 100.0 % 0.46 [ 0.24, 0.91 ]
Subtotal (95% CI) 141 142 100.0 % 0.46 [ 0.24, 0.91 ]
Total events: 11 (Vitamin C), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
2 Vitamin C versus placebo
Steyn 2003 3/100 3/100 100.0 % 1.00 [ 0.21, 4.84 ]
Subtotal (95% CI) 100 100 100.0 % 1.00 [ 0.21, 4.84 ]
Total events: 3 (Vitamin C), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 5.6. Comparison 5 Vitamin C, Outcome 6 Perinatal death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 5 Vitamin C
Outcome: 6 Perinatal death
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C versus placebo
Steyn 2003 1/90 2/92 100.0 % 0.51 [ 0.05, 5.54 ]
Total (95% CI) 90 92 100.0 % 0.51 [ 0.05, 5.54 ]
Total events: 1 (Vitamin C), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
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Analysis 5.7. Comparison 5 Vitamin C, Outcome 7 Neonatal death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 5 Vitamin C
Outcome: 7 Neonatal death
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C versus placebo
Steyn 2003 2/89 3/92 100.0 % 0.69 [ 0.12, 4.03 ]
Total (95% CI) 89 92 100.0 % 0.69 [ 0.12, 4.03 ]
Total events: 2 (Vitamin C), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
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Analysis 5.8. Comparison 5 Vitamin C, Outcome 8 Preterm birth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 5 Vitamin C
Outcome: 8 Preterm birth
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C and vitamin E versus placebo
Chappell 1999 6/141 5/142 100.0 % 1.21 [ 0.38, 3.87 ]
Subtotal (95% CI) 141 142 100.0 % 1.21 [ 0.38, 3.87 ]
Total events: 6 (Vitamin C), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
2 Vitamin C versus placebo
Steyn 2003 50/100 35/100 100.0 % 1.43 [ 1.03, 1.99 ]
Subtotal (95% CI) 100 100 100.0 % 1.43 [ 1.03, 1.99 ]
Total events: 50 (Vitamin C), 35 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
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Analysis 5.9. Comparison 5 Vitamin C, Outcome 9 Small-for-gestational age.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 5 Vitamin C
Outcome: 9 Small-for-gestational age
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C and vitamin E versus placebo
Chappell 1999 33/141 45/142 100.0 % 0.74 [ 0.50, 1.08 ]
Total (95% CI) 141 142 100.0 % 0.74 [ 0.50, 1.08 ]
Total events: 33 (Vitamin C), 45 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
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Analysis 5.10. Comparison 5 Vitamin C, Outcome 10 Very preterm birth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 5 Vitamin C
Outcome: 10 Very preterm birth
Study or subgroup Vitamin C Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin C versus placebo
Steyn 2003 26/100 20/100 100.0 % 1.30 [ 0.78, 2.17 ]
Total (95% CI) 100 100 100.0 % 1.30 [ 0.78, 2.17 ]
Total events: 26 (Vitamin C), 20 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
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Analysis 6.1. Comparison 6 Vitamin A, Outcome 1 Total fetal loss (including miscarriages or combined
miscarriages and stillbirths).
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 1 Total fetal loss (including miscarriages or combined miscarriages and stillbirths)
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vitamin A versus placebo
Katz 2000 6070 5653 0.0392 (0.0613) 100.0 % 1.04 [ 0.92, 1.17 ]
Subtotal (95% CI) 6070 5653 100.0 % 1.04 [ 0.92, 1.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 B-carotene versus placebo
Katz 2000 5650 5653 0.0296 (0.0613) 100.0 % 1.03 [ 0.91, 1.16 ]
Subtotal (95% CI) 5650 5653 100.0 % 1.03 [ 0.91, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
3 Vitamin A versus B-Carotene
Katz 2000 6070 5650 0.01 (0.0609) 100.0 % 1.01 [ 0.90, 1.14 ]
Subtotal (95% CI) 6070 5650 100.0 % 1.01 [ 0.90, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
4 Vitamin A or B-carotene versus placebo
Katz 2000 11720 5653 0.0488 (0.0706) 100.0 % 1.05 [ 0.91, 1.21 ]
Subtotal (95% CI) 11720 5653 100.0 % 1.05 [ 0.91, 1.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
5 Vitamin A (with/without multivitamins) versus multivitamins or placebo
Fawzi 1998 538 536 -0.2231 (0.2106) 100.0 % 0.80 [ 0.53, 1.21 ]
Subtotal (95% CI) 538 536 100.0 % 0.80 [ 0.53, 1.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
6 Vitamin A + iron + folate versus iron + folate
Kumwenda 2002 340 357 0.3577 (0.3883) 81.4 % 1.43 [ 0.67, 3.06 ]
Schmidt 2001 122 121 -0.0101 (0.8118) 18.6 % 0.99 [ 0.20, 4.86 ]
Subtotal (95% CI) 462 478 100.0 % 1.34 [ 0.67, 2.65 ]
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 2.19, df = 5 (P = 0.82), I2 =0.0%
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Analysis 6.2. Comparison 6 Vitamin A, Outcome 2 Early or late miscarriage.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 2 Early or late miscarriage
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin A (with/without multivitamins) versus multivitamins or placebo
Fawzi 1998 13/539 17/536 100.0 % 0.76 [ 0.37, 1.55 ]
Subtotal (95% CI) 539 536 100.0 % 0.76 [ 0.37, 1.55 ]
Total events: 13 (Vitamin A), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 Vitamin A + iron + folate versus iron + folate
Kumwenda 2002 7/340 5/357 100.0 % 1.47 [ 0.47, 4.59 ]
Subtotal (95% CI) 340 357 100.0 % 1.47 [ 0.47, 4.59 ]
Total events: 7 (Vitamin A), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
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Analysis 6.3. Comparison 6 Vitamin A, Outcome 3 Stillbirth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 3 Stillbirth
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin A (with/without multivitamins) versus multivitamins or placebo
Fawzi 1998 25/539 24/536 100.0 % 1.04 [ 0.60, 1.79 ]
Subtotal (95% CI) 539 536 100.0 % 1.04 [ 0.60, 1.79 ]
Total events: 25 (Vitamin A), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
2 Vitamin A + iron + folate versus iron + folate
Kumwenda 2002 8/340 6/357 66.0 % 1.40 [ 0.49, 3.99 ]
Schmidt 2001 3/122 3/121 34.0 % 0.99 [ 0.20, 4.82 ]
Subtotal (95% CI) 462 478 100.0 % 1.26 [ 0.53, 3.01 ]
Total events: 11 (Vitamin A), 9 (Control)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
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Analysis 6.4. Comparison 6 Vitamin A, Outcome 4 Neonatal death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 4 Neonatal death
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vitamin A versus placebo
Katz 2000 5327 4887 0.0862 (0.0882) 100.0 % 1.09 [ 0.92, 1.30 ]
Subtotal (95% CI) 5327 4887 100.0 % 1.09 [ 0.92, 1.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
2 B-carotene versus placebo
Katz 2000 4901 4887 0.0862 (0.091) 100.0 % 1.09 [ 0.91, 1.30 ]
Subtotal (95% CI) 4901 4887 100.0 % 1.09 [ 0.91, 1.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
3 Vitamin A versus B-Carotene
Katz 2000 5327 4901 0 (0.0858) 100.0 % 1.00 [ 0.85, 1.18 ]
Subtotal (95% CI) 5327 4901 100.0 % 1.00 [ 0.85, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Vitamin A or B-carotene versus placebo
Katz 2000 10228 4887 0.0862 (0.091) 100.0 % 1.09 [ 0.91, 1.30 ]
Subtotal (95% CI) 10228 4887 100.0 % 1.09 [ 0.91, 1.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Chi2 = 0.74, df = 3 (P = 0.86), I2 =0.0%
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Analysis 6.5. Comparison 6 Vitamin A, Outcome 5 Preterm birth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 5 Preterm birth
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vitamin A versus placebo
Katz 2000 6070 5653 0.0392 (0.0784) 100.0 % 1.04 [ 0.89, 1.21 ]
Subtotal (95% CI) 6070 5653 100.0 % 1.04 [ 0.89, 1.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
2 B-carotene versus placebo
Katz 2000 5650 5653 0.01 (0.0807) 100.0 % 1.01 [ 0.86, 1.18 ]
Subtotal (95% CI) 5650 5653 100.0 % 1.01 [ 0.86, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
3 Vitamin A versus B-Carotene
Katz 2000 6070 5650 0.0296 (0.0791) 100.0 % 1.03 [ 0.88, 1.20 ]
Subtotal (95% CI) 6070 5650 100.0 % 1.03 [ 0.88, 1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
4 Vitamin A or B-carotene versus placebo
Katz 2000 11720 5653 0.0198 (0.0698) 100.0 % 1.02 [ 0.89, 1.17 ]
Subtotal (95% CI) 11720 5653 100.0 % 1.02 [ 0.89, 1.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
5 Vitamin A (with/without multivitamins) versus multivitamins or placebo
Fawzi 1998 539 536 0.07 (0.1266) 100.0 % 1.07 [ 0.84, 1.37 ]
Subtotal (95% CI) 539 536 100.0 % 1.07 [ 0.84, 1.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.19, df = 4 (P = 1.00), I2 =0.0%
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Analysis 6.6. Comparison 6 Vitamin A, Outcome 6 Birthweight.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 6 Birthweight
Study or subgroup Vitamin A Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vitamin A + iron + folate versus iron + folate
Kumwenda 2002 285 2895 (523.34) 309 2805 (562.51) 100.0 % 90.00 [ 2.68, 177.32 ]
Total (95% CI) 285 309 100.0 % 90.00 [ 2.68, 177.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Not applicable
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Analysis 6.7. Comparison 6 Vitamin A, Outcome 7 Small-for-gestational age.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 7 Small-for-gestational age
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin A (with/without multivitamins) versus multivitamins or placebo
Fawzi 1998 48/539 57/536 100.0 % 0.84 [ 0.58, 1.21 ]
Total (95% CI) 539 536 100.0 % 0.84 [ 0.58, 1.21 ]
Total events: 48 (Vitamin A), 57 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
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Analysis 6.8. Comparison 6 Vitamin A, Outcome 8 Multiple pregnancy.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 8 Multiple pregnancy
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Vitamin A versus placebo
Katz 2000 5551 5146 0.3001 (0.1595) 100.0 % 1.35 [ 0.99, 1.85 ]
Subtotal (95% CI) 5551 5146 100.0 % 1.35 [ 0.99, 1.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
2 B-carotene versus placebo
Katz 2000 5148 5146 0.3148 (0.161) 100.0 % 1.37 [ 1.00, 1.88 ]
Subtotal (95% CI) 5148 5146 100.0 % 1.37 [ 1.00, 1.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.051)
3 Vitamin A versus B-Carotene
Katz 2000 5551 5148 0.0296 (0.1467) 100.0 % 1.03 [ 0.77, 1.37 ]
Subtotal (95% CI) 5551 5148 100.0 % 1.03 [ 0.77, 1.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
4 Vitamin A or B-carotene versus placebo
Katz 2000 10699 5146 0.3293 (0.1431) 100.0 % 1.39 [ 1.05, 1.84 ]
Subtotal (95% CI) 10699 5146 100.0 % 1.39 [ 1.05, 1.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
Test for subgroup differences: Chi2 = 2.80, df = 3 (P = 0.42), I2 =0.0%
0.01 0.1 1 10 100
Favours vitamin A Favours control
93Vitamin supplementation for preventing miscarriage (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.9. Comparison 6 Vitamin A, Outcome 9 Very preterm birth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 9 Very preterm birth
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vitamin A (with/without multivitamins) versus multivitamins or placebo
Fawzi 1998 38/539 34/536 100.0 % 1.11 [ 0.71, 1.74 ]
Total (95% CI) 539 536 100.0 % 1.11 [ 0.71, 1.74 ]
Total events: 38 (Vitamin A), 34 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
0.1 0.2 0.5 1 2 5 10
Favours vitamin A Favours control
Analysis 6.10. Comparison 6 Vitamin A, Outcome 10 Infant anaemia.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 10 Infant anaemia
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Infant anaemia at 6 weeks’ of age - vitamin A + iron + folate versus iron + folate
Kumwenda 2002 64/273 117/289 100.0 % 0.58 [ 0.45, 0.75 ]
Subtotal (95% CI) 273 289 100.0 % 0.58 [ 0.45, 0.75 ]
Total events: 64 (Vitamin A), 117 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.18 (P = 0.000029)
2 Infant anaemia at 12 months - vitamin A + iron + folate versus iron + folate
Kumwenda 2002 129/227 139/251 100.0 % 1.03 [ 0.88, 1.20 ]
Subtotal (95% CI) 227 251 100.0 % 1.03 [ 0.88, 1.20 ]
Total events: 129 (Vitamin A), 139 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
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Analysis 6.11. Comparison 6 Vitamin A, Outcome 11 Poor growth at childhood follow up.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 6 Vitamin A
Outcome: 11 Poor growth at childhood follow up
Study or subgroup Vitamin A Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Weight (g) at 6 weeks: vitamin A + iron + folate versus iron + folate
Kumwenda 2002 273 4627 (908.75) 273 4458 (908.75) 100.0 % 169.00 [ 16.55, 321.45 ]
Subtotal (95% CI) 273 273 100.0 % 169.00 [ 16.55, 321.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
2 Length (cm) at 6 weeks: vitamin A + iron + folate versus iron + folate
Kumwenda 2002 273 53.7 (3.3) 273 53 (3.3) 100.0 % 0.70 [ 0.15, 1.25 ]
Subtotal (95% CI) 273 273 100.0 % 0.70 [ 0.15, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
3 Weight (g) at 4 months: vitamin A + iron + folate versus iron + folate
Schmidt 2001 72 6100 (850) 76 6200 (870) 100.0 % -100.00 [ -377.14, 177.14 ]
Subtotal (95% CI) 72 76 100.0 % -100.00 [ -377.14, 177.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
5 Length (cm) at 4 months: vitamin A + iron + folate versus iron + folate
Schmidt 2001 72 60.7 (2.55) 76 61.2 (2.62) 100.0 % -0.50 [ -1.33, 0.33 ]
Subtotal (95% CI) 72 76 100.0 % -0.50 [ -1.33, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 10.74, df = 3 (P = 0.01), I2 =72%
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Analysis 7.1. Comparison 7 Multivitamin, Outcome 1 Total fetal loss (including miscarriages or combined
miscarriages and stillbirths).
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 1 Total fetal loss (including miscarriages or combined miscarriages and stillbirths)
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Multivitamin + folic acid versus no multivitamin/folic acid
Czeizel 1994 312/2819 260/2683 80.6 % 1.14 [ 0.98, 1.33 ]
ICMR 2000 9/231 17/235 5.1 % 0.54 [ 0.25, 1.18 ]
MRC 1991 47/461 47/454 14.3 % 0.98 [ 0.67, 1.44 ]
Subtotal (95% CI) 3511 3372 100.0 % 1.09 [ 0.95, 1.25 ]
Total events: 368 (Multivitamin), 324 (Control)
Heterogeneity: Chi2 = 3.70, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Multivitamin without folic acid versus no multivitamin/folic acid
MRC 1991 39/453 47/454 100.0 % 0.83 [ 0.56, 1.25 ]
Subtotal (95% CI) 453 454 100.0 % 0.83 [ 0.56, 1.25 ]
Total events: 39 (Multivitamin), 47 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
3 Multivitamins with/without folic acid versus no multivitamins/folic acid
MRC 1991 86/914 47/454 100.0 % 0.91 [ 0.65, 1.27 ]
Subtotal (95% CI) 914 454 100.0 % 0.91 [ 0.65, 1.27 ]
Total events: 86 (Multivitamin), 47 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
4 Multivitamin + folic acid versus folic acid
Kirke 1992 9/93 9/93 16.8 % 1.00 [ 0.42, 2.41 ]
MRC 1991 47/461 44/449 83.2 % 1.04 [ 0.70, 1.54 ]
Subtotal (95% CI) 554 542 100.0 % 1.03 [ 0.72, 1.48 ]
Total events: 56 (Multivitamin), 53 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
5 Multivitamin without folic acid versus folic acid
Kirke 1992 9/95 9/93 17.1 % 0.98 [ 0.41, 2.36 ]
MRC 1991 39/453 44/449 82.9 % 0.88 [ 0.58, 1.32 ]
Subtotal (95% CI) 548 542 100.0 % 0.90 [ 0.62, 1.30 ]
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(. . . Continued)
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 48 (Multivitamin), 53 (Control)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
6 Multivitamin with/without folic acid versus folic acid
Kirke 1992 16/188 9/93 16.9 % 0.88 [ 0.40, 1.91 ]
MRC 1991 86/914 44/449 83.1 % 0.96 [ 0.68, 1.36 ]
Subtotal (95% CI) 1102 542 100.0 % 0.95 [ 0.69, 1.30 ]
Total events: 102 (Multivitamin), 53 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
7 Multivitamin with/without vitamin A versus vitamin A or placebo
Fawzi 1998 31/537 52/537 100.0 % 0.60 [ 0.39, 0.91 ]
Subtotal (95% CI) 537 537 100.0 % 0.60 [ 0.39, 0.91 ]
Total events: 31 (Multivitamin), 52 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
8 Multivitamins versus control
People’s League 1942 57/2510 69/2511 100.0 % 0.83 [ 0.58, 1.17 ]
Subtotal (95% CI) 2510 2511 100.0 % 0.83 [ 0.58, 1.17 ]
Total events: 57 (Multivitamin), 69 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
9 Multivitamin + vitamin E versus multivitamin without vitamin E or controls
Rush 1980 11/267 25/556 100.0 % 0.92 [ 0.46, 1.83 ]
Subtotal (95% CI) 267 556 100.0 % 0.92 [ 0.46, 1.83 ]
Total events: 11 (Multivitamin), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
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Analysis 7.2. Comparison 7 Multivitamin, Outcome 2 Early or late miscarriage.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 2 Early or late miscarriage
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Multivitamin + folic acid versus no multivitamin/folic acid
Czeizel 1994 301/2819 251/2683 81.5 % 1.14 [ 0.97, 1.34 ]
ICMR 2000 6/231 14/235 4.4 % 0.44 [ 0.17, 1.11 ]
MRC 1991 45/461 44/454 14.1 % 1.01 [ 0.68, 1.49 ]
Subtotal (95% CI) 3511 3372 100.0 % 1.09 [ 0.94, 1.26 ]
Total events: 352 (Multivitamin), 309 (Control)
Heterogeneity: Chi2 = 4.13, df = 2 (P = 0.13); I2 =52%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Multivitamin without folic acid versus no multivitamin/folic acid
MRC 1991 39/453 44/454 100.0 % 0.89 [ 0.59, 1.34 ]
Subtotal (95% CI) 453 454 100.0 % 0.89 [ 0.59, 1.34 ]
Total events: 39 (Multivitamin), 44 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
3 Multivitamin with/without folic acid versus no multivitamin/folic acid
MRC 1991 84/914 44/454 100.0 % 0.95 [ 0.67, 1.34 ]
Subtotal (95% CI) 914 454 100.0 % 0.95 [ 0.67, 1.34 ]
Total events: 84 (Multivitamin), 44 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
4 Multivitamin + folic acid versus folic acid
Kirke 1992 9/93 9/93 17.5 % 1.00 [ 0.42, 2.41 ]
MRC 1991 45/461 42/449 82.5 % 1.04 [ 0.70, 1.56 ]
Subtotal (95% CI) 554 542 100.0 % 1.04 [ 0.72, 1.49 ]
Total events: 54 (Multivitamin), 51 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
5 Multivitamin without folic acid versus folic acid
Kirke 1992 7/95 9/93 17.7 % 0.76 [ 0.30, 1.96 ]
MRC 1991 39/453 42/449 82.3 % 0.92 [ 0.61, 1.39 ]
Subtotal (95% CI) 548 542 100.0 % 0.89 [ 0.61, 1.31 ]
Total events: 46 (Multivitamin), 51 (Control)
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(. . . Continued)
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
6 Multivitamin with/without folic acid versus folic acid
Kirke 1992 16/188 9/93 17.6 % 0.88 [ 0.40, 1.91 ]
MRC 1991 84/914 42/449 82.4 % 0.98 [ 0.69, 1.40 ]
Subtotal (95% CI) 1102 542 100.0 % 0.96 [ 0.70, 1.33 ]
Total events: 100 (Multivitamin), 51 (Control)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
7 Multivitamin + vitamin E versus multivitamin without vitamin E or controls
Rush 1980 3/267 6/556 100.0 % 1.04 [ 0.26, 4.13 ]
Subtotal (95% CI) 267 556 100.0 % 1.04 [ 0.26, 4.13 ]
Total events: 3 (Multivitamin), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
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Analysis 7.3. Comparison 7 Multivitamin, Outcome 3 Stillbirth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 3 Stillbirth
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Multivitamin + folic acid versus no multivitamin/folic acid
Czeizel 1994 11/2819 9/2683 60.6 % 1.16 [ 0.48, 2.80 ]
ICMR 2000 3/231 3/235 19.5 % 1.02 [ 0.21, 4.99 ]
MRC 1991 2/461 3/454 19.9 % 0.66 [ 0.11, 3.91 ]
Subtotal (95% CI) 3511 3372 100.0 % 1.03 [ 0.51, 2.09 ]
Total events: 16 (Multivitamin), 15 (Control)
Heterogeneity: Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Multivitamin without folic acid versus no multivitamin/folic acid
MRC 1991 0/453 3/454 100.0 % 0.14 [ 0.01, 2.76 ]
Subtotal (95% CI) 453 454 100.0 % 0.14 [ 0.01, 2.76 ]
Total events: 0 (Multivitamin), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
3 Multivitamin with/without folic acid versus no multivitamin/folic acid
MRC 1991 2/914 3/454 100.0 % 0.33 [ 0.06, 1.97 ]
Subtotal (95% CI) 914 454 100.0 % 0.33 [ 0.06, 1.97 ]
Total events: 2 (Multivitamin), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
4 Multivitamin + folic acid versus folic acid
Kirke 1992 0/93 0/93 Not estimable
MRC 1991 2/461 2/449 100.0 % 0.97 [ 0.14, 6.88 ]
Subtotal (95% CI) 554 542 100.0 % 0.97 [ 0.14, 6.88 ]
Total events: 2 (Multivitamin), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
5 Multivitamin without folic acid versus folic acid
Kirke 1992 2/95 0/93 16.8 % 4.90 [ 0.24, 100.62 ]
MRC 1991 0/453 2/449 83.2 % 0.20 [ 0.01, 4.12 ]
Subtotal (95% CI) 548 542 100.0 % 0.99 [ 0.20, 4.88 ]
Total events: 2 (Multivitamin), 2 (Control)
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(. . . Continued)
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 2.15, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.02 (P = 0.99)
6 Multivitamin with/without folic acid versus folic acid
Kirke 1992 2/188 0/93 19.9 % 2.49 [ 0.12, 51.28 ]
MRC 1991 2/914 2/449 80.1 % 0.49 [ 0.07, 3.48 ]
Subtotal (95% CI) 1102 542 100.0 % 0.89 [ 0.19, 4.15 ]
Total events: 4 (Multivitamin), 2 (Control)
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
7 Multivitamin versus control
People’s League 1942 57/2510 69/2511 100.0 % 0.83 [ 0.58, 1.17 ]
Subtotal (95% CI) 2510 2511 100.0 % 0.83 [ 0.58, 1.17 ]
Total events: 57 (Multivitamin), 69 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
8 Multivitamin + vitamin E versus multivitamin without vitamin E or controls
Rush 1980 8/267 19/556 100.0 % 0.88 [ 0.39, 1.98 ]
Subtotal (95% CI) 267 556 100.0 % 0.88 [ 0.39, 1.98 ]
Total events: 8 (Multivitamin), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
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Analysis 7.4. Comparison 7 Multivitamin, Outcome 4 Pre-eclampsia.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 4 Pre-eclampsia
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Multivitamin versus control
People’s League 1942 100/2510 143/2511 100.0 % 0.70 [ 0.55, 0.90 ]
Total (95% CI) 2510 2511 100.0 % 0.70 [ 0.55, 0.90 ]
Total events: 100 (Multivitamin), 143 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
0.1 0.2 0.5 1 2 5 10
Favours multivitamin Favours control
Analysis 7.5. Comparison 7 Multivitamin, Outcome 5 Perinatal death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 5 Perinatal death
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Multivitamin + folic acid + iron + zinc + vitamin A versus folic acid + iron + zinc + vitamin A
Christian 2003 919 3389 0.1072 (0.0645) 100.0 % 1.11 [ 0.98, 1.26 ]
Total (95% CI) 919 3389 100.0 % 1.11 [ 0.98, 1.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Multivitamin, Outcome 6 Neonatal death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 6 Neonatal death
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Multivitamin + folic acid versus no multivitamin/folic acid
Czeizel 1994 2507 2423 0.4639 (0.8428) 100.0 % 1.59 [ 0.30, 8.30 ]
Subtotal (95% CI) 2507 2423 100.0 % 1.59 [ 0.30, 8.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Multivitamin + vitamin E versus multivitamin without vitamin E or controls
Rush 1980 256 531 0.3617 (0.2342) 100.0 % 1.44 [ 0.91, 2.27 ]
Subtotal (95% CI) 256 531 100.0 % 1.44 [ 0.91, 2.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
3 Multivitamin versus control
People’s League 1942 2453 2442 0 (0.1481) 100.0 % 1.00 [ 0.75, 1.34 ]
Subtotal (95% CI) 2453 2442 100.0 % 1.00 [ 0.75, 1.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Multivitamin + folic acid + iron + zinc + vitamin A versus folic acid + iron + zinc + vitamin A
Christian 2003 870 3252 0.1399 (0.0861) 100.0 % 1.15 [ 0.97, 1.36 ]
Subtotal (95% CI) 870 3252 100.0 % 1.15 [ 0.97, 1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Chi2 = 1.92, df = 3 (P = 0.59), I2 =0.0%
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Analysis 7.7. Comparison 7 Multivitamin, Outcome 7 Preterm birth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 7 Preterm birth
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Multivitamin + folic acid versus no multivitamin/folic acid
Czeizel 1994 2819 2683 0.0086 (0.0541) 100.0 % 1.01 [ 0.91, 1.12 ]
Subtotal (95% CI) 2819 2683 100.0 % 1.01 [ 0.91, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
2 Multivitamin + folic acid + iron + zinc + vitamin A versus folic acid + iron + zinc + vitamin A
Christian 2003 704 2616 -0.0177 (0.0423) 100.0 % 0.98 [ 0.90, 1.07 ]
Subtotal (95% CI) 704 2616 100.0 % 0.98 [ 0.90, 1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
3 Multivitamin + vitamin E versus multivitamin without vitamin E or controls
Rush 1980 263 551 -0.0132 (0.079) 100.0 % 0.99 [ 0.85, 1.15 ]
Subtotal (95% CI) 263 551 100.0 % 0.99 [ 0.85, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.15, df = 2 (P = 0.93), I2 =0.0%
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Analysis 7.8. Comparison 7 Multivitamin, Outcome 8 Birthweight.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 8 Birthweight
Study or subgroup Multivitamin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Multivitamin + folic acid versus no multivitamin/folic acid
Czeizel 1994 2471 3291 (488) 2391 3288 (478) 100.0 % 3.00 [ -24.15, 30.15 ]
Total (95% CI) 2471 2391 100.0 % 3.00 [ -24.15, 30.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 7.9. Comparison 7 Multivitamin, Outcome 9 Small-for-gestational age.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 9 Small-for-gestational age
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Multivitamin + folic acid versus no multivitamin/folic acid
Czeizel 1994 2471 2391 0.0828 (0.0753) 100.0 % 1.09 [ 0.94, 1.26 ]
Subtotal (95% CI) 2471 2391 100.0 % 1.09 [ 0.94, 1.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Multivitamin + folic acid versus no multivitamin/folic acid (birthweight < 2500 g)
ICMR 2000 96 90 -0.0969 (0.1896) 100.0 % 0.91 [ 0.63, 1.32 ]
Subtotal (95% CI) 96 90 100.0 % 0.91 [ 0.63, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
3 Multivitamin + folic acid + iron + zinc + vitamin A versus folic acid + iron + zinc + vitamin A
Christian 2003 704 2616 -0.0177 (0.0193) 100.0 % 0.98 [ 0.95, 1.02 ]
Subtotal (95% CI) 704 2616 100.0 % 0.98 [ 0.95, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
4 Multivitamin+folic acid+iron+zinc+vitamin A versus folic acid+iron+zinc+vitamin A (birthweight < 2500 g)
Christian 2003 705 2620 -0.0506 (0.0281) 100.0 % 0.95 [ 0.90, 1.00 ]
Subtotal (95% CI) 705 2620 100.0 % 0.95 [ 0.90, 1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Chi2 = 3.16, df = 3 (P = 0.37), I2 =5%
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Analysis 7.10. Comparison 7 Multivitamin, Outcome 10 Congenital malformations.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 10 Congenital malformations
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Multivitamin + folic acid versus no multivitamin/folic acid
Czeizel 1994 7/2471 6/2391 54.8 % 1.13 [ 0.38, 3.35 ]
MRC 1991 12/461 5/454 45.2 % 2.36 [ 0.84, 6.65 ]
Subtotal (95% CI) 2932 2845 100.0 % 1.69 [ 0.81, 3.53 ]
Total events: 19 (Multivitamin), 11 (Control)
Heterogeneity: Chi2 = 0.93, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
2 Multivitamin without folic acid without versus no multivitamin/folic acid
MRC 1991 8/453 5/454 100.0 % 1.60 [ 0.53, 4.86 ]
Subtotal (95% CI) 453 454 100.0 % 1.60 [ 0.53, 4.86 ]
Total events: 8 (Multivitamin), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
3 Multivitamin with/without folic acid versus no multivitamin/folic acid
MRC 1991 20/914 5/454 100.0 % 1.99 [ 0.75, 5.26 ]
Subtotal (95% CI) 914 454 100.0 % 1.99 [ 0.75, 5.26 ]
Total events: 20 (Multivitamin), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
4 Multivitamin + folic acid versus folic acid
Kirke 1992 2/93 1/93 12.4 % 2.00 [ 0.18, 21.68 ]
MRC 1991 12/461 7/449 87.6 % 1.67 [ 0.66, 4.20 ]
Subtotal (95% CI) 554 542 100.0 % 1.71 [ 0.72, 4.04 ]
Total events: 14 (Multivitamin), 8 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
5 Multivitamin without folic acid versus folic acid
Kirke 1992 5/95 1/93 12.6 % 4.89 [ 0.58, 41.10 ]
MRC 1991 8/453 7/449 87.4 % 1.13 [ 0.41, 3.10 ]
Subtotal (95% CI) 548 542 100.0 % 1.61 [ 0.67, 3.85 ]
Total events: 13 (Multivitamin), 8 (Control)
Heterogeneity: Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.06 (P = 0.29)
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(. . . Continued)
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Multivitamin with/without folic acid versus folic acid
Kirke 1992 7/188 1/93 12.5 % 3.46 [ 0.43, 27.73 ]
MRC 1991 20/914 7/449 87.5 % 1.40 [ 0.60, 3.29 ]
Subtotal (95% CI) 1102 542 100.0 % 1.66 [ 0.76, 3.63 ]
Total events: 27 (Multivitamin), 8 (Control)
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
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Analysis 7.11. Comparison 7 Multivitamin, Outcome 11 Multiple pregnancy.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 11 Multiple pregnancy
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Multivitamin + folic acid versus no multivitamin/folic acid
Czeizel 1994 93/2471 64/2391 95.7 % 1.41 [ 1.03, 1.92 ]
ICMR 2000 1/137 3/142 4.3 % 0.35 [ 0.04, 3.28 ]
Total (95% CI) 2608 2533 100.0 % 1.36 [ 1.00, 1.85 ]
Total events: 94 (Multivitamin), 67 (Control)
Heterogeneity: Chi2 = 1.47, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 1.95 (P = 0.051)
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Analysis 7.12. Comparison 7 Multivitamin, Outcome 12 Maternal anaemia.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 12 Maternal anaemia
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Multivitamin + folic acid + iron + zinc + vitamin A versus folic acid + iron + zinc + vitamin A (any anaemia)
Christian 2003 183 630 -0.0809 (0.0555) 100.0 % 0.92 [ 0.83, 1.03 ]
Subtotal (95% CI) 183 630 100.0 % 0.92 [ 0.83, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
2 Multivitamin + folic acid + iron + zinc+vitamin A versus folic acid + iron + zinc + vitamin A (severe anaemia)
Christian 2003 183 630 -0.2007 (0.2237) 100.0 % 0.82 [ 0.53, 1.27 ]
Subtotal (95% CI) 183 630 100.0 % 0.82 [ 0.53, 1.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
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Analysis 7.13. Comparison 7 Multivitamin, Outcome 13 Breastfeeding.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 13 Breastfeeding
Study or subgroup Multivitamin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mulitivitamin versus control
People’s League 1942 2088/2443 2117/2435 100.0 % 0.98 [ 0.96, 1.01 ]
Total (95% CI) 2443 2435 100.0 % 0.98 [ 0.96, 1.01 ]
Total events: 2088 (Multivitamin), 2117 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
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Analysis 7.14. Comparison 7 Multivitamin, Outcome 14 Additional outcomes - infant death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 7 Multivitamin
Outcome: 14 Additional outcomes - infant death
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Multivitamin + folic acid + iron + zinc + vitamin A versus folic acid + iron + zinc + vitamin A
Christian 2003 870 3252 0.0934 (0.0809) 100.0 % 1.10 [ 0.94, 1.29 ]
Total (95% CI) 870 3252 100.0 % 1.10 [ 0.94, 1.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Folic acid, Outcome 1 Total fetal loss (including miscarriages or combined
miscarriages and stillbirths).
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 1 Total fetal loss (including miscarriages or combined miscarriages and stillbirths)
Study or subgroup Folic acid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Folic acid + multivitamin versus no folic acid/multivitamin
Czeizel 1994 312/2819 260/2683 80.6 % 1.14 [ 0.98, 1.33 ]
ICMR 2000 9/231 17/235 5.1 % 0.54 [ 0.25, 1.18 ]
MRC 1991 47/461 47/454 14.3 % 0.98 [ 0.67, 1.44 ]
Subtotal (95% CI) 3511 3372 100.0 % 1.09 [ 0.95, 1.25 ]
Total events: 368 (Folic acid), 324 (Control)
Heterogeneity: Chi2 = 3.70, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Folic acid without multivitamin versus no folic acid/multivitamin
MRC 1991 44/449 47/454 100.0 % 0.95 [ 0.64, 1.40 ]
Subtotal (95% CI) 449 454 100.0 % 0.95 [ 0.64, 1.40 ]
Total events: 44 (Folic acid), 47 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
3 Folic acid with/without multivitamin versus no folic acid/multivitamin
MRC 1991 91/910 47/454 100.0 % 0.97 [ 0.69, 1.35 ]
Subtotal (95% CI) 910 454 100.0 % 0.97 [ 0.69, 1.35 ]
Total events: 91 (Folic acid), 47 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
4 Folic acid + multivitamin versus multivitamin
Kirke 1992 9/93 9/95 18.5 % 1.02 [ 0.42, 2.46 ]
MRC 1991 47/461 39/453 81.5 % 1.18 [ 0.79, 1.77 ]
Subtotal (95% CI) 554 548 100.0 % 1.15 [ 0.80, 1.67 ]
Total events: 56 (Folic acid), 48 (Control)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
5 Folic acid without multivitamin versus multivitamin
Kirke 1992 9/93 9/95 18.7 % 1.02 [ 0.42, 2.46 ]
MRC 1991 44/449 39/453 81.3 % 1.14 [ 0.75, 1.72 ]
Subtotal (95% CI) 542 548 100.0 % 1.12 [ 0.77, 1.62 ]
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(. . . Continued)
Study or subgroup Folic acid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 53 (Folic acid), 48 (Control)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
6 Folic acid with or without multivitamin versus multivitamin
Kirke 1992 18/186 9/95 18.6 % 1.02 [ 0.48, 2.19 ]
MRC 1991 91/910 39/453 81.4 % 1.16 [ 0.81, 1.66 ]
Subtotal (95% CI) 1096 548 100.0 % 1.14 [ 0.82, 1.57 ]
Total events: 109 (Folic acid), 48 (Control)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
7 Folic acid + iron versus iron
Fleming 1968 0/35 2/40 100.0 % 0.23 [ 0.01, 4.59 ]
Subtotal (95% CI) 35 40 100.0 % 0.23 [ 0.01, 4.59 ]
Total events: 0 (Folic acid), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 8.2. Comparison 8 Folic acid, Outcome 2 Early or late miscarriage.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 2 Early or late miscarriage
Study or subgroup Folic acid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Folic acid + multivitamin versus no folic acid/multivitamin
Czeizel 1994 301/2819 251/2683 81.5 % 1.14 [ 0.97, 1.34 ]
ICMR 2000 6/231 14/235 4.4 % 0.44 [ 0.17, 1.11 ]
MRC 1991 45/461 44/454 14.1 % 1.01 [ 0.68, 1.49 ]
Subtotal (95% CI) 3511 3372 100.0 % 1.09 [ 0.94, 1.26 ]
Total events: 352 (Folic acid), 309 (Control)
Heterogeneity: Chi2 = 4.13, df = 2 (P = 0.13); I2 =52%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Folic acid without multivitamins versus no folic acid/multivitamin
MRC 1991 42/449 44/454 100.0 % 0.97 [ 0.65, 1.44 ]
Subtotal (95% CI) 449 454 100.0 % 0.97 [ 0.65, 1.44 ]
Total events: 42 (Folic acid), 44 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
3 Folic acid with/without multivitamin versus no folic acid/multivitamin
MRC 1991 87/910 44/454 100.0 % 0.99 [ 0.70, 1.39 ]
Subtotal (95% CI) 910 454 100.0 % 0.99 [ 0.70, 1.39 ]
Total events: 87 (Folic acid), 44 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
4 Folic acid + multivitamin versus multivitamin
Kirke 1992 9/93 7/95 15.0 % 1.31 [ 0.51, 3.38 ]
MRC 1991 45/461 39/453 85.0 % 1.13 [ 0.75, 1.71 ]
Subtotal (95% CI) 554 548 100.0 % 1.16 [ 0.80, 1.69 ]
Total events: 54 (Folic acid), 46 (Control)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
5 Folic acid without multivitamin versus multivitamin
Kirke 1992 9/93 7/95 15.1 % 1.31 [ 0.51, 3.38 ]
MRC 1991 42/449 39/453 84.9 % 1.09 [ 0.72, 1.65 ]
Subtotal (95% CI) 542 548 100.0 % 1.12 [ 0.77, 1.64 ]
Total events: 51 (Folic acid), 46 (Control)
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(. . . Continued)
Study or subgroup Folic acid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
6 Folic acid with/without multivitamin versus multivitamin
Kirke 1992 18/186 9/93 18.7 % 1.00 [ 0.47, 2.14 ]
MRC 1991 87/910 39/453 81.3 % 1.11 [ 0.77, 1.59 ]
Subtotal (95% CI) 1096 546 100.0 % 1.09 [ 0.79, 1.51 ]
Total events: 105 (Folic acid), 48 (Control)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
7 Folic acid + iron versus iron
Fleming 1968 0/35 1/40 100.0 % 0.38 [ 0.02, 9.03 ]
Subtotal (95% CI) 35 40 100.0 % 0.38 [ 0.02, 9.03 ]
Total events: 0 (Folic acid), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
0.01 0.1 1 10 100
Favours folic acid Favours control
114Vitamin supplementation for preventing miscarriage (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.3. Comparison 8 Folic acid, Outcome 3 Stillbirth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 3 Stillbirth
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Folic acid + multivitamin versus no folic acid/multivitamin
Czeizel 1994 11/2819 9/2683 60.6 % 1.16 [ 0.48, 2.80 ]
ICMR 2000 3/231 3/235 19.5 % 1.02 [ 0.21, 4.99 ]
MRC 1991 2/461 3/454 19.9 % 0.66 [ 0.11, 3.91 ]
Subtotal (95% CI) 3511 3372 100.0 % 1.03 [ 0.51, 2.09 ]
Total events: 16 (Treatment), 15 (Control)
Heterogeneity: Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Folic acid without multivitamin versus no folic acid/multivitamin
MRC 1991 2/449 3/454 100.0 % 0.67 [ 0.11, 4.02 ]
Subtotal (95% CI) 449 454 100.0 % 0.67 [ 0.11, 4.02 ]
Total events: 2 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
3 Folic acid with/without multivitamin versus no folic acid/multivitamin
MRC 1991 4/910 3/454 100.0 % 0.67 [ 0.15, 2.96 ]
Subtotal (95% CI) 910 454 100.0 % 0.67 [ 0.15, 2.96 ]
Total events: 4 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
4 Folic acid + multivitamin versus multivitamin
Kirke 1992 0/93 2/95 83.1 % 0.20 [ 0.01, 4.20 ]
MRC 1991 2/461 0/453 16.9 % 4.91 [ 0.24, 102.06 ]
Subtotal (95% CI) 554 548 100.0 % 1.00 [ 0.20, 4.99 ]
Total events: 2 (Treatment), 2 (Control)
Heterogeneity: Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.00 (P = 1.0)
5 Folic acid without multivitamin versus multivitamin
Kirke 1992 2/95 0/93 50.4 % 4.90 [ 0.24, 100.62 ]
MRC 1991 2/449 0/453 49.6 % 5.04 [ 0.24, 104.78 ]
Subtotal (95% CI) 544 546 100.0 % 4.97 [ 0.58, 42.29 ]
Total events: 4 (Treatment), 0 (Control)
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
6 Folic acid with/without multivitamin versus multivitamin
Kirke 1992 0/186 2/95 83.2 % 0.10 [ 0.00, 2.12 ]
MRC 1991 4/910 0/453 16.8 % 4.49 [ 0.24, 83.13 ]
Subtotal (95% CI) 1096 548 100.0 % 0.84 [ 0.20, 3.53 ]
Total events: 4 (Treatment), 2 (Control)
Heterogeneity: Chi2 = 3.12, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.24 (P = 0.81)
7 Folic acid + iron versus iron
Fleming 1968 0/35 1/40 100.0 % 0.38 [ 0.02, 9.03 ]
Subtotal (95% CI) 35 40 100.0 % 0.38 [ 0.02, 9.03 ]
Total events: 0 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 8.4. Comparison 8 Folic acid, Outcome 4 Pre-eclampsia.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 4 Pre-eclampsia
Study or subgroup Folic acid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Folic acid + iron versus iron
Fleming 1968 2/35 2/40 100.0 % 1.14 [ 0.17, 7.69 ]
Total (95% CI) 35 40 100.0 % 1.14 [ 0.17, 7.69 ]
Total events: 2 (Folic acid), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
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Analysis 8.5. Comparison 8 Folic acid, Outcome 5 Perinatal death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 5 Perinatal death
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Folic acid + iron + zinc + multivitamin + vitamin A versus vitamin A
Christian 2003 3392 916 -0.0315 (0.0674) 100.0 % 0.97 [ 0.85, 1.11 ]
Total (95% CI) 3392 916 100.0 % 0.97 [ 0.85, 1.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 Folic acid, Outcome 6 Neonatal death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 6 Neonatal death
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Folic acid + multivitamin versus no folic acid/multivitamin
Czeizel 1994 2507 2423 0.4624 (0.8428) 100.0 % 1.59 [ 0.30, 8.28 ]
Subtotal (95% CI) 2507 2423 100.0 % 1.59 [ 0.30, 8.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Folic acid + iron + zinc + multivitamin + vitamin A versus vitamin A
Christian 2003 3246 876 -0.0458 (0.0915) 100.0 % 0.96 [ 0.80, 1.14 ]
Subtotal (95% CI) 3246 876 100.0 % 0.96 [ 0.80, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Chi2 = 0.36, df = 1 (P = 0.55), I2 =0.0%
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Analysis 8.7. Comparison 8 Folic acid, Outcome 7 Preterm birth.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 7 Preterm birth
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Folic acid + multivitamin versus no folic acid/multivitamin
Czeizel 1994 2819 2683 0.0086 (0.0541) 100.0 % 1.01 [ 0.91, 1.12 ]
Subtotal (95% CI) 2819 2683 100.0 % 1.01 [ 0.91, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
2 Folic acid + multivitamin versus no folic acid/multivitamin
Fleming 1968 35 40 0.0086 (0.2212) 100.0 % 1.01 [ 0.65, 1.56 ]
Subtotal (95% CI) 35 40 100.0 % 1.01 [ 0.65, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
3 Folic acid + iron + zinc + multivitamin + vitamin A versus vitamin A
Christian 2003 2635 685 0.0212 (0.0438) 100.0 % 1.02 [ 0.94, 1.11 ]
Subtotal (95% CI) 2635 685 100.0 % 1.02 [ 0.94, 1.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.03, df = 2 (P = 0.98), I2 =0.0%
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Analysis 8.8. Comparison 8 Folic acid, Outcome 8 Birthweight.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 8 Birthweight
Study or subgroup Folic acid Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Folic acid + multivitamin versus no folic acid/multivitamin
Czeizel 1994 2471 3291 (488) 2391 3288 (478) 100.0 % 3.00 [ -24.15, 30.15 ]
Subtotal (95% CI) 2471 2391 100.0 % 3.00 [ -24.15, 30.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
2 Folic acid versus placebo
Correia 1982 16 3440 (304) 13 3128 (255) 100.0 % 312.00 [ 108.52, 515.48 ]
Subtotal (95% CI) 16 13 100.0 % 312.00 [ 108.52, 515.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.01 (P = 0.0027)
Test for subgroup differences: Chi2 = 8.70, df = 1 (P = 0.00), I2 =89%
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Analysis 8.9. Comparison 8 Folic acid, Outcome 9 Small-for-gestational age.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 9 Small-for-gestational age
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Folic acid + multivitamin versus no folic acid/multivitamin
Czeizel 1994 2471 2391 0.0828 (0.0753) 100.0 % 1.09 [ 0.94, 1.26 ]
Subtotal (95% CI) 2471 2391 100.0 % 1.09 [ 0.94, 1.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Folic acid + iron + zinc + multivitamin + vitamin A versus vitamin A
Christian 2003 2635 685 -0.0269 (0.0291) 100.0 % 0.97 [ 0.92, 1.03 ]
Subtotal (95% CI) 2635 685 100.0 % 0.97 [ 0.92, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
3 Folic acid + iron versus iron (birthweight < 2500 g)
Fleming 1968 35 40 0.0569 (0.4031) 100.0 % 1.06 [ 0.48, 2.33 ]
Subtotal (95% CI) 35 40 100.0 % 1.06 [ 0.48, 2.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
4 Folic acid + multivitamin versus no folic acid/multivitamin (birthweight < 2500 g)
ICMR 2000 96 90 -0.0969 (0.1896) 100.0 % 0.91 [ 0.63, 1.32 ]
Subtotal (95% CI) 96 90 100.0 % 0.91 [ 0.63, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
5 Folic acid + iron + zinc + multivitamin + vitamin A versus vitamin A (birthweight < 2500 g)
Christian 2003 2640 685 -0.0605 (0.0257) 100.0 % 0.94 [ 0.90, 0.99 ]
Subtotal (95% CI) 2640 685 100.0 % 0.94 [ 0.90, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 3.64, df = 4 (P = 0.46), I2 =0.0%
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Analysis 8.10. Comparison 8 Folic acid, Outcome 10 Congenital malformations.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 10 Congenital malformations
Study or subgroup Folic acid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Folic acid + multivitamin versus no folic acid/multivitamin
Czeizel 1994 7/2471 6/2391 54.8 % 1.13 [ 0.38, 3.35 ]
MRC 1991 12/461 5/454 45.2 % 2.36 [ 0.84, 6.65 ]
Subtotal (95% CI) 2932 2845 100.0 % 1.69 [ 0.81, 3.53 ]
Total events: 19 (Folic acid), 11 (Control)
Heterogeneity: Chi2 = 0.93, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
2 Folic acid without multivitamin versus no folic acid/multivitamin
MRC 1991 7/449 5/454 100.0 % 1.42 [ 0.45, 4.43 ]
Subtotal (95% CI) 449 454 100.0 % 1.42 [ 0.45, 4.43 ]
Total events: 7 (Folic acid), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
3 Folic acid with/without multivitamin versus no folic acid/multivitamin
MRC 1991 19/910 5/454 100.0 % 1.90 [ 0.71, 5.04 ]
Subtotal (95% CI) 910 454 100.0 % 1.90 [ 0.71, 5.04 ]
Total events: 19 (Folic acid), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
4 Folic acid + multivitamin versus multivitamin
Kirke 1992 2/93 5/95 38.0 % 0.41 [ 0.08, 2.05 ]
MRC 1991 12/461 8/453 62.0 % 1.47 [ 0.61, 3.57 ]
Subtotal (95% CI) 554 548 100.0 % 1.07 [ 0.51, 2.26 ]
Total events: 14 (Folic acid), 13 (Control)
Heterogeneity: Chi2 = 1.87, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.18 (P = 0.86)
5 Folic acid without multivitamin versus multivitamin
Kirke 1992 1/93 5/95 38.3 % 0.20 [ 0.02, 1.72 ]
MRC 1991 7/449 8/453 61.7 % 0.88 [ 0.32, 2.41 ]
Subtotal (95% CI) 542 548 100.0 % 0.62 [ 0.26, 1.49 ]
Total events: 8 (Folic acid), 13 (Control)
Heterogeneity: Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.06 (P = 0.29)
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(. . . Continued)
Study or subgroup Folic acid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Folic acid with or without multvitamin versus multivitamin
Kirke 1992 3/186 5/95 38.3 % 0.31 [ 0.07, 1.26 ]
MRC 1991 19/910 8/453 61.7 % 1.18 [ 0.52, 2.68 ]
Subtotal (95% CI) 1096 548 100.0 % 0.85 [ 0.43, 1.67 ]
Total events: 22 (Folic acid), 13 (Control)
Heterogeneity: Chi2 = 2.64, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.48 (P = 0.63)
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Analysis 8.11. Comparison 8 Folic acid, Outcome 11 Multiple pregnancy.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 11 Multiple pregnancy
Study or subgroup Folic acid Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Folic acid + multivitamin versus no folic acid/multivitamin
Czeizel 1994 93/2471 64/2391 95.7 % 1.41 [ 1.03, 1.92 ]
ICMR 2000 1/137 3/142 4.3 % 0.35 [ 0.04, 3.28 ]
Subtotal (95% CI) 2608 2533 100.0 % 1.36 [ 1.00, 1.85 ]
Total events: 94 (Folic acid), 67 (Control)
Heterogeneity: Chi2 = 1.47, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 1.95 (P = 0.051)
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Analysis 8.12. Comparison 8 Folic acid, Outcome 12 Maternal anaemia.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 12 Maternal anaemia
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Folic acid + iron + zinc + multivitamin + vitamin A versus vitamin A (any anaemia)
Christian 2003 634 179 -0.1805 (0.042) 100.0 % 0.83 [ 0.77, 0.91 ]
Subtotal (95% CI) 634 179 100.0 % 0.83 [ 0.77, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.30 (P = 0.000017)
2 Folic acid + iron + zinc + multivitamin + vitamin A versus vitamin A (severe anaemia)
Christian 2003 634 179 -0.1938 (0.1737) 100.0 % 0.82 [ 0.59, 1.16 ]
Subtotal (95% CI) 634 179 100.0 % 0.82 [ 0.59, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
3 Folic acid + iron versus iron (severe anaemia)
Fleming 1968 35 50 0.0569 (0.7296) 100.0 % 1.06 [ 0.25, 4.42 ]
Subtotal (95% CI) 35 50 100.0 % 1.06 [ 0.25, 4.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 0.11, df = 2 (P = 0.95), I2 =0.0%
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Analysis 8.13. Comparison 8 Folic acid, Outcome 13 Placental weight.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 13 Placental weight
Study or subgroup Folic acid Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Folic acid versus placebo
Correia 1982 16 531 (80) 13 435 (96) 100.0 % 96.00 [ 30.73, 161.27 ]
Total (95% CI) 16 13 100.0 % 96.00 [ 30.73, 161.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0039)
Test for subgroup differences: Not applicable
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Analysis 8.14. Comparison 8 Folic acid, Outcome 14 Additional outcomes - infant death.
Review: Vitamin supplementation for preventing miscarriage
Comparison: 8 Folic acid
Outcome: 14 Additional outcomes - infant death
Study or subgroup Vitamins Control log [Relative risk] Relative risk Weight Relative risk
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Folic acid + iron + zinc + multivitamin + vitamin A versus vitamin A
Christian 2003 3246 876 -0.0555 (0.0809) 100.0 % 0.95 [ 0.81, 1.11 ]
Total (95% CI) 3246 876 100.0 % 0.95 [ 0.81, 1.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Additional outcomes
Study ID Outcome Vitamin - N Vitamin - Me-
dian
Vitamin -
Range
Placebo - N Placebo - Me-
dian
Placebo -
Range
Steyn 2003 Median birth-
weight
100 2491 240-3834 100 2664 334-4680
A P P E N D I C E S
Appendix 1. Search strategy
1. miscarriage*
2. spontaneous abortion
3. recurrent abortion
4. habitual abortion
5. spontaneous pregnancy loss
6. recurrent pregnancy loss
7. early pregnancy loss
8. early pregnancy bleeding
9. fetal death
10. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
11. vitamin*
12. retinol*
13. carotenoid*
14. thiamin*
15. riboflavin
16. niacin or nicotinamide or nicotinic acid
17. pantothenic acid or pantothenate
18. pyridox*
19. cyanocobalamin or cobalamin
20. ascorb*
21. calciferol
22. tocopherol* or alpha-tocopherol
23. folate*
24. folic acid
25. phylloquinone
26. menaquinone
27. #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #11 or #12
28. #10 and #27
29. random*
30. controlled-clinical-trial
31. #29 or #30
32. #28 and #31
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WH A T ’ S N E W
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